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ABSTRACT 
This portfolio comprises a culmination of research work spanning 
three years of full- time training on the Practitioner Doctorate 
course in Psychotherapeutic and Counselling Psychology (PsychD) 
at the University of Surrey. The research comprises three research 
reports: a literature review, and two qualitative studies. The 
literature review explores the psychedelic renaissance, focusing on 
the resurgence of studies into utility of psychedelic drugs as an 
adjunct to psychotherapy. The first empirical study is a Thematic 
Analysis of therapists who have worked with clients when they 
were under the influence of a psychedelic during a research trial. 
The study seeks to explore how they experienced the interplay 
between the drugs and psychotherapeutic practice. The analysis 
revealed three master themes: i) ‘The Facilitation of Process ii) 
‘The Therapeutic Relationship’ iii) ‘The Power of a 
Transcendental Experience. The second empirical study used 
Interpretative Phenomenological Analysis (IPA) analysis to 
explore the lived experienced of having MDMA assisted 
psychotherapy to treat people with a diagnosis of PTSD. Analysis 
revealed three major themes: i) ‘Existential Freedom’, ii) ‘Beyond 
the Cartesian Split’, and iii) ‘A Journey Back in Time’.  
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RESEARCH DEVELOPMENT DOSSIER 
Introduction  
This dossier contains three pieces of research submitted during my 
four years of training on the PsychD course. The three pieces of 
work all explore how novel psychopharmacological interventions 
may impact on psychotherapy. I will introduce each piece in more 
detail below. 
 
Project 1 – Is it time for Counselling Psychology to join the 
psychedelic revolution? 
 
This review sought to explore the empirical literature that has 
emerged from what is commonly referred to as the ‘psychedelic 
renaissance’. The review highlights the promising potential of this 
novel treatment, pointing to a rapidly emerging body of 
randomised control trials that are demonstrating their utility. The 
review also indicates that there are several risk factors involved 
with this intervention, most prominent is perhaps the unpredictable 
nature of how they will impact on the client. Finally, the review 
considers how this research sits within CoP and argues that since it 
is presenting evidence to support its utility within the 
psychotherapeutic domain that it is important for CoP to begin 
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engaging with this field. I became increasingly aware during the 
process that there was a dearth of qualitative studies in this field. 
This reinforced the critical stance that I have developed throughout 
my training regarding utility of objectivist epistemologies. 
Regularly during the process of reviewing studies I was left 
yearning for a richer more in depth understanding of the 
experience of working with and being on these substances.  
 
Project 2 – How do psychedelics impact the psychotherapeutic 
process? A thematic analysis of qualitative interviews with 
practitioners who have delivered psychedelic assisted 
psychotherapy. 
 
As outlined above, my literature review highlighted the significant 
dearth of qualitative studies in the area of psychedelic research. 
Whilst it demonstrated that utility of psychedelics alongside 
psychotherapy has promise it also indicated that there was much 
need to better understand the how of this process. Thus I embarked 
on this project as a starting point in attending to this gap. Using 
Thematic Analysis (TA) I explored the subjective experiences of 
therapists who had delivered therapy to clients when under the 
influence of a psychedelic. I was seeking to better understand how 
psychedelic consumption might interact with psychotherapeutic 
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processes during therapy. I thought that this might also draw out 
both how they could be helpful and also where they may be 
concerns about their utility given the risk factors highlighted in the 
literature review. 
 
Project 3 – An Interpretative Phenomenological Analysis of 
MDMA assisted psychotherapy for PTSD.   
This project was born out of the literature review and my second 
year project. Having denoted in the previous project that, therapists 
in the study thought that there was much psychotherapeutic 
potential for psychedelic substances to be used alongside 
psychotherapy, it seemed important to better understand the lived-
experience of the clients who had been administered these 
substances. At the time when I was embarking on this piece of 
research the literature was becoming more focussed in terms of 
where the novel drugs were most likely to be used in the near 
future. Predictions and forecasts in the literature suggested that the 
most evidence based, and thus most likely to be administered as a 
treatment option soonest, was MDMA assisted psychotherapy for 
PTSD. Thus I felt that the most necessary and helpful place to 
explore would be in this narrower area. In light of this, this project 
used Interpretative Phenomenological Analysis to explore the 
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lived-experience of having psychotherapy whilst under the 
influence of MDMA.  
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Year 1 Literature Review: 
Is it time for Counselling Psychology to join the psychedelic 
revolution? 
Introduction   
Recent empirical trials have demonstrated that psychedelic 
substances could be a safe and effective adjunct to psychotherapy 
in the treatment of many psychological problems such as 
obsessive-compulsive disorder (OCD), post-traumatic stress 
disorder (PTSD), death anxiety and substance abuse (Winkelman, 
2014; Mithoefer et al., 2011; Gasser et al., 2015; Johnson et al., 
2017). Prior to the current prohibition status, psychedelics plants 
had been utilised as medicine by humanity for thousands of years 
(Winkelman, 2014). The large recreational consumption of 
psychedelics in the ‘sixties’, a time of radical societal and political 
change, resulted in the formation of a negative impression of the 
substances and consequently their prohibition in 1970 (Grinspoon 
and Bakalar, 1979). Such prohibition may have led to the field of 
Counselling Psychology (CoP) not hearing about their positive 
psychotherapeutic effects. 
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Past studies have shown that, alongside psychotherapy, 
psychedelic substances can intensify the change process in therapy, 
help individuals access difficult emotions and assist in the 
strengthening of trust in the therapeutic relationship (Grof, 1980). 
These findings may be of particular interest and relevance to CoP 
as the field emphasises the importance and benefits of the 
therapeutic relationship above all other components of 
psychotherapy (Clarkson, 2003). Moreover, stronger transference, 
and improved self-reflection are additional specific effects induced 
by psychedelic experiences during psychotherapy (Passie & 
D¨urst, 2009). Considering these positive findings, it is therefore 
surprising that there is no literature into how psychedelic 
psychotherapy may enhance the field of CoP. Hence, this review 
aims to provide an overview of topics within the literature 
regarding psychedelic psychotherapy, and the recent empirical 
findings, to evaluate how such research may impact CoP. To do so, 
it is important to acknowledge the current risks behind using 
psychedelics in therapy, such as the importance of taking 
psychedelics in a safe setting, at an appropriate dose and with an 
appropriate knowledge of the effects one may expect to feel.   
 
Rationale 
	 14	
Many preliminary studies are suggesting that psychedelics may be 
of benefit to psychotherapeutic practice. These studies have 
suggested that using a psychedelic as an adjunct to psychotherapy 
can enable clients to access repressed memories, increase reflective 
capacity and introspection, and help strengthen the therapeutic 
relationship (Grof, 1980; Tupper et al., 2015). As well as these 
psychotherapeutic processes being routinely utilised by counselling 
psychologists, CoP is also a pluralistic profession that values a vast 
range of treatment and research (Milton, 2016; Woolfe et al., 
2010). It therefore seems appropriate for CoP to engage and 
develop the field of psychedelic-assisted psychotherapy. 
 
Current psychotropic medications are often considered to block 
many psychotherapeutic processes such as engagement with 
emotion in psychotherapy (Tschoner et al., 2007). The 
psychotherapeutic effects that psychedelics offer can be seen to 
attend to such a limitation and can enhance psychotherapy 
(Mithoefer et al., 2011). Such effects may offer a chance for 
psychiatry and psychotherapy to better complement each other’s 
practice. Currently, psychiatry is undertaking research into 
psychedelic assisted psychotherapy. Unlike psychiatry however, 
the discipline of CoP puts an emphasis on utilising 
psychotherapeutic treatments in mental health; it therefore seems 
	 15	
of importance for CoP to support psychiatry in evolving and 
enhancing psychotherapeutic treatments. Additionally, as current 
research suggests that psychedelic psychotherapy can be a short 
treatment model that could match, or even better, the current 12-
week model used in IAPT services available on the NHS, there is 
further rationale for CoP to investigate psychedelic assisted 
psychotherapy. 
 
Furthermore, Vera and Speight (2003) suggest that CoP should 
endeavour to have a responsibility beyond direct therapy to issues 
of social justice. They acknowledge dissatisfaction with CoP’s 
attention to social causes given CoP’s involvement in the 
development of feminist theories. As much of feminist practice 
involves recognition that individual struggles are often rooted in 
oppressive political social and cultural forces, they postulate that 
such struggles cannot be resolved in the absence of changing the 
structures and systems that they arise from. It can therefore be 
argued that CoP should explore whether there is a political agenda 
behind the prohibition of psychedelic drugs, which have been 
shown to have such profound positive implications for 
psychotherapy (Tupper et al., 2015; Cahart Harris et al., 2012). If 
an individual’s struggles can be alleviated with these substances, 
CoP could benefit psychotherapeutic practice significantly by 
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taking an interest in balancing out the dominant prohibitive 
discourses with the resistive discourses that refute this. 
 
Indeed, the need for more social justice–oriented attitudes in 
counselling psychology has been strongly argued and supported by 
practitioners for a number of years (Vera & Speight, 2003). Social 
justice oriented counselling psychologist’s ideas are heavily 
influenced by feminist movements; they discuss the importance of 
sharing power and giving voice to marginalised individuals, 
allowing oppressed groups to emerge (Bond, Belenky, & 
Weinstock, 2000),). It has long been argued that individuals who 
have used psychedelics as mind altering tools for psychological 
progression are a marginalised group (Letcher, 2006). Thus given 
the extensive supporting literature of the profound positive benefits 
of psychedelics to psychotherapy it could be argued that, in line 
with CoP’s strong social justice oriented aspirations, it may be 
appropriate for CoP to provide a voice for this group. This 
literature review will thus seek to understand and present such 
discourses in the hope of empowering them, noting their potential 
benefits for future therapeutic practice in CoP. In addition, giving 
voice to such marginalised groups has also been argued to allow 
those who traditionally hold power to re-examine their perceptions 
and opinions, and acknowledge the potential strengths of the 
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marginalised group’s ideas (Letcher, 2006). Again, in terms of 
psychedelic therapy, counselling psychology may be able to 
impact such a cause where the strengths are so often going 
unnoticed despite the compelling literature. 
 
An additional motive for such a lit review to be conducted from a 
CoP perspective is in response to Van Duerzen’s (1990) powerful 
paper on the philosophical underpinnings of counselling 
psychology. She articulates her desire for counselling 
psychologists to remain open and accommodating of the notion 
that there is “a lot more to psychology than is written in the 
academic text books”. The author identifies counselling 
psychology as a place where “we can rediscover what has been so 
skilfully hidden elsewhere” (Van Duerzen, 1990). This quote 
invites attention to be drawn to the discourses that had potentially 
enabled psychedelic research to be “hidden”, by not only CoP but 
also psychology more broadly, despite the expansive positive 
findings. In this review I hope to shine light on such discourses in 
order for practitioners to move closer to engaging with the research 
in a more objective capacity, as opposed to within the tight 
confines of the current prohibitive discourses which dominate the 
field (Letcher, 2006). Here, attention is drawn to the ways in 
which, the attitudes that CoP has towards current psychotropic 
	 18	
drugs on the market, may impair the way that they approach the 
literature on psychedelics, despite the profound differences in 
effects between the two classes of substances (Carhart-Harris et al., 
2012; Carhart-Harris & Goodwin, 2017).  
 
A brief history   
Psychedelics have been used as sacramental tools by non-western 
cultures for thousands of years (Nichols, 2004). Many religions 
around today have been shaped by their use. For example “Soma” 
often appears in Sanskrit texts that heavily influence the Hindu 
religion. Anthropologists believe that Soma is derived from the 
hallucinogenic Amanita Muscaria mushroom (Nichols, 2004). 
Psychedelic research, in western cultures, was inspired by studies 
on peyote in 1896 (Nichols, 1994). Ibogaine was studied in the 
1920s prior to a large rise in psychedelic studies correlating with 
the discovery of LSD during World War 2 (Grof, 1980). Returning 
soldiers fuelled such research as psychedelics were used as 
pyschomimetics to further understand various psychoses. Freud’s 
ideas of dreams being “royal roads” for studying the unconscious, 
emphasised the power and importance of accessing the 
unconscious in a conscious state (Grof, 1973).  
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From the 50’s onwards psychedelic research boomed (Carhart-
Harris & Goodwin, 2017). In Gloucestershire, England, Dr Ronald 
Sandison pioneered psycholytic therapy with the aid of LSD in 
accessing repressed areas of his patient’s psyches. On the other 
side of the Atlantic Albert Hoffman, LSD’s founder, was 
collaborating with Timothy O’ Leary in investigating the power of 
administering LSD to overcome mental health difficulties (Grof, 
1980). Word of their therapeutic capabilities spread and studies 
involving psychedelics such as mescaline, psilocybin and LSD 
were being conducted all over the world. Indeed, between 1950 
and 1965 1,000 papers were published on LSD alone (Grof, 1980). 
The studies led to the treatments of 4,000 patients. Adverse 
incidents were remarkably low and psychiatrists began to evolve 
the best method for psychedelic exposure, often using the methods 
from Eastern cultures; the aim of which was to create a relaxed and 
facilitative environment (Grof, 1980). 
 
Despite the success of psychedelic research, by 1966 LSD was 
made illegal in the USA. The seemingly miraculous effects of LSD 
were popularised by writers such as Aldous Huxley who stated “I 
was seeing what Adam has seen on the morning of his creation – 
the miracle, moment by moment of naked existence.’ Academics 
such as Dr Timothy Leary, a clinical psychologist from Harvard, 
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began to promote the use of psychedelic drugs to the public. 
Ironically the US government, the creators of psychedelic 
prohibition, also promoted the use of LSD in the public (Friedman, 
2006). The project “MK-Ultra” was designed to develop LSD as a 
truth serum for military use. Random members of the public were 
unknowingly administered LSD and examined by a team of 
researchers in a famously unethical experiment. Upon illegalisation 
the US government blamed LSD for causing left-wing behaviours, 
opposition to the Vietnam War and negative social changes 
(Friedman, 2006). The funding for LSD research was soon cut by 
the government resulting in research coming to a dramatic halt 
(Friedman, 2006). Whilst research stopped, recreational use 
continued to increase often in impure and contaminated forms 
leading to public euphoria into the potential toxicity of a physically 
harmless compound (Gable, 1993). There are two clear dominant 
discourses regarding psychedelics since these events, the 
“pathological” and the “prohibition” discourses. 
  
The 30-year hiatus in psychedelic research appeared to mark the 
demise of the discovery of a potentially remarkable tool for mental 
health practitioners. Once compared to be for psychology what the 
microscope was for Biology, it appeared that western cultures had 
missed a unique opportunity to understand the human psyche 
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(Grof, 1980). In 1990 however the renaissance of psychedelic 
research was initiated at the University of New Mexico. A small 
study was approved to investigate the effect of N,N-
Dimethyltryptamine (DMT) on human participants (Carhart-Harris 
& Goodwin, 2017). By investigating a relatively unknown 
psychedelic substance, public and media-driven sensationalism 
were minimalised allowing for uncompromised, responsible and 
reliable research (Tupper et al., 2015). In 2002 studies at the 
University of South Carolina began investigating the therapeutic 
effects of 3,4-methylenedioxy-methamphetamine (MDMA) in 
treating PTSD following approval from the national institute of 
health and university’s institutional review board (Carhart-Harris 
& Goodwin, 2017). Research into the therapeutics of psychedelics 
has since grown extensively, similarly to the initial LSD research 
in the 1950s. In America, studies are underway at the universities 
of California, Arizona, Harvard, Duke and Purdue investigating a 
range of psychedelics including MDMA, psilocybin and LSD, on 
PTSD, addictions and anxiety disorders (Tupper et al., 2015; 
Carhart-Harris et al., 2012). In England, Imperial College have 
undertaken studies into LSD and psilocybin, neuroimaging the 
patient’s brain after consumption (Carhart- Harris et al., 2012). 
 
Recent psychedelic psychotherapeutic studies 
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Recent research into the benefits of psychedelics as an adjunct to 
psychotherapy has begun investigating a wide selection of mental 
health difficulties, such as obsessive-compulsive disorder (OCD), 
depression, social anxiety and many more (Tupper et al., 2015). 
The majority of research historically has focused on their effects 
with, substance dependency, PTSD and death anxiety, in 
individuals who are terminally ill (Mangini, 1998). Due to the 
scope of this academic piece, this review will focus on the most 
recent studies involving these particular mental health conditions, 
as at present they have the most vast and substantiated literature 
base, thus they can provide readers with a deeper understanding of 
their benefits. The studies below were selected because unlike 
other research being conducted into psychedelics at the moment, 
they involved the use of psychotherapy in the trial, which is most 
relevant to the field of CoP. The majority of the studies are 
quantitative and at present there are few studies, which have 
looked at the individual’s experiences of psychotherapeutic 
treatments with psychedelics as an adjunct from a qualitative 
perspective. Moreover, since the renaissance in psychedelic 
research, there are no qualitative studies that investigate the effect 
of psychedelic-assisted psychotherapy on the therapeutic 
relationship. 
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Psilocybin and alcoholism 
Bogenschutz et al. (2015)  carried out a ‘proof of concept’ study 
investigating the effects of using psilocybin, the psychoactive 
compound found in psilocybin mushrooms, alongside therapy in 
the treatment of alcohol dependency. The research model used has 
been further outlined in a recent publication by Bogenschutz et al. 
(2017), the research involved ten participants with a DSM-IV 
diagnosis of alcohol dependence.  Participants were given 
psilocybin once in a supervised session and partook in 
motivational enhancement therapy (MET) sessions before and after 
the dose. In the four weeks prior to the administering of psilocybin, 
there was no statistical difference between individuals who had 
received MET and those who hadn't. Following administration of 
psilocybin, the abstinence rates significantly increased. 
Furthermore, abstinence rates were maintained when investigated 
36 weeks later. The strength of experience of the psilocybin effects 
were shown to strongly predict decline in drinking 5-6 weeks after 
the treatment. In addition, the intensity of the experience also 
significantly predicted decline in cravings and increases in 
abstinence self-efficacy. In terms of safety, no adverse events were 
reported. Although their study showed promise in using psilocybin 
as an adjunct to psychotherapy, the small sample size makes it hard 
to definitively say that it was the psilocybin-mediated 
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psychotherapy that increased abstinence. The sampling of 
participants may also include potential biases, as it is possible that 
an individual who has previously had a favourable experience 
using psilocybin recreationally is more likely to participate in such 
a trial. Nonetheless, the authors suggest that such preliminary 
findings offer a strong rationale for further research into the effects 
of psilocybin as an adjunct to psychotherapy with large samples. 
From a CoP perspective, it would be interesting to understand how 
the psilocybin administration impacted the therapeutic relationship, 
as this is not documented. It would thus be useful to conduct 
qualitative research regarding the participants’ experiences. It 
would also be of benefit to understand how different traditional 
psychotherapeutic approaches may impact the findings, such as 
using a person-centred model as opposed to MET. 
 
Psilocybin and tobacco 
There have been many reports of successful abstention from 
various addictions after psilocybin psychotherapy (Johnson et al., 
2017; Bogenschutz et al., 2016). Since the renaissance, a study into 
the treatment of tobacco addiction with psilocybin was conducted 
at John Hopkins University in Maryland. The study represented the 
first of its kind in investigating the power of psychedelic mediated 
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psychotherapy on smoking cessation (Johnson et al. 2014). The 
trial involved administering psilocybin to 15 patients, all of whom 
were heavy smokers. Each individual received 15 weeks smoking 
cessation treatment involving regular sessions of cognitive 
behavioural therapy (CBT). Psilocybin was administered at week 
5, 7 and 13. Afterwards, the patients were encouraged to listen to 
music and have an introspective experience. During CBT the 
individuals were told that today would be their last day of 
smoking. Six months after the trial, 80% of the patients had 
remained abstinent from smoking; an impressive statistic 
considering that none had used nicotine replacement therapies. In 
contrast to this study current traditional psychotherapies, without 
psychedelics as an adjunct, is estimated to have a success rate of 
between 11 and 33%; a drastic reduction when compared to 
psilocybin treatment (Cahill et al., 2014; Garcia Romeu et al., 
2015). These statistics further highlight how psychedelic 
psychotherapy could be revolutionary for the recovery of 
individuals who suffer from addiction. Whilst these findings are 
positive, it is important to take into account the lack of control 
group in the study. Although abstinence results are far higher than 
using traditional CBT, without a control group it is impossible to 
rule out other factors contributing to the high abstinence rates such 
as the competence of the therapists.   
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Interestingly, Johnson et al (2017) has recently published a long-
term follow up on the trial. Sixteen months following the study, 
60% of the participants had remained abstinent of smoking and 
nicotine suggesting that the effect of psychedelic mediated 
psychotherapy can be long term. Johnson et al. (2017) also asked 
the participants to rate their experience of the psychedelic 
mediated psychotherapy. 13 of the 15 individuals rated their 
experience as one of the most meaningful and spiritually 
significant experience of their lives. Even taking into account the 
small sample size and lack of control group, such resounding 
results certainly seem worthy of further study. It would be 
interesting to investigate the individual’s experiences following the 
psychedelic psychotherapy as historically psychedelic 
consumption has been linked with, intense transference, reduction 
in feelings of guilt, and an increased felt sense of trust in the 
therapeutic relationship (Grof, 1980).  
 
MDMA and PTSD 
PTSD is an anxiety disorder which is characterised by hyper 
arousal, intense re-experiencing of past events and avoidance 
symptoms.  Currently the most utilised form of psychotherapy for 
PTSD is cognitive behavioural therapy (CBT). A review of CBT 
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and current pharmaco-therapeutic treatments being used in PTSD 
found that dropouts vary between 20-30% and response rates are 
between 50% and 75% (Cloitre, 2009; Hembree et al., 2003; 
Rothbaum et al., 2006). There is therefore a large subset of the 
PTSD population who are termed ‘treatment resistant’ (Watts et al. 
2013). 
 
Studies have shown that MDMA induces a 2-4 hour experience 
wherein participants experience feelings of euphoria, increased 
self-confidence and extroversion, sociability, improved well-being 
and a decreased fear response (Cloitre, 2009). Such findings 
informed the rationale for the potential uses of MDMA in the 
treatment of PTSD as it's often characterised by an uncontrolled 
fear response (Mithoefer et al. 2011). Many psychotherapeutic 
approaches with this client group involve inducing these 
autonomic responses by revisiting the traumatic experiences in the 
therapy sessions. However, treatment is often ineffective as clients 
find the feelings evoked in revisiting the trauma intolerable 
(Rothbaum et al., 2006).  
 
Thus Mithoefer (2011) conducted a study that demonstrated that 
MDMA-assisted psychotherapy is effective in individuals with 
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chronic and treatment-resistant PTSD. The study had a between 
subjects design and involved a control group. The results 
demonstrated that MDMA-assisted psychotherapy, when compared 
with the same psychotherapy with an absence of MDMA, 
produced significant improvements in participant’s PTSD 
symptoms. 83% of participants in the MDMA group no longer 
held a diagnosis of PTSD as opposed to 25% in the placebo group. 
In addition, the results had been sustained at a follow-up of 2 years 
(Mithoefer, 2013).  Furthermore, no adverse drug events were 
noted and there was no impairment of cognitive function. 
Moreover, this research showed that all individuals who received 
MDMA assisted-psychotherapy who were unable to work prior to 
the treatment had subsequently returned to work.  
 
Although Mithoefer’s study showed considerable promise for 
utilising MDMA as an adjunct to psychotherapy, there were 
undoubtedly several weaknesses that could have confounding 
implications. Firstly, as the study was a phase 2 trial, the sample 
size was small which affects the reliability of the results. Secondly, 
the control group has a longer history of psychotherapy than the 
MDMA group which could suggest a more ‘treatment resistant’ 
sample; when statistically analysed however this covariate proved 
non-significant. Thirdly the majority of participants in the trial 
	 29	
were female and of Caucasian ethnicity suggesting that gender 
and/or ethnicity variations to MDMA-assisted psychotherapy may 
exist. Nonetheless the positive results of Mithoefer’s study has led 
to further phase two studies being carried out involving giving war 
veterans who have a diagnosis of treatment-resistant PTSD, 
MDMA-assisted psychotherapy (Sessa, 2017). Phase three studies 
are also expected to begin in the UK in 2018 (Sessa, 2017). 
  
LSD and death anxiety 
Individuals who are nearing the end of their life often don’t obtain 
satisfactory emotional relief with the current treatment options 
available (Gasser et al. 2014). Chronic pain, depression, anxiety 
and unresolved relationship issues are all problems that this client 
group struggle with (Gasser et al., 2014). As death anxiety is 
increasingly being recognised as a significant public health 
concern it seemed of additional importance to discuss here (Gasser 
et al., 2014). 
 
Gasser et al. (2014) conducted a double-blind control trial to 
investigate the efficacy of LSD assisted psychotherapy. Twelve 
participants, all of whom were experiencing anxiety associated 
with their life-threatening diseases, were administered drug-free 
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psychotherapy supplemented with two LSD assisted sessions. The 
study demonstrated that at a 2-month follow up, the State-Trait 
Anxiety measure utilised showed positive trends for reduction in 
anxiety. The reductions in anxiety were sustained at a 6-month 
follow up. In addition, the study investigated the safety of LSD 
consumption and reported no chronic or acute adverse effects in 
relation to the treatment administered. A major limitation to the 
study however was the effectiveness of the double blinding; 
through altered behaviour, it is quite identifiable, both for 
therapists and participants, who has been given a dose of LSD. 
Although it is possible to use a low dose of LSD in the control 
group, this will undoubtedly raise efficacy of the comparator group 
and thus compromise effect size.   
 
Recently, Gasser et al., (2015) has published a qualitative study on 
the experience of receiving LSD-assisted psychotherapy on the 
same cohort. Participants reported positive personality changes 
including increasing openness and a deeper awareness. 77.9% also 
reported a reduced fear of death and an improved quality of life 
following the LSD-assisted psychotherapy. When asked about the 
effects of LSD on therapy, clients reported faster progress, easier 
access to their emotions and an increased feeling of safety (Gasser 
et al., 2015).  However, similarly to the studies discussed 
	 31	
previously, there was no mention of how the therapeutic 
relationship was impacted such as the felt experience between the 
client and therapist and the level of psychological connection. 
These elements of psychotherapy are widely regarded for being 
vital for positive change (Clarkson, 2003). Perhaps qualitative 
research would be useful, as the phenomenological underpinnings 
would capture the subjective experiences of participants.   
 
Overall, the results of the studies detailed provide interesting 
findings for the use of psychedelics as an adjunct to 
psychotherapy. It is important to be cautious with the findings 
though due to the small sample sizes. Psychedelics offer such 
profoundly different and personal experiences, that it is important 
to conduct much larger studies to gain an understanding of their 
potential to be generalised to wider population (Tupper et al., 
2015). There is also a current lack of qualitative research in the 
field, leaving a gap for CoP to attend to by exploring the 
phenomenological experience of both clients and therapists who 
undertake and practice psychedelic psychotherapy. Indeed, as CoP 
is underpinned by phenomenological philosophy and also puts an 
emphasis on the subjective lived experience of an individual in 
therapy, it may offer the perfect platform to perform such research 
(Clarkson, 2003).  Furthermore the BPS (2013) guidelines state 
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that counselling psychologists, as reflective scientific practitioners, 
should seek to engage in research that could improve 
psychological treatments. As present research into psychedelic-
assisted psychotherapy demonstrates that it could provide both a 
more efficient and more available option than current treatments 
for a range of client groups, it also seems important for CoP to 
engage and contribute to further research (Tupper et al., 2015). 
 
A critical evaluation of psychedelics and the therapeutic 
relationship 
Martin Buber (1937) proposed an understanding of the relation 
between the self and the other that is widely recognised in 
psychotherapy today. Buber denoted that people are ‘twofold’. He 
argued that we respond to the people who we encounter as either 
an “I-Thou” or an “I-It”. The “I-Thou” relationship refers to an 
authentic, holistic relationship between two people. This is the 
form of relationship that is mostly sought in humanistic 
psychotherapy. In contrast, Buber notes that “I-It” relationships are 
more in relation to one’s self and can be understood as a 
monologue as opposed to a dialogue. In addition, Buber (1937) 
states that an individual can only become an “I” in the mutual 
recognition with the other (Hudson, 2010).  Thus, an individual’s 
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self-existence is dialogical in nature and is fundamentally 
comprised of encounters with others.  
 
These interesting ideas that inform much of the emphasis on 
intersubjectivity in CoP are important to consider in relation to the 
psychedelic research that has been presented here.  Much of the 
historical literature has suggested that a large proportion of the 
psychedelic experience is profoundly introspective and involves 
deep self-awareness (Grof, 1980).  However, it does not comment 
on the way in which such substances impact the individual’s 
relationship with others and the wider world. Indeed to date, no 
study has placed particular emphasis on this part of psychotherapy 
in relation to psychedelic treatments. When considering Buber’s 
contribution to the field and its subsequent attitudes towards 
relationship, this seems of significant importance as an area of 
research in the future. It is important to explore what happens in 
the shared inter-subjective space of client and therapist if the client 
is in such an introspective mode of being. 
 
 In addition, most psychotherapeutic approaches now acknowledge 
the therapeutic relationship as fundamental to psychotherapy 
(Clarkson, 2003). An important aspect of this is considered to be 
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the shared empathic understanding between the therapist and client 
(Mearns & Thone, 2007). Empathy is typically conceptualised as 
the process in which therapists seek to enter their client’s unique 
phenomenological world. Arguably, this poses difficulties in 
relation to psychedelic assisted psychotherapy, as firstly, if the 
substances induce such a deep level of introspection that the client 
no longer experiences the intersubjective “I-Thou” nature of their 
relationship, they may not have a felt experience of the empathy 
that the therapist is communicating to them.  Secondly, in terms of 
the therapist being able to provide empathy, if the client’s 
experience is of such a depth of introspection, and the ideas that 
are emerging are in such an abstract form (Grof, 1980), it may be 
difficult for the therapist to connect and empathise with the client, 
again inhibiting the therapeutic relationship.  Thus this element of 
psychedelic therapy research needs to be explored in much greater 
detail (Tupper et al., 2015).  
 
Risks of psychedelic psychotherapy 
Despite the possibilities that psychedelic treatment offers, the 
uncontrolled use of such substances does undeniably have risks 
attached. It should be reiterated however that the proposition of 
this literature review is to evaluate whether psychedelics have 
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benefits in a controlled clinical setting, as opposed to recreational 
use. Indeed, there is a wealth of research regarding the importance 
of the setting, the expectancies of the user and the awareness of the 
dose administered; all of which are controlled in the therapeutic 
environment (Friedman, 2006). There are also several meta-
analyses that have investigated the link of psychedelic and 
psycholytic therapies and adverse effects on over a thousand 
participants (Carhart-Harris & Goodwin, 2017). These analyses 
concluded that psychedelics are safe to administer in 
psychotherapy, investigating parameters such as suicidal rates, 
psychoses and hospital rates (Friedman, 2006). Moreover Nichols 
(2004) conducted an extensive search of various medical research 
databases such as medline on LSD induced psychoses finding only 
three incidents within the last 20 years.  
 
Psychedelics may however have a negative effect upon individuals 
with a family history of psychotic disorders such as schizophrenia 
or on individuals who have pre-existing mental illness (Walsh, 
2003). A study conducted by House (2007) compared the 
diagnoses of patients with LSD-induced psychoses and those with 
a diagnosis of schizophrenia with no psychedelic consumption. 
Both groups showed similar psychopathological symptoms as well 
as having a significantly high rate of psychoses within their family 
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history. In obtaining these results, it was concluded that the 
psychoses that were supposedly induced by LSD, may have 
occurred later in life by other triggers. Such a finding therefore 
indicates that the family history of psychoses is an important factor 
to consider on whether psychedelic psychotherapy is given. Grawe 
(1995) investigated the findings of several toxicologists who 
compared frequently used psychedelic compounds in the potential 
for harm, such as their potential for dependence. The findings 
concluded that none of the psychedelics used in research cause 
physiological toxicity or show any evidence of having an addictive 
potential (Gable et al., 1993). These findings along with the fact 
that no reputable researchers have found any direct toxic effect, are 
surprising when considering how widely touted their toxicity is 
(Carhart-Harris & Goodwin, 2017). Some research does exist 
however on the use of psychedelics causing accidents such as an 
individual developing hyperthermia due to overexertion and 
exhaustion under MDMA influence at a rave (Gowing et al., 
2002). These incidents further outline the importance of an 
appropriate ‘set’ and ‘setting’ which is provided within the 
psychotherapeutic room. 
 
The continued prohibition dilemma 
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Despite new studies being conducted in psychedelic research, 
funding still remains a major issue for the future. Since 1967, 
psychedelics were classified as schedule 1 drugs under the United 
Kingdom’s misuse of drugs regulations (Carhart-Harris & 
Goodwin, 2017). Psychedelic drugs have also been classified as 
Class A since the UK misuse of drugs act in 1971. In the same year 
Psychedelic drugs were also classified as schedule 1 of the United 
Nations Convention on psychotropic substances; a classification 
system required to be accepted to receive UN membership. The 
classification was decided due to the UN deeming psychedelic 
drugs as having no accepted medical use and a great potential to 
cause harm, despite the previous two decades of research 
contradicting this (Carhart-Harris & Goodwin, 2017). Indeed, John 
Ehlrichman, Richard Nixons former assistant, infamously admitted 
that the harmful effects of psychedelics had been greatly 
exaggerated and that media had been manipulated to exacerbate 
this for political advantage (Friedman, 2006). Despite 
Ehlrichman’s confession and the evidence that psychedelic drugs 
do not cause dependence or toxicity, they still remain classified as 
schedule 1 (Gable et al., 1993; Grawe, 1995). Considering that 
heroin and cocaine, two drugs that do cause dependence and 
toxicity, are classified as schedule 2, psychedelics classification in 
schedule 1 seems misleading to the public. Indeed organisations 
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are beginning to question such outdated restrictions (Tupper et al., 
2015) 
 
As well as the bureaucratic obstacles imposed by such strict 
classifications, the financial implications greatly limit future 
psychedelic research. For example UN’s schedule 1 classification 
has resulted in only one manufacturer offering psilocybin at a 
quality that is sufficient for research (Carhart-Harris & Goodwin, 
2017). The Imperial College psychedelic group were quoted an 
extortionate £100,000 for 1g of psilocybin, the equivalent of 50 
doses (Carhart-Harris & Goodwin, 2017). Furthermore, in the UK 
for a hospital to store a schedule 1 drug a license must be bought 
for £5,000. Regular police checks are also required and transport is 
extensively over regulated. Even for a schedule 1 drug to be 
prescribed, the prescriber must hold a license that costs £3,000. 
The theoretical cost of providing licenses for 100 volunteers in a 
field study is thus £305,000 for licenses alone (Carhart-Harris & 
Goodwin, 2017). The financial burden is increased by the negative 
burden of schedule 1 classification discouraging grant funders 
(Carhart-Harris & Goodwin, 2017). The difficulties in conducting 
research, which are outlined here, lend themselves to an 
exploration of the dominant discourses that might be maintaining 
them.  
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Discourse 
Considering the strong bureaucratic, financial and political 
obstacles, that face researchers in conducting clinical 
investigations of a compound that could be revolutionary for 
psychotherapeutic use, it is helpful to understand the discourses 
behind such prohibition. As mentioned earlier, CoP seeks to give a 
voice to marginalised groups and ideas (Vera & Speight, 2003). By 
adopting such a social justice oriented attitude, repressed voices 
may be heard and thus result in positive change for the field of 
psychotherapy. This quest seems well applied to psychedelic 
discourses as the predominant prohibition discourses are proving 
extremely inhibiting of psychedelic research (Carhart-Harris & 
Goodwin, 2017). 
 
Indeed, from a Foucauldian point of view, psychedelics appear to 
have suffered from “scientific classification”, meaning they have 
been socially constructed on the observation of how they appear to 
symptomatically and objectively affect an individual (Letcher, 
2006). Discourse, meaning the way of understanding an object, 
therefore becomes relevant when talking about psychedelics 
(Phillips and Jörgensen, 2002). Such western discourses, such as 
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‘pathological’ and ‘prohibition’ discourses, which dictate that 
psychedelics have no therapeutic benefits, have arisen from the 
scientific classification. From these dominant discourses, resistive 
discourses have arisen in counteraction; these include 
‘psychological’ and ‘psychedelic’, ‘entheogenic’. 
 
Two functions related to discourses are relevant when referring to 
psychedelics. The first is how they function to divide individuals 
into set, boundaried and objectified subjects. The second is how 
they draw boundaries around how an individual can act and what 
they can say. A scientific classification results in not only objects 
becoming classified but also individuals (Letcher, 2006).  
 
Objectifying an object 
These dividing practices that occur from such categorisation are 
perfectly demonstrated in the predominant cultural discourse of the 
word “drugs”. “Drugs” can usually have two wide antithetical 
interpretations in western culture. The first is pharmaceutical 
drugs, which are produced by giant, regulated and thus reliable 
companies and are administered by well-trained health-care 
professionals for analgesic or pharmacological actions. The 
second, refers to a group of plants, chemicals and plant extracts 
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which are grown, extracted or synthesised illicitly and self-
administered by an untrained hand for pleasure, escape, curiosity 
and introspection. Consequently however such substances are 
criminalised, usually due to a high toxicity to public health 
(Letcher, 2006). The different types of substance in the second 
category are wide and highly variable and have variations in their 
qualities, including psychophysical effects, chemical action, 
toxicity, ecstatic states and dependence. However these 
experiences are overridden by a shared delineation of potentially 
being abused (Letcher, 2006). Moreover, if an individual was to 
self-medicate such a substance they would be labelled the 
undesirable term of “drug abuser” and would be consigned to the 
boundaries of society, becoming a target in the much talked about 
“war on drugs” (Voase, 2003). The main negative connotation of 
“drug abuser” is thought to be mainly due to the constructed image 
of an individual injecting heroin and becoming a vector of disease 
or a “drugged up criminal” (Jay, 2000; Davenport-Hines, 2001). In 
contrast, using a drug from the first category results in less 
negative stigmas and the use of highly addictive drugs such as 
caffeine and alcohol are not even considered as a drug and are 
merely “drinks” (Letcher, 2006). Such attitudes in society seem 
important to draw practitioners awareness too as they may impact 
on the way that clinicians engage with research.  
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Discourses result in boundaries 
In addition, the negative discourse behind “drug” also results in 
boundaries of what individuals can say and do. Foucault explains 
that discursive practices are virtually impossible to think outside of 
and that to do so would be mad, incomprehensible and out of 
reason (Voase, 2003). Therefore, to postulate the possible use of 
the “drug” psychedelics as a positive aid in psychotherapy is 
against the dominant scientific-materialist discourse. Letcher 
(2006) suggests that in counteracting such a discourse an 
individual could be labelled as mad, delusional or as a drug-
consuming hippy. Such negative discourses appear to be why 
funding agencies are uncomfortable in providing funding for 
psychedelic psychotherapy investigations. In funding such a study 
the agency fears societal judgement and thus the agency becoming 
less reputable (Letcher, 2006). Again, it is likely that such 
discourses will have impacted the way that CoP practitioners 
engage with such research.  
 
The pathological discourse 
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Literature has termed “pathological” and “prohibition” discourses 
as dominant when thinking about psychedelics in regard to 
Foucauldian scientific classification (Letcher, 2006).  
 
The pathological discourse refers to the emphasis of psychedelics 
as drugs that induce physiological and mental toxicity (Letcher, 
2006). The origins of this discourse can be split into the 
pathological discourses of mushroom based psychedelics and that 
of LSD. The former is a long-lasting delineation that originated 
from antiquity when mushrooms were either considered to be 
edible, or poisonous. Experiences ingesting psilocybin mushrooms 
were considered poisonous as opposed to psychedelic or 
transcendent, resulting in one’s recovery being regarded as a 
fortunate escape (Letcher 2006). In the 18th and 19th century this 
led to treatments including emetics, stomach pumping and the 
ingestion of leeches to treat such conditions. Indeed, Ford (1926) 
named a distinguished type of mushroom poisoning named 
mycetimus cerebralis, based on the hallucinogenic symptoms. 30 
years later psilocybin and mescaline were identified as causing 
these effects however as mentioned earlier, their toxicity is less 
than that of caffeine (Gable, 1993). 
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Around the same time, Lewin (1924) invented the term 'narcotic', 
classing drugs that cause hallucinations as “phantastica”. Lewin 
proposed that the effects induced by phantastica drugs were the 
same as psychosis, putting them down to the excitation of nerves 
causing a disruption to the function of the brain. This materialist 
neurological basis behind the hallucinations helped introduce the 
neuro-scientific discourse of hallucinations causing psychosis in 
western medicine (Letcher, 2006). 
 
Indeed the link between hallucinogens and subsequent psychosis 
became further fixed in the 1960s and the 1970s after the US 
government made LSD illegal and described their properties as 
mind-altering and psychosis inducing (Grof, 1980). Moreover, as 
LSD became illegal the drug was synthesised in homemade labs 
resulting in toxic impurities that caused morbidity or mortality as 
opposed to the actual LSD itself. Such cases led to moral panic 
over the use of psychedelics and further confirmed the pathological 
discourse (Stevens 1989). 
 
Lewin’s description of “phantastica” was a brief term that did not 
catch on following the 1940s, however the pathological discourse 
that was created by the term reveals various assumptions that are 
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now assumed of psychedelics (Letcher, 2006). These included the 
terms “schizogen” (mimicking or producing schizophrenia), 
“intoxicant” (inducing poisoning), “psychomimetic” (mimicking 
psychotic states) and “hallucinogen” (producing hallucinogenic 
states). The terms created assume that psychedelics cause 
alterations and aberrations to the “normal” human state via their 
poisonous mode of action. Such divergence, impairment, and 
interference of the normal physiological and mental state of the 
human body are assumed to be the reasons behind the production 
of visions and hallucinations, which therefore, although real at the 
time, lack ontological substance (Letcher, 2006). Therefore the 
phenomenological psychedelic experience is one of little value in 
this discourse, except perhaps to empathise with individuals who 
have psychosis. Indeed such assumptions led to many psychiatrists 
encouraging their colleagues and pupils to consume psychedelics 
in order to fully understand the nature of psychosis (Letcher, 
2006).  
 
The prohibition discourse 
As previously mentioned, following the clinical application of 
psychedelic therapy, psychedelic use leaked out into the public 
creating a psychedelic counterculture (Letcher, 2006). As this 
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culture increased, western governments illegalised their use 
(Tupper et al., 2015). This was enforced in both clinical settings 
and recreationally, so as to supposedly protect public health 
(Letcher, 2006). Such an argument does hold power as taken in the 
wrong environment, state or dose psychedelic ingestion has been 
shown to trigger psychotic breakdowns (Letcher, 2006). However 
due to the rarity of these incidents and the much higher risk to 
public health with substances such as alcohol and tobacco this 
appears dubious (Carhart-Harris & Goodwin, 2017; Bogenscutz et 
al., 2017). Indeed, the admissions of Ehlirchman further cast doubt 
about whether the protection of public health was the reason for 
their prohibition.  
 
Due to the prohibition discourse, psychedelics have thus become 
classed as toxic substances with no therapeutic value, of which 
physical and mental health are only negatively affected (Letcher, 
2006). The mere presence of the new psychedelic studies in the 
renaissance provides evidence that the legal boundaries may have 
been reduced. However, the vast amount of time, resources and 
finance that are required in order to create a study that uses 
psychedelics is huge compared to that of other drugs such as 
antidepressants, despite the minimal toxicity levels that 
psychedelics present (Letcher, 2006).   
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It is thus important that we acknowledge and explore the 
prohibition and pathological resistive discourses, as a result of the 
promising empirical research that has been presented in the last 20 
years.  This is arguably especially important to CoP as the field 
aspires to highlight, examine and ultimately change social 
injustices (Vera and Speight, 2003). Arguably the cost imposed by 
the classification of psychedelic drugs, which is supported by the 
prohibition discourse, is a social injustice, considering the findings 
that demonstrate their potential benefits for psychotherapy and low 
safety risks.  
 
Entheogen 
Finally, the resistive discourse of “entheogen” was created by a 
group of academics that wished to further differentiate the 
psychedelic compounds from connotations with the medical model 
and also that of recreational use (Letcher, 2006). The term 
“entheogen”, originating from Greek etymology, means “inspired 
by god” and has religious and sacramental contexts (Letcher, 
2006). By consuming psychedelics as entheogens, this discourse 
refutes the “prohibition” and “pathological” discourses by claiming 
that they are substances that are not illicit or dangerous, nor ones 
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of toxicity. Instead, the entheogenic discourse claims by affecting 
consciousness, religious and ontological experiences of 
significance are produced (Letcher, 2006). Indeed some 
individuals critique the term as too exclusionary, and awkward 
(Saunders 2000; Weil 1998). However, the term has become a 
popular discourse and is used by both new and old age academics 
(Letcher, 2006). Indeed the use of the term has helped in gaining 
funding for psychedelic research as its steers emphasis away from 
the negative connotations of psychedelic compounds (Carhart-
Harris & Goodwin, 2017). This discourse is still not considered 
dominant within mainstream society and thus it seems important to 
continue to explore what the discourse is trying to expose and 
inform society of  (Letcher, 2006). In doing so we might draw 
further light on how psychedelics may be of benefit to 
psychotherapeutic research, and furthermore what the current 
positivist psychedelic research is missing.  
 
Psychedelic research implications for psychological 
prescription privileges  
Having thought about the implications of the prevalent and 
resistive discourses for psychedelic research, it now seems 
important to consider how some of CoP’s common attitudes may 
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impact the way that the field engages with psychedelic-therapy 
literature. Counselling psychologists commonly negate over-
reliance on psychotropic drugs in the treatment of psychological 
problems and disprove of the argument that mental health can be 
wholly conceptualised in the medical model (Hammersley & 
Beeley, 2006).  Thus, the compelling research, which suggests that 
psychedelics have a transformative capacity poses potential 
problems for the field of CoP. To elaborate, it raises the question 
of how counselling psychologists can disapprove of overuse of 
drugs in mental health treatment and not reject psychedelics’ 
compelling potential to support and contribute to the humanistic 
aims. It may be helpful to consider the distinctions between the 
functions of psychedelics and psychopharmacological drugs on the 
market currently when reflecting on how such a question can be 
reconciled. Current psychopharmacological prescriptions can 
generally be seen as constrictive of feelings (McHugh et al., 2013). 
Moreover, in the constriction of emotions, for example sadness in 
relation to the intake of antidepressants, we may come up against a 
tension with regard to CoP’s conceptualisation of sadness as a 
potential stimulus for psychological growth during psychotherapy 
(Friedman, 2006). More problematic is their replacement of 
depressive feelings with numbness thus preventing the opportunity 
for individuals to experience happiness when under the influence.  
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Research has exposed that the biggest predictor of change in 
psychotherapy is the quality of the therapeutic relationship. 
Literature shows that without this component, change is much less 
likely to occur (Clarkson, 2003), therefore if antidepressants 
suppress emotions it could have negative implications on the 
development of feelings in regard to a client’s relationship with 
their therapist. Therein lays a profound difference between 
psychedelics and currently predominant psychopharmacological 
treatments. Psychedelics expand psychological processes. 
Therefore psychedelics could in this regard compliment CoP’s 
direction towards facilitating psychological growth through the 
exploration of emotions and experiences. Thus, they may act as a 
powerful adjunct to humanistic talking therapies. Indeed such 
discussions have occurred previously between psychiatrists over 
the past decade; Victor (1999) expressed sadness towards Western 
culture’s contradistinction between humanistic and biological 
treatments. He contrasts this with other cultures around the world 
that more commonly understand biological and spiritual 
components of existence to be intrinsically connected to each 
other.  
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Conclusion 
To conclude, there is a large evidence base that suggests 
psychedelics can be useful as an adjunct to psychotherapy for a 
variety of mental health disorders (Bogenschutz et al., 2017; 
Lawrenson et al., 2017; Mithoefer et al., 2013). Western mental 
health is experiencing a rapidly growing epidemic in mental health 
difficulties and thus financial resources are being stretched (WHO, 
2003). There is an over reliance on pharmacological drug 
prescriptions, as health care professionals endeavour to manage the 
increasing demand on mental health services (WHO, 2003). Thus 
the research outlined here seems important and worthy of further 
investigation, as the literature presented suggests that combining 
psychotherapy and psychedelic substances can quicken and deepen 
the therapeutic process (Tupper et al., 2015). They may therefore 
help alleviate some of the issues that mental health professionals 
are grappling with.  
 
However, despite the evidence of the therapeutic potential, and low 
risks with psychedelic-assisted psychotherapy, it is important to 
endeavour to be objective.  In the past, psychedelic psychotherapy 
became marginalised and the benefits largely went unseen; 
clinicians became somewhat biased and thus at times oblivious to 
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the inevitable risks and dangers of the substances (Letcher, 2006). 
Thus it is important to continue to investigate the risks with as 
much depth as the therapeutic uses.  Nonetheless, it seems 
important to ensure that we do not allow the strong prohibition and 
pathological discourses to impair our reception of the emerging 
research in to this field, which demonstrates expansive positive 
potential for psychotherapy. Indeed, it is important to look beyond 
the prejudices that are largely associated with recreational drug 
abuse to enable us to tentatively embrace the compelling research 
that is being presented in the current literature in relation to clinical 
uses.  
 
Whilst psychedelic psychotherapy research is in its infancy, the 
evidence of psychedelic therapy from the past should be enough to 
power future research into the uses of these substances as an 
adjunct to psychotherapy (Grof, 1980). It has been strongly 
suggested that the anecdotal nature of some of these studies should 
not act as a deterrent, as this is often the way that medical trials 
begin (Carhart-Harris et al., 2012).  Medicine, neuroscience and 
philosophy are increasingly contesting the scheduling of 
psychedelic substances as drugs with high abuse opportunity and 
few medical uses (Carhart-Harris et al., 2012; Carhart-Harris & 
Goodwin, 2017). However, there are few clinical trials being 
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conducted in the UK and thus it seems important to continue to 
endeavour to carry out such research in order to make a more 
informed conclusion about whether it can benefit CoP (Sessa et al., 
2017).  
 
Finally, it is important to pay further attention to the implications 
of psychedelic assisted psychotherapy for the therapeutic 
relationship. Since CoP has a particular interest in this element of 
psychotherapy (Clarkson, 2003) it seems reasonable to suggest that 
such research would benefit the field greatly. It can therefore be 
argued that as a profession we would benefit from undertaking 
qualitative research into this area. Furthermore, much of the 
research has focused on the experience of the client but it seems 
interesting to also acknowledge the experience of the therapist, 
who from a humanistic standpoint, is of paramount importance to 
the therapeutic process (Clarkson, 2003). Indeed, it would be 
interesting to explore their phenomenological experiences of 
conducting therapy with individuals in a different state of 
consciousness to that which we work with in traditional 
psychotherapeutic practices.  
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Year 2 Empirical Study: 
How do Psychedelics Impact the Psychotherapeutic Process? A 
Thematic Analysis of Qualitative Interviews with Practitioners 
who have Delivered Psychedelic Assisted Psychotherapy. 
Abstract  
4-phosphorloxy-N,N-dimethyltryptamine (psilocybin), Lysergic 
acid diethylamide (LSD) and Methylenedioxymethamfetamine 
(MDMA), are demonstrating encouraging results as an adjunct to 
psychotherapeutic practice following a surge of empirical research 
over the last 10 years.  
  
Method: Psychotherapists, who had worked as therapists on studies 
that involved delivering psychedelics to clients under the influence 
of a psychedelic, were interviewed to explore their experiences of 
working in this capacity. 
  
Results: 3 clear superordinate themes emerged from the analysis: 
1) Facilitation of Process 2) The Therapeutic Relationship and 3) 
The Power of a Transcendental Experience 
  
Conclusions: Psychedelic substances were experienced as useful 
catalysts to psychotherapy. However participants shared concerns 
regarding the impact of the speed at which they accelerated the 
therapeutic process. Proposals are made for future research to be 
conducted into the subjective experience of clients who have had 
this treatment.  
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Introduction 
Over the past sixty years, psychopharmacology has been used to 
treat millions of individuals with different mental health issues. 
Anxiolytics, antipsychotics and anti-depressants help to decrease 
symptoms however also show heavy side effects. Furthermore, 
these drugs often fail to attend to the underlying issues of clients, 
thus their problems perpetuate, leaving individuals dependant on 
the substance (Mithoefer, Grob & Brewton, 2016). Studies have 
shown that evidence-based psychotherapy can be more effective 
than medication at treating individuals who meet the criteria for a 
mental health diagnosis under the Diagnostic Statistical Manual 
(DSM) such as ‘post-traumatic stress disorder’ (PTSD) and 
‘anxiety associated with terminal illness’ (Mithoefer, Grob & 
Brewton, 2016). Indeed, a recent meta-analysis showed that 
individuals experiencing death anxiety had a 3-fold preference for 
psychotherapeutic interventions as opposed to drugs (McHugh & 
Whitton, 2013). However, there remains a large subset of the 
population whose mental suffering is not alleviated by evidence-
based psychotherapy and/or psychopharmacological treatment 
(Mithoefer, Grob & Brewton, 2016). 
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Indeed, previous publications document how individuals with a 
‘psychiatric diagnosis’ often try successive medications in an effort 
to alleviate their symptoms, however many cannot find such relief 
or suffer severe side effects (Watts, Schnurr & Mayo, 2013). 
Furthermore, despite positive effects in psychotherapy, dropping 
out is common and progress is often slow (Mithoefer, Grob & 
Brewton, 2016). Clinicians practising psychotherapy report 
feelings of frustration around being ‘stuck’; clients frequently 
report feeling this ‘stuckness’ (Hammersley & Beeley, 2006). 
Hammersley and Beeley (2006) discuss the ‘stuckness’, 
commenting on how some clients appear unable to get in touch 
with feelings. Others seem to find the session very helpful and 
engaging, then fail to transfer this effectively into their daily lives.  
  
The current limitations of pharmacotherapy and psychotherapy 
therefore fail to sufficiently attend to individuals suffering mental 
health distress. Indeed, these shortcomings are felt in the National 
Health Services (NHS), with long waiting lists topping 12 months 
for psychotherapeutic treatments, largely due to a ‘revolving door’ 
problem wherein clients frequently return as a result of 
unsatisfactory results of previous treatments (Beck, Burdett & 
Lewis, 2015). Improving Access to Psychological Therapies 
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(IAPT) services, delivering cognitive behavioural therapy (CBT), 
represents a new approach by the NHS to satisfy high demand. 
Despite short-term success however, these treatment outcomes 
have been shown to fail in terms of sustainability, with individuals 
often relapsing and returning to services a year later (Beck, Burdett 
& Lewis, 2015).  
  
In line with these limitations of current mental health practices, 
Hammersley and Beeley (2006) comment how longstanding and 
frequently prescribed psychotropic medication might be 
accountable for limitations experienced in psychotherapy. They 
note how in the short-term psychotropic medications alleviate 
symptoms such as crying, distress and tension, however the 
authors assert these symptoms are the way in which we can access 
the underlying issues in psychotherapy. The authors express that a 
vital part of successful therapy often involves clients’ re-
experiencing of emotional pain to work through their past traumas. 
In addition, they comment how clients need to be able to 
experience the relationship with the therapist, on an emotional 
level, and to be in touch with the subtleties of the interactions 
between them. This is in line with CoP’s emphasis on the 
therapeutic relationship in psychotherapy (Woolfe, Strawbridge & 
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Douglas, 2010). This notion is supported in research that conveys 
outcome of therapy to be attributed largely to the quality of the 
relationship between therapist and client (Ardito, 2011). Therefore, 
they suggest that given that the drugs prescribed often reduce the 
client’s capacity to feel and think, they can be incompatible with 
psychotherapy and contribute to the ‘stuckness’ experienced in the 
process.  Finally, the authors suggest that it is too simplistic to take 
a position that medics and psychotherapists have separate areas of 
competence; doctors are embracing skills of counsellors and 
likewise psychotherapists should not disregard psychotropic 
medication. This seems aligned to CoP’s pluralistic and scientist-
practitioner position (Woolfe, Strawbridge & Douglas, 2010). 
Therefore, there appears a need for such a gap in treatment to be 
investigated and attended to.   
  
Over the last ten years, studies have begun investigating the 
potential of psychedelic compounds in mental health treatments 
with promising results (Mithoefer, Grob & Brewton, 2016). Of 
interest to CoP are emerging studies that seek to investigate the use 
of such compounds, as an adjunct to psychotherapy such research 
is outlined below. 
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Utilising psychedelic compounds as an adjunct to 
psychotherapy 
4-phosphorloxy-N,N-dimethyltryptamine (psilocybin), 3,4-
methylenedioxy-methamphetamine  (MDMA) and Lysergic acid 
diethylamide (LSD) are psychedelic compounds which have 
shown promise in treating mental health distress as an adjunct to 
psychotherapy (Mithoefer, Grob & Brewton, 2016). Indeed, a 
resurgence of clinical research over the past 10 years has provided 
promising results for populations considered to be suffering with a 
‘treatment-resistant’ diagnosis, including anxiety associated with 
terminal illness, addiction, depression and, as illustrated below, 
PTSD (Bogenshutz, Forechims,  Wilcos, & Strassman, (2015); 
Carhart-Harris, et al. (2012);  Danforth, Struble, Yazar-Klosinski 
& Grob (2015)  For a detailed account of such research, see Ruger 
(2015), literature review. 
 
MDMA and PTSD 
Mithoefer et al. (2011), conducted an investigation demonstrating 
that MDMA-assisted psychotherapy was effective in treating 
clients with chronic, treatment resistant PTSD. Using a between-
subjects study design, with a control group, the study demonstrated 
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a reduction in PTSD symptoms using psychedelic assisted 
psychotherapy as opposed to psychotherapy alone. 20 individuals 
with treatment resistant PTSD were randomly assigned 
psychotherapy with MDMA (n=12) or an inactive placebo (n=8). 
Individuals were administered MDMA during two 8 hour sessions 
3-5 weeks apart. A non-directive, person-centred approach was 
taken by the therapists in discussing trauma-related material. After 
a 2 month follow up, 85% of participants who were administered 
the active drug no longer held a DSM IV diagnosis of PTSD, 
compared to just 15% in the placebo group. The results were 
sustained upon a 3.5 year follow up. No adverse effects were noted 
from either group of participants. Impressively all clients who were 
previously unable to work due to their PTSD symptoms returned to 
full-time employment. In relation to the aspirations of IAPT 
services in the NHS, whereby short term therapy is utilised to help 
people with mental health difficulties return to work, such a 
finding could have positive implications for the NHS  (Layard et 
al., 2006).  
 
Whilst the research above should be commended for its 
progressive stance in challenging the effectiveness of conventional 
psychotherapy with regard to psychological distress, in taking a 
	 69	
positivist epistemological position and attending only to 
quantifiable outcome measures, this study as well as others, neither 
discuss the impact of MDMA administration to the 
psychotherapeutic process nor attends to the phenomenological 
experiences of both clients and therapists; ethical matters important 
to the field of CoP. Furthermore, As RCTs are often hailed as the 
‘gold standard’ of research the issue arises surrounding a lack of 
critical evaluation regarding assumptions that researchers bring to 
their work. 
  
The limited current understanding of how psychotherapy is 
facilitated by psychedelics 
The way in which psychedelics act as a catalyst to psychotherapy 
remains elusive, with current theories speculative (Mithoefer et al. 
2016). Such observations include, decreased “defensiveness and 
avoidance” and a clearer memory of historic events. Moreover, 
clients’ willingness to explore historic events is also increased, 
along with a better ability to process their experiences (Carhart-
Harris, 2012). Additionally, participants are reported to have new 
awareness for unhealthy emotional and cognitive patterns in 
response to traumatic events and increased capacity to fearlessly 
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offer compassionate reappraisal. These have been hailed as being 
‘ideal effects’ to augment psychotherapy (Mithoefer et al. 2016).  
 
Such speculation is of interest to CoP as it suggests promise for the 
psychotherapeutic process. However, there are also potentially 
some concerns with increased ability to recall memories. Indeed, 
the capacity to maintain difficult memories beyond awareness is 
perhaps best understood in terms of a ‘tolerable’ mode of being, 
enabling the individual to function in the world. Indeed, whilst 
explanations are ontologically distinct, there is some agreement 
within the literature that the ‘removal’ of traumatic memories has a 
protective function. Goldberg (2013), discusses the importance of 
caution regarding therapists’ pace when working with clients’ 
exploration of erstwhile unavailable material, claiming that 
accessing memories rapidly may be traumatic for the client. This 
raises important questions regarding how distressing the 
therapeutic encounter may be for the client subsequently. 
Furthermore, an acceleration in accessing memories also poses 
potentially negative implications for therapists. In accompanying 
the client through the rapidly emerging affective experience, the 
therapist may be rendered insufficiently equipped to hold or 
contain the individual in their experiencing of traumatic material 
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(Goldberg, 2013). However, it remains that all therapeutic 
encounters involving traumatic material require an attendance to 
sufficient levels of self-care on the part of the therapist (Iqbal, 
2015) and that ‘significant’ material may enter the therapeutic 
frame, unannounced, regardless of clinical orientation. Thus 
research that seeks to explore therapist’s experiences of delivering 
this form of psychotherapy seems important to understand the 
impact of psychedelics on the therapeutic process better. 
  
Furthermore, in terms of the impact of using psychedelics on the 
psychotherapeutic process, Mithoefer et al. (2016) speculates that 
MDMA could improve the therapeutic alliance with those clients 
who find it particularly difficult to trust. Whilst this strengthening 
of the clients’ trust presents promise for psychotherapy, arguably 
using a psychedelic substance raises other issues for the 
therapeutic relationship. Indeed, most psychotherapeutic 
approaches acknowledge the therapeutic relationship as 
fundamental to psychotherapy, and a significant aspect of the 
utility of the relationship is the shared empathic understanding 
between the therapist and client, as conceptualised by the process 
in which therapists seek to enter their client’s unique 
phenomenological world (Woolfe, Strawbridge & Douglas, 2010). 
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Arguably, this process may be compromised when the client is 
under the influence of a substance, as the therapist may not be able 
to provide empathy if the client’s experience is of such a depth of 
introspection, and the ideas that are emerging are in such an 
abstract form (Grof, Goodman & Richards,1973). Indeed, it may 
be difficult for the therapist to connect and empathise with the 
client, thus inhibiting the therapeutic relationship and obstructing 
the therapists’ ability to be with the client and meet them at their 
phenomenological experience. Research to date has not explored 
how therapists experience delivering psychotherapy under these 
conditions, thus the impact of the client being under the influence 
of a psychedelic on the therapists ability to enter their world and be 
with them remains largely unknown. 
 
Possible adverse effects of using psychedelics as an adjunct to 
psychotherapy 
Although there is an emergence of evidence supporting the use of 
psychedelics within psychotherapy, research is obliged to attend to 
risk potential for therapists and their clients. Indeed, popular 
discourse, as characterised by using psychedelics within 
recreational settings, has presented a less than positive 
interpretation of their use and studies have reported the harmful 
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effects associated with a range of factors such as delusional 
expectancies, inaccurate dosage and the appropriateness of setting 
(Carhart-Harris, 2012). 
  
A recognised adverse affect of psychedelic use in the recreational 
setting is referred to as ‘Hallucinogen Persistent Perception 
Disorder (HPPD)’ or ‘The re-experiencing, after cessation of use 
of a hallucinogen, of one or more of the perceptual symptoms that 
were experienced during intoxication with the hallucinogen’ 
(DSM-V). With regard to recreational LSD use, HPPD has an 
incidence rate of 5% (Hermle et al. 2008). However, as reported by 
Carhart-Harris and Nutt (2010), unlike those who use specific 
psychedelic substances under controlled conditions, the majority of 
the recreational user population use a range of drugs. Accordingly, 
it is not possible to implicate psychedelics per se in the onset of 
such symptomology. Indeed, a recent meta-analysis (Carharrt-
Harris et al., 2013) examining links between psychedelic 
psychotherapy and suicide rates, psychotic episode and rates of 
hospitalisation (Friedman, 2006) concluded that psychedelics are 
safe to administer in the therapeutic setting. However, it should be 
borne in mind the extent to which a paucity of studies involving 
small sample sizes raises issues of generalisability. 
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Interestingly, to elaborate in terms of safety of such substances, 
Grawe (1995) conducted a study on findings of toxicologists who 
had compared frequently ingested psychedelic compounds in their 
potential to cause harm, including factors like the potential to form 
dependence. His research concluded that none of the psychedelics 
used in research cause physiological toxicity and there was no 
evidence of psychedelics having any addictive potential. Such 
findings, alongside no reputable researchers having found any 
direct toxic effect to date (Carharrt-Harris et al, 2013) are perhaps 
surprising when considering how frequently their toxicity is touted. 
However, research does exist on the potential for psychedelics to 
cause accidents, such as individuals developing hyperthermia due 
to over exertion and exhaustion under MDMA influence Gowing 
et al., 2002). Such incidents further compound the importance of 
acknowledging the potential for these substances to be dangerous 
and the need for a much wider breadth of research to be conducted 
in this area prior to conclusions around their safety being drawn. 
Furthermore, it is important to be mindful of how research may 
filter into popular discourse and draw attention and attraction to 
recreational use, which could put the public at risk. 
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Rationale 
Preliminary research is demonstrating the potential benefit that 
psychedelics can offer to psychotherapeutic practice. Whilst 
research conveys that psychedelics are useful, the impact they have 
on the psychotherapeutic process remains to be investigated. As a 
pluralistic profession, CoP endeavours to acknowledge and utilise, 
a wide range of research and treatment (Milton, 2016). As 
previously discussed, recent studies propose that administering a 
psychedelic can facilitate the strengthening of the therapeutic 
relationship, enhance reflective capacity and introspection, and 
enable patients to access their repressed memories more easily. 
These psychotherapeutic processes are referred to, researched and 
utilised in practice regularly within the field of CoP (Woolfe et al., 
2010). Therefore, if administering a psychedelic may have the 
potential to facilitate such processes, and could provide useful 
opportunities for CoP practice, it is helpful for CoP to begin to 
investigate this model of treatment further. Indeed, if psychedelic 
psychotherapy may be able to offer a short-term treatment model, 
which is not dissimilar in terms of time to the current 12-week 
model offered in IAPT, but has shown more promising results in 
terms of sustainability, then it seems important to investigate this 
form of psychotherapy further, in order to attend to the current 
NHS challenges. 
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Additionally, current psychotropic medication prescriptions 
frequently act as an obstacle to psychotherapeutic processes and 
the use of the therapeutic relationship in psychotherapy 
(Hemmersley & Beeley, 2006). Therefore, since psychiatry is 
endeavouring to engage in research that is attending to this, it 
seems important for CoP to acknowledge, support and engage with 
psychedelic research also. Indeed, the field of psychiatry is 
reporting positive findings for psychedelic psychotherapy but 
recognises that there is still a need for further research before 
conclusions can be drawn regarding efficacy of psychedelics in 
psychotherapy. CoP, unlike psychiatry, is a discipline that 
emphasises psychotherapeutic treatments for mental health issues 
(Milton, 2016), and thus can arguably provide a better platform 
from which to explore the impact of psychedelics on the 
psychotherapeutic process. This could offer the opportunity for the 
two disciplines to complement each other better. 
  
The above rationale is in line with BPS (2013) guidelines, as 
scientific-practitioners, CPs have a responsibility to respect, utilise 
and contribute to empirical research that seeks to develop and offer 
better psychological treatments (BPS, 2013).  Since current 
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research has indicated that this form of psychotherapy may provide 
a more efficient treatment than currently available treatments for a 
range of client groups (Mitohefer, 2016), it seems important for 
CoP to consider and evolve the research further. 
  
Aims and research question 
The proposed study aims to expand on current literature’s 
understanding of the impact of psychedelics on the 
psychotherapeutic process. It will consider themes that emerge 
regarding how psychotherapeutic processes appear impacted 
because of using psychedelics. Thus, the research question, ‘How 
do psychedelics impact the psychotherapeutic process?’ 
  
Method 
  
Research philosophy and design 
The introduction pointed to an absence of qualitative research in 
psychedelic mediated psychotherapy. Qualitative methodology 
allows for individuals’ subjective experiences to be explored at 
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depth, creating a richer understanding of the phenomena, or 
argument, that participants hold. A qualitative methodology 
therefore seemed appropriate when attending to the present study’s 
research aims and questions (Willig, 2013).  
  
Since the research question seeks to explore the impact 
psychedelics have on the psychotherapeutic process, thematic 
analysis seemed the most appropriate choice of methodology (TA). 
This is because TA is a flexible qualitative method that provides 
opportunity to explore why people think, feel or do particular 
things (Braun & Clarke, 2006).  
  
Alternative methods such as IPA emphasise individual 
participant’s lived experience more, rather than concentrating the 
emphasis of the research on the themes that emerge across 
participants. In IPA, researchers code the data items individually, 
looking for themes within each data item first. However, in TA 
researchers develop their analysis across the whole dataset at every 
stage (Braun & Clarke, 2006).  
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Sampling and Participants  
Braun and Clarke (2006) suggest a sample of between 7-20 
participants when using TA, offering researchers the opportunity to 
see themes across the data set. Given the limited research in the 
field thus far, and the subsequent small population of therapists 
working in the field, the sample was kept small. In addition, it was 
felt that the scope of this research supported the need for a small 
sample to ensure that rich analysis could be conducted, with space 
to report the findings elaborately at depth. Therefore, it was 
decided that a sample of 10 and no less than 6 participants would 
be optimal. 
  
Participants were selected purposively; inclusion criteria stipulated 
that individuals must be qualified practitioners of psychotherapy, 
who have provided therapy to patients whilst they had been under 
the influence of a prescribed psychedelic substance. In addition, it 
was stipulated that they had worked in a psychotherapeutic 
capacity in the absence of utilising psychedelics as an adjunct for a 
minimum of two years, in order to ensure that they could give a 
richer insight into how this experience is similar or different. 
Furthermore, inclusion criteria required individuals to have worked 
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in this capacity in a clinical trial, which has been run in the last 10 
years of psychedelic psychotherapy research. 
  
Regarding participant recruitment, the researcher made contact 
with a research fellow in the field at a highly regarded university in 
the U.K.  This individual responded saying that he could not 
facilitate access to the population required however he advised that 
the researcher contact MAPS, an American charity directly 
involved in the funding of this research called the 
Multidisciplinary Association for Psychedelic Studies (MAPS). He 
suggested that they would have access to the contact information 
of the individuals whom had provided therapy to patients on the 
psychedelic assisted psychotherapy trials. Thus the researcher 
contacted this charity. From this point of contact a process of chain 
referral or ‘snowballing’ occurred, following the administrators at 
the charity sending out the email advertisement (Appendix 1). This 
process generated a list of individuals who met the criteria. 7 
individuals contacted the researcher showing interest in the study, 
and all were responded to with information regarding what 
participation would involve and an invitation for them to 
participate (Appendix 2). They all replied and agreed to take part. 
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Description of participants  
Seven individuals who were qualified to deliver psychotherapy 
took part. Two of the participants were primarily qualified as 
psychiatrists, but had been trained in, and used, psychotherapy in 
their practice frequently. All participants had delivered 
psychotherapy without the use of psychedelics in their practice for 
a minimum of three years prior to participation. Theoretical 
orientation and modality preferences were varied across 
participants, including humanistic, cognitive behavioural, 
psychoanalytic, somatic and transpersonal psychotherapy.   
  
Data Collection 
Semi-structured interviews were used to explore the topic flexibly, 
whilst remaining within the area of the study (Braun & Clarke, 
2006) (Appendix 4).  
  
The interviewer endeavoured to enter the personal frame of 
reference of the participant. (Willig, 2013). Thus questions were 
non-directive in order to maximise the potential to explore the 
individual’s experience without influencing the direction of the 
	 82	
material that emerged. The interpretative aspect of TA means that 
the influence of the researcher is ‘inescapable’ in the knowledge 
that is produced. Thus attention was placed upon reflection of my 
role as researcher in the interpretations that emerged at every stage 
of the research process (Larkin &Thompson, 2012; Yardley, 
2000).  
 
Interviews lasted between 45-60 minutes and were recorded and 
transcribed before analysis.  
 
The interviews were conducted using video/phone technologies. 
This decision was made due to financial and time restraints within 
the scope of this study, given that all participants were based in 
America. This approach was further supported when taking into 
account how it contributed to minimising ecological dilemmas in 
terms of the researcher travelling to America. The researcher used 
Skype which is an internet telephony software which allows 
videoconferencing via a web cam. It was considered that the use of 
videoconferencing enabled an experience that was closer to an in-
person encounter (Slade, Emery & Lieberman, 1997). Indeed an 
advantage of skype was that it enabled nonverbal communication 
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to be captured, which felt important in the context of an IPA study. 
In addition, Skype calls are recorded and transcribed in the same 
way as face-to-face interviews (Oliffe, 2010). 
 
Data analysis 
The inductive analysis procedure outlined by Braun and Clarke 
(2006) was employed. Data was initially read to identify and code 
important features of transcripts. Codes were sorted into possible 
themes and all data that was deemed relevant to the theme was 
collated. Finally, data was systematically reviewed to enable 
identification of an appropriate name and definition for each 
theme, and to ensure that themes corresponded to the codes that 
emerged from the participants’ transcripts. 
 
Braun and Clarke (2006) express the need for researchers to make 
the theoretical framework of their study transparent. Different 
theoretical frameworks are underpinned by different assumptions 
about the data, and what it reflects in terms of ‘reality’. TA is not 
underpinned by a particular theoretical position, thus it can be used 
in conjunction with various theoretical frameworks. The present 
study’s question invites a ‘contextualist’ position, which Braun and 
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Clarke (2006) denote sits between realism and constructionism. 
Such a position, allows for the acknowledgement of individual 
experiences of participants and their personally ascribed meanings, 
recognising that the experience is “real” to the individual, whilst 
also acknowledging that experience is always the product of 
interpretation and thus constructed. Therefore, since one was 
looking at how practitioners make sense of their realities, but also 
acknowledged that their realities are inevitably socially 
constructed, this position was deemed appropriate. 
  
Ethical considerations 
Ethical approval was applied for and granted (Appendix 5) and 
steps were taken to ensure that the study met with both the BPS 
and HCPC codes of conduct. 
  
Participants were informed of the risks and benefits of partaking 
and their right to withdraw at any point, as well as where they can 
seek help should they need support during or after the study. 
Participants were required to give informed consent and did so 
prior to partaking in the study (Appendix 2). 
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Following participation, individuals were debriefed on the aims of 
the study (Appendix 3) and their confidentiality was, and will 
continue to be, maintained. All names used in the analysis of this 
study are pseudonyms.  
 
Findings 
Three master themes and seven sub-themes emerged from analysis 
(See table 1). Further, an integrative theme was observed to 
emerge. Integrative themes have previously been used in TA 
research where the theme seems to thread across themes (see, 
King, Caroll, Newton & Dornan, 2002). Including this theme 
enabled the latent tone of participants accounts to be represented.   
 
Table 1. 
Master Theme Sub-Theme 
1. Facilitation of Process 1. Increased access to and 
engagement with 
memories. 
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2. Emotional Processing 
3. Consolidation and 
Integration of experience 
2. The Therapeutic 
Relationship 
1. Openness, Trust and 
Authenticity 
2. Transference and 
Reparative relationships 
3. The Power of a 
Transcendental Experience 
1. Changes in Narrative and 
‘Meaning making’ 
2. Spiritual Connection 
N.B The Integrative theme was ‘Therapists as advocates of 
psychedelics’ 
 
Overall the data appeared to reflect that participants considered 
their experiences to have led them to see psychedelics as a useful 
adjunct to their psychotherapeutic work. They all stated that 
psychedelics appeared to “speed up” a number of therapeutic 
processes and also to give their clients a sense of “safety” during 
the therapy. This is reflected frequently throughout this analysis.  
 
Integrative theme: Therapists as advocates of psychedelics 
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The above theme was incorporated in order to capture how all 
participants seemed to use language, which suggested they hold 
strong positive attitudes towards psychedelics. Perhaps this 
indicates an underlying bias of positive attitude towards 
psychedelics within the sample. On the other hand, their strong 
expression of positivity may be a reflection of MDMA producing 
such strong benefits to the therapeutic process that this would be a 
common conclusion regardless. Such language can be seen in the 
majority of excerpts presented below. Whilst it has not been 
possible to elaborate and comment on each example, I have drawn 
attention to several occasions where this appears communicated in 
a strong way. 
 
An example of such positive language is demonstrated in Ben’s 
discussion of his transition from being perhaps hesitant about the 
benefits of psychedelics to feeling very convinced about their uses: 
 
“I think I was really converted, I remember being really sceptical, 
and then in the first session that I was in it was really clear to me 
how powerful the acceleration of the therapeutic process is.” 
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The word “really” is used twice in the above quote, perhaps this 
reflects Ben’s need to communicate the strength of positivity that 
he feels towards psychedelic and may also serve as a means of 
convincing the interviewer of this position. Moreover, the use of 
the word ‘converted’ may imply a sense of powerful change in his 
opinion and highlights his firm position regarding their uses. 
 
Another example of such a positive transition of position to 
perhaps advocate of psychedelics can be seen in the following 
extract from Natalia: 
 
“Well when you see it work, and it was the part of a double blind 
design so we supposedly did not know who was getting the real 
medicine, you could see the effects and you know when you just see 
something work. So, really I suppose that I see them as another 
useful tool to bring into the therapy room, not dissimilar to tools 
like mindfulness.” 
 
Natalia repeats himself in the above quote, regarding his 
experience of observing the substance to “work”. Perhaps the 
	 89	
function of this reiteration is his endeavour to advocate for their 
utility. Additionally, he compares them to a well-regarded and 
utilised contemporary therapeutic technique (mindfulness) (Cigolla 
& Brown, 2011) perhaps in order to further support and advocate 
for their utility therapeutically. 
 
The analysis will now be presented below, demonstrating the three 
master themes and 7 of the 8 sub-themes. Unfortunately, due to 
word-limit not all themes can be discussed here. All master themes 
will be presented but sub-theme 2, of master theme 3, will not be 
presented. A pragmatic decision was made to focus on themes 
which most closely answered the research question, and were 
particular areas of interest for CoP practice e.g psychotherapeutic 
processes and the therapeutic relationship.  
 
Master Theme: Facilitation of process 
 
The use of the psychedelic substances appeared to enable many of 
the internal processes, associated with psychotherapy, to occur. All 
participants commented that they had observed a reduction in their 
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client’s fear and anxiety levels as a result of the psychedelic, and 
suggested that this facilitated necessary internal processes to occur 
more easily and safely. 
 
Sub-theme 1. Increased access to, and engagement with, 
memories 
 
Participants spoke about how their client’s had appeared more able 
and willing to get in touch with memories associated with their 
trauma, as a result of a reduction in feelings of fear around the 
memory content following psychedelic administration. This is 
conveyed in the following excerpt from Josh: 
 
“Yes, so I think that MDMA seems to be like an ideal drug for 
people for PTSD, just because of the way that it seems to give 
people access to parts of their memories, that are very like anxiety 
provoking, and fear inducing. And because it's able to seemingly 
reduce that level of fear and anxiety, they can then go and 
approach those traumatic memories and process them with a 
feeling of safety.” 
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Here Josh explains how individuals may feel safer to engage with 
difficult memories and as a result are more able to work through 
the trauma. In terms of the integrative theme, the use of the word 
‘ideal’ perhaps suggests a strong bias. Again, perhaps such 
language implicates a position of advocacy for the drug. Matt 
appears to have had a similar experience when working with 
individuals under the influence of a psychedelic substance, this is 
reflected in the following statements: 
 
“There is some percentage of people where CBT does not achieve 
the desired effects and usually for reasons to do with not engaging 
with the full memory. I think that MDMA facilitates that further. If 
we believe that people who are treatment resistant to PTSD are not 
really allowing themselves to touch on the traumatic memory, that 
they are doing so only in a very superficial way, then the way I 
understand MDMA is that it seems to relax the person and this 
helps you to touch the things which felt quite threatening to look at 
before. If you are enabled to touch those memories you can then do 
the processing. So it's the MDMA which allows access to the 
memory material which then can be processed.” 
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Again Matt comments on the psychedelic enabling the individual 
to engage with their traumatic experiences without feeling too 
afraid, and as a result processing them with more ease. He explains 
that he feels that often individuals, who have not been successful in 
his therapy, where he uses CBT alone, were not able or prepared to 
approach such memories because of feelings of fear. His 
comparison of CBT with and without psychedelics supports one’s 
understanding that he deems the psychedelic to be the mediating 
factor. Helen refers to a similar experience of working with 
trauma: 
 
“And you know sometimes when you are working with trauma; the 
main issue is that the person is hyper-vigilant. It is really difficult 
to even work on trauma because you are just having to regulate 
people to stay out of that hyper-aroused state. And what I saw with 
the MDMA is, that it helps to decrease activity, so it seems to 
decrease the fear response. And then people are so much more 
able to access trauma and talk about it from a place, rather than 
going into a state of dissociation, and so it is almost too good to be 
true. But what we are finding is that years after the study results 
are still holding.” 
	 93	
 
Again, in line with the integrative theme, in the above example the 
term “almost too good to be true” perhaps implies a sense that 
Helen feels slightly sceptical about her own powerfully positive 
experience. However, perhaps what follows this comment is a 
defence of her own questioning. Indeed her discussing later “study 
results” gives the sense that it is important for her to corroborate 
her experience of them as very positive. Such defending may 
implicate a desire for Helen to convince or advocate for 
psychedelic uses, despite her acknowledgment of the positive 
effects she observed seeming somewhat unbelievable to her. 
 
Josh appears to share a similar experience to Helen with regards to 
his observation of access to memories being facilitated as a result 
of a decrease in dissociation:  
 
“During the experience she was constantly having waves of 
memory sort of coming to her, and very often with this patient it 
would be new memories, things that she hadn't experienced or 
remembered in the past. She had a very strong predisposition to 
dissociation and so I think that was what usually happened to her, 
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any time she would approach some of this information she would 
dissociate and not deal with it, and then under the MDMA and that 
lessening in the fear, like she wasn't dissociating, and so all of a 
sudden all these memories are coming back.” 
 
In the below example, Ben acknowledges how he found the 
MDMA to enable the individual to engage with the emotions that 
are associated with their memory. He reports that as a result his 
clients seemed more able to process their experiences. Indeed, in 
Ben’s experience the particular utility of the psychedelic was that it 
enabled individuals to connect the memory with the corresponding 
emotion. 
 
“The MDMA shifts people to the emotional quality of a memory 
that they can do much better than they can do without it.” 
 
In the above example Ben’s use of the words “much better” to 
discuss what can be achieved with and without MDMA perhaps 
reflects a strong positive attitude towards the drug and again may 
aligns to a sense of advocacy in participants’ narratives. 
	 95	
 
Sub-theme 2. Emotional processing  
 
Participants discussed how their client’s seemed to become more 
‘in touch’ with their emotions when under the influence of the 
psychedelic substance, and in the sessions that followed.  For 
example, this is reflected in the following two excerpts from Dan: 
 
“Generally speaking one of the things that I saw a lot of, 
especially in men but also women, is increased emotional 
openness. That is one thing that people talk a lot about, during and 
after their experience, that they feel more sensitive to their 
emotions and the people around them” 
 
Dan goes on to say: 
 
“…I think mostly psychotherapy is done when people are at their 
cognitive, or intellectual level, people are talking about and 
thinking about things. Sometimes you may get someone, you know, 
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to slow down and feel or be emotional. But basically, the 
emotional part can be very challenging to reach when we are 
sitting and talking to someone, because often when we sit and talk 
it's an intellectual exercise. But I think when they have the 
psychedelic they are more able and allowing of their feelings and 
emotions and even afterwards the person is more open to you and 
more able to sometimes go back to those kinds of emotional or 
other known difficult places and revisit them.” 
 
In the above statements Dan suggests that clients were more 
emotionally available during their psychedelic sessions, he finds 
this to enable the psychotherapeutic process not only during the 
session but afterwards in following sessions as well, commenting 
that the individual appeared more able to return to such states. He 
notes this as a marked difference in his experience of 
psychotherapy without the use of a psychedelic and with.  
 
In line with the integrative theme, there appears a difference in the 
language surrounding how Dan talks of psychotherapy in the 
absence of psychedelics when compared with. Indeed he uses the 
word “sometimes” and “ very challenging” when talking about 
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psychotherapy alone, perhaps implying a negativity or frustration 
towards this practice. In contrast, Dan repeatedly uses the term 
“more” in a positive manner when discussing psychotherapy with 
psychedelics. Again his distinct difference in tone when discussing 
the two forms of therapy may indicate a desire to advocate for 
psychedelic psychotherapy above other therapies. 
 
Matt appears to have observed similar responses in his clients 
when using the psychedelic, as reflected in the following: 
 
“There is a big difference in my understanding between the use of 
SSRIs and the use of MDMA, SSRIS are all about reducing the 
symptoms, and that's it nothing changes. MDMA actually 
facilitates healing and recovery through the experiencing and 
processing of emotions.” 
 
Here he explains how in his experience, in contrast with 
medication such as SSRIS, the psychedelic appeared to enable his 
clients to get in touch with their feelings allowing emotional 
processing.  
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Helen’s experiences seem to support these observations: 
 
“The things I was surprised about were the speed, you know, at 
which people progressed and the access that they had to their 
vulnerability and emotions.” 
 
Here we possibly see again the overarching observation of 
participants, in terms of ‘speed’. Helen appears to have found that 
the psychedelic substances accelerated her clients’ ability to be in 
touch with their feelings and vulnerability. 
 
 
Sub-theme 3. Consolidation and integration of the experience 
 
Whilst all participants appeared to speak positively of the speed at 
which individuals were able to connect with their memories and 
emotions, there was also a lot of acknowledgement of the 
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difficulties that it could cause for the integration process of the 
experience. Indeed, participants seemed to talk about how it could 
be difficult for clients to continue to hold their experiences of the 
psychedelic sessions in mind, and use the experience to positive 
affect moving forwards. Also, participants discussed how it 
appeared difficult for individuals to make sense of, and manage, 
the material that emerged from their psychedelic sessions as a 
result of the speed at which it was accessed.. This appears to be 
reflected in the following statement from Ben: 
 
“I think the most difficult thing for people is to integrate changes 
that happen so quickly, because the change happens so fast that 
the brain has to catch up.” 
 
A very similar statement was made by Mary: 
 
“The downside is that, because it is so fast, it is also pretty 
shocking, and so it can be a little difficult to integrate. And there's 
a sense of feeling like “oh no I'm going to lose the connection I 
made, I'm going to lose it because now I don't have the influence of 
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M.D.M.A…I think that it is hard you know when you do something 
so fast and there is such drastic change that happens, it can be 
pretty difficult to integrate so fast. So, like in regular session 
because things move so slowly, so that’s the drawback. So it goes 
so slowly that the integration process is really just kind of like 
automatically there because it’s just such small steps, you know, so 
it can take years to do the same thing.” 
 
In the above excerpt Mary seems to talk about individuals 
struggling to deal with the speed at which the experience occurs, 
referring to how it can be ‘shocking’. We also see here that she 
appears to note the difficulties that clients experience, in terms of 
consolidation, as a result of speed, due to expressing feeling 
anxious about losing the positive benefits that they had reaped 
from the psychedelic session.  
 
Mary compares the differences between psychotherapy with and 
without the use of the psychedelic, commenting that in 
psychotherapy without the psychedelic, difficulties with 
integration do not present themselves as such a problem. She 
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appears to recognise this to be due to the pace being slower and 
therefore happening more naturally. 
 
In addition, Josh seemed to talk about the importance of the 
individual being offered the opportunity to process the experience 
during personal therapy, following the psychedelic experience. 
Earlier in this report we saw him speak positively of the way in 
which he felt psychedelics enabled individuals to access elements 
of their minds, however below he appears to think that there are 
difficulties in doing so and suggests that psychotherapy is 
particularly important after the experience: 
 
“If people don’t have their own therapist to go back to they may be 
left high and dry with a lot of new stuff to process. I think that the 
hope was that the processing part of it all would go quickly, just 
like the other parts, like building quick relationships, trust and 
openness you know, but processing the trauma seems to take a 
long time.” 
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Master theme: The Therapeutic Relationship 
All participants appeared to speak of the psychedelic 
psychotherapy sessions as enhancing their therapeutic alliance with 
clients. This is reflected in a number of statements, for example 
Matt said: 
 
“In most cases it certainly added to the therapeutic alliance” 
 
In Matt’s example perhaps the use of the word “certainly” reflects 
the strength of his positive attitude towards using psychedelics and 
may serve to persuade others of their benefits.  
 
Dan reports observing similar responses to the psychedelic assisted 
sessions, explaining that the therapeutic relationship felt stronger 
during and following those sessions. 
 
“So, it enhances the therapeutic alliance. Well, I mean that's what 
I noticed, when the drug is administered and after those sessions 
usually people feel closer to the therapist.” 
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Sub-theme 1. Trust, openness and authenticity 
All participants appeared to recall experiencing trust and openness 
to have been enhanced within their relationship with clients both 
during the psychedelic assisted session and in the sessions that 
followed. This is perhaps reflected in the following comment from 
Helen: 
 
“Sometimes it can take forever for the clients to really open up to 
the therapist. The rapport is so important in the healing process. In 
the beginning there was sort of a questioning or a discomfort, just 
like how it is normally in any therapeutic situation really. And then 
after MDMA sessions, just more and more increased comfort, 
more eye contact, more revealing of themselves, more able to ask 
for support. People with trauma often experience difficulties in 
asking outside people for support because of the lack of trust, even 
simple things like ‘could you get me a tissue, or can u get me some 
water’.” 
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Here Helen seems to explain how she observed clients being more 
able and comfortable to speak openly and honestly about their 
needs from others and her as the therapist. She compares how prior 
to the MDMA sessions clients seemed to be similar in their ability 
to trust the therapist to that which she had experienced during her 
therapy practice in the absence of psychedelics, but that there was 
a significant difference in their style of relating after the 
psychedelic.  
 
Similar to the example given of the integrative theme above, Helen 
appears to use strong language to distinguish between her 
experiences of psychotherapy with and without psychedelics. She 
explains how she has experienced it to take “forever” at times for 
clients to open up. Whereas after the administering of the MDMA 
she talks about how this is starkly different using the words like 
“more” repeatedly to describe clients’ abilities to interact Again 
perhaps this reflects a need to advocate for their uses and suggests 
a powerful positive attitude.  
 
Josh seems to go on to support this observation of perhaps more 
authenticity and openness in clients as a result of the MDMA 
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session. Like Helen, he talks of observing a distinct difference 
between his experiences of working psychotherapeutically with 
individuals in the absence of the psychedelic and with it: 
 
“I worked with one patient for so many months, and at the end of 
so many months she would still tell me “actually, I wasn't honest 
and open with you last week or at our last session”, and it's hard 
because you've worked together for months, you are hoping that at 
that stage you've shown yourself to be trustworthy as a therapist. 
And still you are hearing from the patient that they’re telling you 
part truth or lies. And with the MDMA therapy people would 
sometimes opt not to tell you things but they would usually say “I 
am experiencing something and am just not ready to talk about it”. 
But then in that case you know something is happening, and there 
is usually a good chance that they would want to go back and 
explore it with you later. Yes, it was very dramatic the difference in 
being able to interact and relate with people on MDMA.” 
 
In the above exchange, Josh appears to articulate his frustrations 
about the pace at which individuals are able to trust him as a 
therapist during psychotherapy without the psychedelic. He reports 
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a different experience when working with individuals under the 
influence of a psychedelic, stating that they were more open, 
particularly in terms of what they were not saying during sessions. 
 
Similarly, Mary appeared to observe a reduction in clients’ fear 
surrounding what they should talk about and how they should act. 
This again perhaps marks an example of the increased sense of 
safety that is seen throughout all participant’s experiences. Mary 
observed that her clients seemed less concerned with their 
therapist’s opinions of them, and therefore were more able to be 
authentic. Also of note in the following excerpt is Mary’s 
observation that this positive change in style of relating, to a large 
extent, continues in the sessions that follow: 
 
“They are not… there isn’t that questioning so much about what to 
say, what to do, what is my therapists going to think about me, 
should I say this, should I not say this. They become much more 
comfortable with asking for what they need. They are able to ask 
you for things that normally they would not ask you like if they… 
even simple things when they're in preparatory session if they want 
a glass of water, they might not ask… whereas the treatment 
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session, they are actually pretty needy.  And that change is usually 
very sustained in the sessions that follow.” 
 
Interestingly, in the excerpts of Mary and Helen above, they both 
use the same example of the “glass of water”, perhaps this reflects 
a dominant group narrative amongst therapists and may further 
imply a positive bias or sense of need for advocacy across the 
sample. 
 
Participants appeared to feel that the psychedelics facilitated the 
Trust, openness and honesty of clients during the psychotherapy. 
Ben talks about this in terms of increased ‘trust’: 
 
“I sense the MDMA really does accelerate the development of 
trust. I'm kind of basing it on the fact that we have three 
preliminary sessions. In those 3 sessions it feels like the first three 
sessions of any psychotherapy and then the next 3 sessions after 
the first MDMA session are really different on the level of trust. 
It’s just really clear to me how the psychotherapy and the 
relationship are essential to the MDMA process.” 
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Here, Ben explains how he observed distinct differences in the way 
clients engaged with the therapeutic relationship before and after 
the psychedelic session, in terms of their trust for the therapist. He 
discusses how he feels that the drug and the psychotherapy are an 
important combination. Josh’s experience may support what Ben 
suggests about the importance of the combination of the 
psychedelic in conjunction with the psychotherapy: 
 
Josh:…well I think it was both the MDMA and the psychotherapy 
together, but I do think that it was the MDMA that allowed us to 
discuss those things openly.” 
 
Sub theme 2. Transference and ‘reparative’ experiences 
Four participants talked in terms of ‘transference’ with regards to 
what they witnessed when individuals were under the influence of 
the psychedelic substance. Transference is most widely recognised 
in a psychodynamic theoretical context and was first coined by 
Freud when describing clients experiencing their therapist as 
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having qualities that reflect those of prominent people in their 
childhood (Freud, 1905).  
 
Here participants discussed how they felt that the psychedelic 
facilitated insight into, and processing of, transference 
relationships. For example, in the next example Ben discusses how 
he felt that the MDMA facilitated the processing of transference as 
a result of the client noticing the way in which their early 
experiences influenced how they approached their present life. 
 
“I felt like it was really important for people, especially with an 
early trauma, to be able to see, with the support of MDMA, that the 
lenses that they see people through are coloured by earlier 
experiences of their relationships with their parents.” 
 
In the following excerpt Josh is talking about an example where 
one of his clients was experiencing transference of him as her 
father, due to some unavoidable incidences of lateness on his part 
during the therapy. He notes how what felt enabling about the 
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psychedelic was the individual’s ability to raise the issue with him 
and talk about the feelings that were aroused for her as a result: 
 
“My schedule was extremely busy while I was participating in the 
study, and so with one of the subjects there was an occasion where 
I ran late, you know like very unavoidably, but it did bother the 
patient a lot and I think she found that she was reacting to me very 
negatively because of that. I think that part of it is she had felt that 
her trust was betrayed, and that she was let down by her Dad 
growing up, so that’s who I was representing to her, and what I 
think the MDMA did was it allowed her to bring it up, what I 
suspect is that if she hadn’t taken the MDMA she wouldn’t have 
mentioned it and would've just kind of ignored it even though she 
was feeling emotions based on that…” 
 
Mary’s words support Josh’s experience of the substance being 
useful in assisting clients in processing of transference. 
 
“You know they were really able to have corrective experiences. 
The treatment really lends itself to have transference of mother and 
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father. Even if the therapists are younger, there is that sense of like 
you are his mum and dad, and because of how the MDMA helps 
with the trust from there you see the person really heal and process 
that transference stuff, so in that way it offers a corrective 
experience. For instance, like they often have a transference with 
me as a mother, and like because of the increased sense of safety 
one guy, who was really shy and reserved, like he felt a lot of 
shame, actually asked if I could give him a hug and stroke his 
head. And so we could then talk about that. And in the somatic 
style of therapy that I was working with then they can actually 
have that experience. And so this corrective experience allows 
them to trust a bit more and move beyond those old stuck ways of 
interacting with their world.” 
 
Here Mary articulates that she feels that where clients are 
experiencing the therapist as a parental figure the psychedelic can 
facilitate the processing of this. She explains that she understands 
this to be a result again of the substance enabling the individual to 
feel trusting and safe enough to do so. Mary suggests that, 
similarly to Josh’s observations, in her experience the client was 
more able to express when they were having a transference 
experience and furthermore to make their needs known to her. 
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Major Theme:  The power of a ‘transcendental’ experience  
Here, the theme refers to the impact that the psychedelic 
experience has on the client’s relationship to their wider context. 
Participants appear to consider that clients experience a connection 
with something ‘larger than themselves’ and that this enables them 
to broaden or change their perspective. One gets the impression 
that, in a metaphorical sense, the client’s horizons are widened 
from the experience.  
 
It is of note that some participants commented that it is difficult for 
them to describe or articulate what they observed, regarding this 
matter, as a result of the limitations of language. For example, in 
the following statement Josh is discussing his observations of the 
client experiencing what he terms a “transcendental” experience, 
and he explains the limitations of language regarding this subject:  
 
“It is such an interesting area of English because I don't think we 
really have the vocabulary for it.” 
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Sub-theme 1. Changing of narrative  
Some of the participants reported noticing individuals shift in the 
way that they made sense of themselves, in relation to their 
experiences of trauma, as result of the psychedelic enabling them 
to perhaps ‘zoom out’ on their experiences. They discuss how 
there appeared to be a change in their clients’ narratives as a 
result.  
 
In Ben’s comment below he talks about how individuals are able to 
engage with their trauma during the psychedelic session, and to 
make sense of how it impacted their development and growth in a 
meaningful way. He explains how they reach this position of, 
acceptance, perhaps as a result of them meeting themselves with 
more compassion. He comments that clients experience a “moment 
of enlightenment” and explains how it appears to have 
a “spiritual” context. This supports participants’ sense that 
individuals have a useful transcendental experience during the 
psychedelic sessions. He notes how he feels the positive function 
of this experience for the client is that they move from a position 
of seeing themselves as a “victim”, suggesting a change or 
movement in their personal narrative around their life experiences. 
Finally, he also distinguishes between how this shift often appears 
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to occur with ease during the psychedelic sessions, contrasting 
with just psychotherapy: 
 
“Inside the session people go to the scene of the crime, they speak 
of the trauma and they really can see it from a much broader 
perspective, a lot of times it is being more compassionate to 
themselves and understanding that they needed to go through what 
they went through in order to grow up and change. Like they have 
this, this kind of moment of enlightenment, where they realise it 
was something that they needed to experience to learn what they 
needed to. So this like spiritual dimension of understanding comes 
through pretty easily, it really moves them from their victim 
perspective of “something was taken from me and I’ll never be the 
same” that kind of perspective changes with the MDMA session. 
So people work in years of therapy to come to a place of 
acceptance about what happened to them and a lot of people I 
have worked with never get there after too many years of therapy.” 
 
Helen again comments on this observation of an expansion of 
awareness and a “spiritual” experience, suggesting a 
transcendental component to the psychedelic experience. 
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Moreover, she gives the impression that the function of this 
expansion of awareness is to facilitate the clients’ ‘meaning 
making’, and relationship to the wider context of their life. This is 
implicated in the types of questions that Helen suggests come up 
for individuals under the influence of MDMA. They appear to 
have an existential context to them, and to encourage the 
individual to think about the greater meaning to their existence. 
Moreover, this excerpt supports much of Ben’s observations, in 
terms of the client making sense of their trauma and inviting it to 
be a part of themselves that they can tolerate and show gratitude 
for. She again, like Ben, talks about how she noticed clients reach 
a place where they no longer engage with the world from a 
position of feeling a “victim” but instead recognise the trauma as 
an experience that is valuable to them. 
 
“Psychedelics can really expand our awareness people have like a, 
sort of a, spiritual experience. Sometimes the questions that come 
up for people in MDMA sessions can be like ‘What is my purpose 
in life and how can I get that back?”, like really, “What is the 
point of my life”. Somehow they move from seeing their trauma 
story as this horrible, terrible thing that they will never get over, to 
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actually an essential part of their identity of their life and who they 
are” 
 
Discussion 
Research findings 
Here, the therapists’ experiences of the impact of psychedelics on 
the psychotherapeutic process are explored. Overall therapists 
acknowledged that using psychedelic substances enabled the 
psychotherapeutic process. The accounts supported the notion that 
psychedelic-substance-mediated-psychotherapy occurs at an 
accelerated pace whilst offering clients a sense of “safety” in the 
process. Such experiences support Mithoefer et al’s. (2016) review 
into psychedelic psychotherapy, where it is speculated that 
psychedelics facilitate psychotherapy in various ways, including a 
“decrease in avoidance and defensiveness accompanied by clearer 
memory of past events”. This theme emerged in sub-theme 
‘Increased access to, and engagement with, memories’. Indeed, 
therapists reported that individuals no longer dissociated when 
approaching difficult memories. 
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However, therapists’ accounts also reflect that acceleration creates 
difficulties in the therapeutic process, including consolidation and 
integration of the experience. Indeed, the accounts convey the 
importance of sufficient psychotherapy being offered to clients so 
that adequate time for processing material evoked is ensured. 
These reports support the literature presented earlier regarding 
concerns about the impact of expediting the accessing of difficult 
memories. It raises concerns regarding unprocessed material 
remaining with clients beyond this therapeutic experience. Perhaps 
the therapists’ accounts imply a need for further research to 
develop a more specialised therapeutic model when utilising 
psychedelics in psychotherapy. 
  
A limitation of the current study is highlighted in terms of the 
range of psychotherapeutic approaches deployed by therapists. 
Conversely, whilst only a preliminary study with a small sample 
size, one must consider the study where MDMA was administered 
to individuals who met the criteria for a diagnosis of ‘treatment-
resistant’ PTSD. This study, demonstrating symptom reduction at a 
3.5 year follow up, suggests that treatment does enable some form 
of experiential integration. However, this study, positivist in its 
epistemology, did not allow for participants’ experiences to be 
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explored and it is difficult to conclude whether, despite the 
quantifiable reduction in their symptoms, participants found it to 
be a therapeutic experience. This point exemplifies an important 
distinction between symptom reduction and qualitative experience 
and needs further exploration in research. 
  
The acceleration of psychedelic-mediated-psychotherapy creates 
potential opportunities for attending to important issues such as 
lengthy waiting lists in mental health services. However, issues 
relating to consolidation and integration of this powerful 
experience, under condensed treatment conditions, necessarily 
brings into question issues of ethically ‘best practice’ for 
clients.  Whilst, in line with IAPT, it might support clients going 
back to work and symptom reduction, in line with IAPT’s 
motivation, it does not necessarily implicate that clients’ sense of 
‘well-being’ is improved. Further exploration of the 
phenomenological experience of individuals undergoing this 
treatment would invite more understanding of how more intensive 
therapies impact individuals. This may assist in attending to overall 
efficacy of such treatments, and perhaps wider discourses 
regarding what one hopes to achieve with psychotherapy and 
associated need socio-economically for speed of recovery. 
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Implications for psychotherapy 
The analysis suggests that participants believe psychedelics can 
enhance psychotherapy. Hammersely and Beeley (2006) note how, 
due to the client's unwillingness to revisit traumatic memories, or 
experience difficult emotions, clients and therapists may become 
‘stuck’ during a course of psychotherapy. Due to a reduction in 
feelings of fear and anxiety and consequential experiences of 
“safety” during therapy, clients appear more able to revisit, and 
engage with, traumatic memories and to process associated 
emotions accordingly. Psychedelic psychotherapy may therefore 
help to mitigate the feelings of being ‘stuck’. 
 
Perhaps the above raises interesting questions regarding the 
purpose of psychotherapy in relation to whether feelings of 
‘unsafety’ and ‘stuckness’ invoked in therapy are worthwhile 
and/or beneficial. On the one hand, perhaps important 
interpersonal skills develop during the slow process of forming a 
relationship and moving from feeling unsafe towards a sense of 
safety in the psychotherapy.  Psychedelic mediated inhibition of 
such processes may not necessarily represent long term benefit for 
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the client. Conversely, it should be remembered that the therapists 
here were working with individuals considered as ‘treatment-
resistant’ prior to engaging with the psychedelic psychotherapy, 
thus suggesting that it was very challenging for them to make use 
of the psychotherapy when feeling unsafe, thus perhaps the 
facilitation of safety is necessary in enabling them to use the space 
optimally. Accordingly, further research looking at which client 
groups may benefit most from psychedelic psychotherapy is 
warranted.  
  
In line with the speculative remarks in Mithoefer et al.’s (2016) 
review, all participants here supported the notion that psychedelics 
may enable the psychodynamic concepts of ‘transference’ and 
‘reparative experiences’ to occur. Working with, understanding 
and processing transference in the therapeutic relationship is 
accepted as a fundamental aspect of psychoanalytic practice. 
Fonagy (1991) explains that the way in which therapists 
experience clients through the transferential relationship enables 
them to gain useful insight into their internal working models and 
to work with clients to understand and process earliest experiences. 
Here, work was acknowledged to be achieved more readily 
following individuals having been administered the substance. 
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Therefore, this study supports that, in terms of psychodynamic 
practice, the psychedelic substance facilitates a key area of the 
work. 
 
Continuing with the participants’ comments that transference 
processes were supported in their experience, an absence of 
discussion of ‘negative transference’ is noteworthy in participants’ 
accounts. Negative transference, or ‘rupture in relationship’ from a 
humanistic perspective, is accepted to be an important aspect of the 
psychotherapeutic process. It is interesting to consider whether the 
sense of connection, warmth and safety that participants reported 
their clients experiencing inhibits the opportunity for important 
feelings of anger and hostility to be evoked and 
processed.  Moreover, perhaps this reflects participants’ agenda to 
present positive experiences as a means of promoting the benefits 
of psychedelics. Indeed, the integrative theme of “Psychotherapists 
as advocates of psychedelics” gives the impression that it is 
perhaps important for participants to report positive aspects of 
psychedelics and, thus potentially overlook parts of therapy that 
are more challenging, but arguably of equal benefit in the 
psychotherapeutic process, such as tension in the relationship. 
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In terms of the theme ‘The power of a ‘transcendental’ 
experience’, participants imply that this element of the 
psychotherapy is very introspective and that insight is perhaps 
gained through the psychedelic facilitating an expansion of the 
client’s consciousness and subsequent changes in the way that they 
relate to, or see themselves. Such introspection raises questions 
about what is facilitating change in the client; i.e. perhaps 
introspection occurs as a function of the psychedelic, even in the 
absence of the psychotherapy. Nonetheless, participants’ accounts 
indicate the importance of the combination: “It’s just really clear 
to me how the psychotherapy and the relationship are essential to 
the MDMA process.” and “well I think it was both the MDMA and 
the psychotherapy together, but I do think that it was the MDMA 
that allowed us to discuss those things openly.”  It may be difficult 
to disentangle with precision the cause of shift for the client. 
Further research looking at the seemingly powerful 
phenomenology of such experiences may further shed light on 
such matters. 
  
A treatment where psychiatry and psychotherapy complement 
each other further? 
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Overall, participants’ accounts suggest that they find psychedelics 
to offer an effective adjunct to psychotherapy. Furthermore, the 
findings provide a contribution to an existing dialogue surrounding 
the limitations of currently available psychotropic prescriptions, 
which have been said to create obstacles for psychotherapy 
(Hammersley & Beeley, 2006). In contrast to current prescriptions, 
which have been considered by psychotherapists to inhibit the 
therapeutic process, participants here report experiencing 
psychedelics to enhance their psychotherapeutic practice. This is 
reflected in the master themes ‘Facilitation of process’ and ‘The 
therapeutic relationship’. In contrast to how Hammersley & 
Beeley's (2006) discussion of how anti-depressants often create 
problems in terms of individuals being unable to get in touch with 
their emotions - an essential part of psychotherapy - the current 
analysis suggests that participants experienced psychedelics as 
complementary to their clients’ getting in touch with their 
emotions. Indeed participants suggest that perhaps this is achieved 
even more readily than when clients are not under the influence of 
any substances at all. Furthermore, the present analysis suggests 
that therapists experienced psychedelics to facilitate the therapeutic 
relationship and enable individuals to feel more comfortable with 
their therapists. Extensive research demonstrates the therapeutic 
relationship to be the main indicator of successful psychotherapy, 
	 124	
above any particular treatment model (Ardito, 2011). Given CoP’s 
commitment to the therapeutic relationship, this is an area of 
psychedelic research that warrants further research. 
  
Limitations 
Given the personal and professional investment demonstrated by 
the therapist here it may be argued that the participants had a 
positive bias towards the use of psychedelics as an adjunct to 
psychotherapy. However, I formed the impression that this was 
mitigated somewhat by the depth of participants’ accounts. Indeed, 
participants shared both the strengths and the weaknesses that they 
perceived of this treatment model. This is particularly apparent in 
the instance of the theme of ‘Consolidation and integration of the 
experience’ wherein participants reported problems that they felt 
were associated with the way psychedelics accelerate 
psychotherapeutic process to occur.  
  
A further limitation is in the lack of parity across therapist 
orientations. For example, some therapists reported using ‘somatic’ 
techniques in their work, whereas others did not. A lack of 
commonality creates complications in terms of determining the 
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positive impacts attributable to the psychedelic and the outcome of 
specific therapeutic technique. To some extent this was 
compensated for in the interview schedule seeking to tap into 
therapists’ personal comparisons of their own practice with and 
without the psychedelic. In addition, questions relating to how the 
participants responded in therapy before, during and after the 
psychedelic session attended to this. Future research attending 
more specifically to psychedelic use as an adjunct to particular 
therapeutic modalities may further elucidate which processes are 
facilitated by each model and whether psychedelics lend 
themselves to particular therapeutic models or clients above others. 
Indeed, the present findings’ themes seem to align to a range of 
modalities. To give brief examples, one can see benefits to CBT in 
terms of exposure work for PTSD, with regard to the theme of 
‘increased access to and engagement with memories’. Moreover, 
with regards to psychodynamic therapy, reference is made to 
psychedelics supporting working with ‘transference’ and 
‘reparative experiences’ of early experiences, and finally there is 
reference to components of existential practice with regard to 
discussions of ‘meaning making’ and ‘broadening of 
perspectives/horizons’ which can be seen in the theme of ‘The 
power of a ‘transcendental’ experience’.  
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Conclusion 
Participants’ accounts in the present study support and strengthen 
research that has illuminated psychedelics as a promising adjunct 
to psychotherapy. Research to date is at the preliminary stage and 
further studies are needed prior to reaching strong conclusions. 
This requirement acquires salience in relation to therapists’ 
difficult experiences of the rapid acceleration of the 
psychotherapeutic processes. It therefore seems important to carry 
out further qualitative research exploring the lived experience of 
clients who have undergone psychedelic psychotherapy. In doing 
so, a better understanding of the experience of the treatment and 
how such acceleration of processes feel for the individual may 
emerge. This is particularly important given the current socio-
economic needs within the mental health sector. 
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Appendix 1. 
 
Information Sheet 
 
Full study title: What is the rationale for using psychedelics as an adjunct to 
psychotherapy: A thematic analysis of qualitative interviews with practitioners who 
have delivered psychedelic assisted psychotherapy. 
 
Dear participant, 
 
I am a trainee counselling  psychologist at the University of Surrey and I would like to 
invite you to take part in a study that I am conducting. 
 
What is the purpose of the study? 
The study I am conduction aims to explore what practitioners rationales are for using 
psychedelics to assist in psychotherapy. I would be grateful if you would read the 
information sheet provided in order for you to be informed about what participation 
would involve.  
 
Taking part 
Taking part in the study will involve being asked to attend a 45-60 minute interview that 
will be recorded. In this interview you will be asked a number of open questions about 
your views on using psychedelics as an adjunct to psychotherapy, and your experience of 
working with individuals when they are under the influence of a psychedelic.  
 
Are there possible disadvantages to taking part? 
During or after participating in this study it is possible that you may feel upset as a result 
of the material that is discussed. If the interview does upset you in some way you are 
encouraged to seek help from… You will lso be given breaks during the interview if you 
should wish to. 
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What if there is a problem? 
If you would like to complain about any area of the study you may contact the researcher. 
You can also contact Dr Stelios Gkouskos, the supervisor of the 
project  (s.gkouskos@surrey.ac.uk). 
 
Who has reviewed the study? 
The University of Surrey Faculty of health and medical sciences ethics committee has 
ethically approved this study.   
 
Will all information shared be confidential and secure? 
Interview are to be recorded using a Dictaphone and then transcribed onto a password 
secure document. The information you share will be kept strictly confidential. Only the 
researcher and the researcher’s supervisor Dr. Stelios Gkouskos will have access to the 
information. When the project is complete all data and personal information collected 
will be destroyed. In the write up of the research all identifiable information will be 
changed in order to protect participant confidentiality.  
 
Decision regarding whether to take part in the study 
If you were to take part in this study you would be invited to set up a date and time that 
was convenient for you and the researcher to complete the interview. The interview 
would take place in a safe, quiet and neutral location that invites you to talk freely about 
your experience. Please note that participation in this study is voluntary and you are free 
to decline to participate. In addition should you partake in the study you are free to leave 
the study at any time. 
 
Yours sincerely, 
 
Michelle Ruger 
Counselling Psychologist in training 
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Researcher contact details: 
Michelle Ruger, email: m.ruger@surrey.ac.uk 
 
Supervisor 
Dr. Stelios Gkouskos, s.gkouskos@surrey.ac.uk 
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Appendix 2. 
 
Consent Form 
 
Study Title: What is the rationale for using psychedelics as an adjunct to 
psychotherapy: A thematic analysis of qualitative interviews with practitioners who 
have delivered psychedelic assisted psychotherapy 
 
● I confirm that I have read and understood the information sheet/letter of invitation 
for this study.  
 
● I have been informed of the purpose, risks, and benefits of taking part.  
 
● I understand what my involvement will entail and any questions have been 
answered to my satisfaction.  
 
● I understand that my participation is entirely voluntary, and that I can withdraw at 
any time without prejudice.  
 
● I understand that all information obtained will be confidential.  
 
● I agree that research data gathered for the study may be published provided that I 
cannot be identified as a subject. 
 
● Contact information has been provided should I (a) wish to seek further 
information from the investigator at any time for purposes of clarification (b) wish 
to make a complaint.  
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       Participant’s Signature---------------------------------------------------------------------------
-- 
 
       Date ------------------------------------------------------------------------------------------------
-- 
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Appendix 3 
 
Debrief Form 
Study Title: What is the rationale for using psychedelics as an adjunct to 
psychotherapy: A thematic analysis of qualitative interviews with practitioners who 
have delivered psychedelic psychotherapy 
Dear participant, 
 
Thank you for participating in this research.  
 
This study looked to what practitioners rationales are for working with individuals when 
they are under the influence of a psychedelic substance. In addition, it hoped to elucidate 
more understanding of the types of psychological processes which can be facilitated 
when using psychedelic as an adjunct to psychotherapy. The rationale for this study was 
that recent research has shown that psychedelics can act as a beneficial adjunct to 
psychotherapy and so it is possible that practitioners may be required to practice under 
these conditions in the future. To date no research has explored what practitioners 
rationales are and furthermore what psychological processes are facilitated in psychedelic 
assisted psychotherapy. Therefore this study is seeking to understand this better. It is 
hoped that the research will enable a better understanding of the rationale behind 
psychedelic assisted psychotherapy and the psychological processes that are facilitated by 
the substances. If you have any further questions regarding this study please do not 
hesitate to contact the researcher. 
 
As previously mentioned it is possible that partaking in this research may have evoked 
some difficult feelings or left you feeling in some way negatively effected. If you feel 
that you would like psychological support please contact  
 
Yours sincerely, 
 
Michelle Ruger 
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Researcher contact details: 
Michelle Ruger, email: m.ruger@surrey.ac.uk 
 
Supervisor 
Dr. Stelios Gkouskos, email: s.gkouskos@surrey.ac.uk 
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Appendix 4 
 
Project Title: What is the rationale for using psychedelics as an adjunct to 
psychotherapy: A thematic analysis of qualitative interviews with practitioners who 
have delivered psychedelic assisted psychotherapy 
 
Interview Schedule 
 
1. Can you explain your rationale for using psychedelics as an adjunct 
to    psychotherapy?  
Prompts: personal clinical experience, research evidence base, what mode of 
psychotherapy 
 
2.In your experience do you think psychedelics facilitate the psychotherapeutic process 
and how?  
Prompts: Strengthening therapeutic alliance, increased self-reflective capacity, reduced 
anxiety, types of psychological processes that are facilitated 
 
3.Can you describe your experience of working with an individual when they are under 
the influence of a psychedelic?  
Prompts: different from psychotherapy without psychedelics, relationship between you 
and the client.  
  
4.Can you describe the differences that you observed in the same patient in sessions 
before, during and after they had been administered a psychedelics?   
Prompts: More open, increased self awareness, motivated, spirituality, increased 
cognitive flexibility 
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Year 3 Empirical Study: 
An Interpretative Phenomenological Analysis of MDMA 
assisted psychotherapy for PTSD.   
Abstract  
Methylenedioxymethamfetamine (MDMA), is demonstrating 
encouraging results as an adjunct to psychotherapeutic practice in 
the treatment of PTSD, following a surge of empirical research 
over the last 10 years.  
  
Method: Individuals who had participated in a clinical trial 
wherein they were administered MDMA for treatment resistant 
PTSD were interviewed to explore the lived experience of MDMA 
assisted psychotherapy.  
  
Results: 3 clear superordinate themes emerged from the analysis: 
1) Existential freedom 2) Beyond the Cartesian-split and 3) A 
journey through time 
  
Conclusions: Participants conveyed that they found the experience 
to be powerful and transformative in terms of their relationship to 
themselves, others and the world. Proposals are made for future 
research to be conducted into the psychological models that might 
be best suited for this treatment.  
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INTRODUCTION  
Antipsychotics, anxiolytics and antidepressants are widely 
prescribed to treat mental health conditions despite severe side 
effects and limited efficacy (Tshoner et al. 2007; Watts et al. 2013; 
Beesley & Hammersly, 2006). By attending only to the symptoms 
of mental health, instead of the underlying problems, individuals 
may become dependent on taking such psychotropic medications. 
Furthermore, people often report feeling “numb” or “disconnected” 
when under the influence of such drugs (Beesley & Hammersly, 
2006). Many studies have shown that psychotherapy is both a more 
effective and preferred treatment for individuals who have been 
diagnosed with Post Traumatic Stress Disorder (PTSD) and other 
anxiety disorders. Indeed, a meta-analysis carried out by McHugh 
& Whitton (2013) showed a 3fold preference for psychotherapeutic 
interventions over psychopharmacological treatments (Van Schaik, 
2004). Despite psychotherapy being a more preferred treatment, 
many individuals who are diagnosed with a psychiatric disorder 
still do not experience an alleviation of their mental suffering with 
this line of treatment (Tupper et al. 2015; Watts et al. 2013; Cahill 
et al. 2014). A large proportion of individuals experiencing mental 
suffering are therefore left in need. 
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Such limitations in alleviating mental health suffering, has led to 
novel therapeutic treatments whereby MDMA is administered 
alongside psychotherapy (Tupper et al. 2015). Many studies 
utilising MDMA as an adjunct to psychotherapy have had 
encouraging results with high rates of remission. These studies 
suggest that MDMA can help improve self-awareness, increase 
access to repressed memories and facilitate psychological 
processes (Mithoefer et al. 2011; Tupper et al., 2015; Ruger, 2016; 
Sessa, 2017; Thal & Lommen, 2018). Furthermore, unlike current 
psychotropic medications that are often taken for a lifetime and in 
the absence of psychotherapy, MDMA treatment is only 
administered a few times and in conjunction with a course of 
psychotherapy (Mithoefer et al. 2011; Oehen et al. 2013). The 
most predominant area of research for MDMA assisted 
psychotherapy is with individuals who have a diagnosis of 
treatment-resistant PTSD (Thal & Lommen, 2018). 
 
Trauma, development and PTSD 
 
Characterised as a trauma and stress related disorder, Post 
Traumatic Stress Disorder (PTSD) has similarities to anxiety and 
dissociative disorders. The exposure of an individual to a traumatic 
event, such as one that could cause serious injury or loss of life, 
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contributes to the symptoms of the disorder. These symptoms 
include flashbacks, nightmares and profound psychological 
distress. Furthermore, aspects of life that may remind the sufferer 
of a traumatic event can cause extreme distress as well as a 
negative physiological response. These traumatic reminders, and 
the thoughts and feelings that surround them, are often avoided by 
the individual. A sufferer of PTSD may also experience a negative 
change in mood and increased arousal and reactivity (Thal & 
Lommen, 2018). 
 
It is estimated that 50-90% of people suffer a traumatic life event , 
however the estimated risk of developing PTSD is 6-10% 
(Wittchen et al. 2009; Kessla et al. 2005). This difference has be 
explained with regards to the early years of a child’s attachment 
relationship with their primary caregiver, which it is proposed 
becomes a basis for emotional containment and the development of 
intimate relationships in adulthood (Van der Kolk, 2015). Damage 
to a child’s early attachment relationship can lead to the person 
being vulnerable to anxiety based disorders such as PTSD, 
reducing the capacity to form interpersonal relationships and cause 
feelings of low self-esteem. Furthermore, growing up in an chaotic 
and fearful environment leads to the release of stress hormones 
such as cortisol which in turn, condition the amygdala towards an 
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exaggerated sense of fear as well as inhibiting fear extinction 
responses exercised by the prefrontal cortex (PFC) (Lee & Hankin, 
2009). The imbalance between the amygdala and the PFC is what 
characterises PTSD and can lead to many patients seeking an 
escape from their fear through addiction, self-harm and suicide 
(Sessa, 2017). 
 
The shortfalls in current PTSD treatment 
 
Currently, CBT is the most common form of psychotherapy used 
for individuals diagnosed with PTSD. As well as CBT, other 
trauma-based therapies are often utilised including cognitive 
processing therapy (CPT) and eye movement desensitisation and 
reprocessing (EMDR)(Benedeck et al. 2009). A meta-analysis 
conducted by Bradley et al. (2005), concluded that trauma-focused 
therapies showed a similar efficacy for individuals suffering with 
PTSD, with improvement of symptoms in 44% of individuals. 
Indeed, trauma focused therapies have been found to be more 
effective than other treatments. (Flatten et al., 2011). 
 
Treatment of PTSD can involve revisiting traumatic experiences, 
which often the client finds intolerable rendering psychotherapy 
ineffective, thus leading to response rates of 44% (Rothbaum et al., 
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2006; Morina et al. 2014).  Dropout rates are also high and range 
from between 20-30% (Cloitre, 2009; Hembree et al., 2003; 
Rothbaum et al., 2006). These can be attributed to the effect of the 
trauma leading to a negative impact on the individual’s capacity to 
form trusting interpersonal relationship such as the therapeutic 
relationship (Doukas et al. 2014). 
 
Around 20-30% of individuals diagnosed with PTSD respond to 
pharmacotherapy with the selective serotonin reuptake inhibitors 
(SSRI) sertraline and paroxetine, which are recommended as 
secondary treatment options (Jeffreys 2009). Hammersley and 
Beesley (2006) discuss how reducing symptoms such as distress, 
crying and tension, may prevent the underlying cause being 
accessed, thus hindering the therapeutic process and long term 
recovery. 
 
PTSD is estimated to cost the NHS £5.6 billion per year and has a 
cost to industry of £3.7 billion (NICE, 2005). There is therefore a 
critical need to improve the current treatment options for PTSD. 
One such psychopharmacological treatment 3,4-
Methylenedioxymethamphetamine (MMDA), has demonstrated 
exciting potential to offer a solution. 
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What is MDMA? 
 
MDMA, a ring substituted amphetamine, has been researched as 
an adjunct to psychotherapy for sufferers of PTSD. The compound 
was utilised in many psychotherapy studies between 1978 and 
1985 following the prohibition of LSD (Sessa and Nutt 2007). Due 
to the illegalisation of MDMA, there had been little research into 
utilising MDMA’s psychotherapeutic potential. The last decade 
however has seen the re-approval of therapeutic trials that use 
MDMA as an adjunct to psychotherapy for a range of mental 
health disorders (Mithoefer et al. 2011; Oehen et al. 2013). 
 
Administered in a controlled clinical setting, MDMA typically 
induces a 2-4 hour experience promoting feelings of increased 
extroversion, sociability, self-confidence and a decreased fear 
response. An uncontrolled fear response being common in 
sufferers of PTSD formed the target of the treatment for utilising 
MDMA in the treatment of PTSD (Mithoefer et al. 2011). MDMA 
also offers anxiolytic effects which, instead of merely diluting the 
feeling of anxiety, creates a detachment between the patient and 
the feeling of immediate threat. This may allow a therapist to help 
the patient reflect on difficult memories from a different emotional 
perspective. (Thal & Lommen, 2018).  
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Current MDMA and PTSD studies 
In 2008, the first clinical trial investigating the use of MDMA as 
an adjunct to psychotherapy with PTSD sufferers began. When 
compared to placebo, the administration of MDMA assisted 
psychotherapy reduced PTSD symptoms, however, the sample was 
too small for conclusions to be made (Bouso et al. 2008). 
 
Mithoefer et al. (2011) thus, undertook a study with an increased 
number of participants (n=20), demonstrating the effectiveness of  
MDMA alongside psychotherapy to treat sufferers of treatment-
resistant PTSD. The study had a randomized, double blind design 
and utilised an inactive placebo. During the first stage of the study, 
participants were either assigned a placebo or a 125mg MDMA 
dose alongside two 8-hour sessions of psychotherapy. Scores on 
the clinician administered PTSD scale (CAPS) were reduced by 
83% in the group that received MDMA assisted psychotherapy and 
25% in the placebo group. Unfortunately, the double blind aspect 
of the study failed as both the participants and the coordinators 
could tell who had been administered MDMA (Mithoefer et al. 
2011). Mithoefer et al. (2013), conducted a follow up study on 16 
of the original participants. Fourteen out of the sixteen participants 
maintained significantly lower CAPS scores than before the 
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MDMA assisted psychotherapy. Additionally, none of the 
participants reported any harm from participating in the study. 
 
Following the success of Mithoefer’s (2011) study, phase two 
studies utilising MDMA-assisted psychotherapy for army veterans 
diagnosed with PTSD are underway. Additionally, further phase 
two studies are underway in Canada, Australia and Israel. Finally, 
phase three studies will begin in the UK in 2018 (Sessa, 2017). 
 
Possible reasons for how MDMA improves therapeutic 
outcomes. 
Current positive outcomes of psychotherapeutic practice in treating 
PTSD correlate with a strong therapeutic relationship between 
client and therapist (Charuvastra and Cloitre 2008). As a symptoms 
of PTSD is a decreased ability to trust, it is harder to form a strong 
therapeutic alliance and thus is likely to be very conducive to the 
therapeutic process. Additionally, it’s common to observe a very 
small window of ‘optimal threshold’, within which clients can do 
the necessary psychological work for PTSD (Foa and Kozak 
1986). It is thought that these challenges can be overcome by 
administering MDMA due to the compound’s upregulation of 
oxytocin, dopamine, noradrenaline and serotonin (Grob et al. 1996; 
Harris et al. 2002) 
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Oxytocin is thought to help in the understanding of emotion and 
increase trust in relationships and emotional empathy (Zak et al. 
2005). In addition, during psychotherapy for PTSD, individuals 
often experience ‘negative’ emotional states, which leaves them 
feeling scared, mistrusting and threatened.  Such feelings of fear 
inevitably colour their relationship to the therapist and the 
therapeutic work. An increase in serotonin may diminish such an 
effect by decreasing anxiety and depression and increasing self-
confidence. Whilst it is claimed that this is conducive to 
psychotherapeutic work, one might wonder whether this also 
inhibits some of the useful psychotherapeutic work that can occurs 
when clients come into contact with their barriers to relationship 
and grapple with the struggle of that. Additionally serotonin alters 
an individual’s perceptions and facilitates a new way of thinking 
about old memories, which is considered to be useful in PTSD 
treatment (Matthews 2006). Dopamine and noradrenaline also raise 
levels of awareness that improves the individual’s ability to recall 
state dependant memories. At the same time, and paradoxically, 
activation of alpha 2 receptors increases relaxation that may 
counter hypervigilance seen in PTSD and support clients to revisit 
the traumatic memories in a manner that feels more tolerable. 
(Thal & Lommen, 2018). 
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MDMA also lessens activity in the amygdala reducing the fear 
response and increases activity in reward pathways, causing 
increased sociability and a smaller reaction to anger (Kirsch et al. 
2005). In a clinically controlled environment, alongside a 
psychotherapist, these combined effects of MDMA allow the 
individual to stay with their memories of trauma without finding 
the experience unbearable. They are also argued to help improve 
the therapeutic relationship as the patient finds it easier to form 
interpersonal relationships in this state (Thal & Lommen, 2018). 
 
MDMA assisted psychotherapy through a counselling 
psychology lens 
The positive results of the studies above therefore show a strong 
rationale for building upon the research into using MDMA as an 
adjunct to psychotherapy for PTSD.  As MDMA psychotherapy 
appears to offer profoundly different, personal experiences, larger 
studies are required to generalise their potential to the wider 
population (Tupper et al. 2015). Furthermore, there is no 
qualitative research into the lived experience of the client who 
experiences MAP, with the majority of research having been 
carried out from a positivist epistemological position. Such studies 
have underlying epistemologies and ontologies that may overlook 
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the idiosyncratic, nuanced nature of the phenomenon. As CoP 
adopts a phenomenological philosophical position, as opposed to 
the current research base, which adopts a medical model, and 
positivist position, and emphasises the therapeutic relationship 
(Strawbridge & Woolfe, 2012), arguably CoP offers a useful 
platform from which to carry out such a study. 
 
Possible risks of MDMA 
As well as having properties that make it useful as an adjunct to 
psychotherapy, MDMA also has problematic effects. For example, 
MDMA upregulates cortisol levels which may increase stress and 
negative feelings. MDMA is an ‘enactogen’ and increases feelings 
of love and warmth however the drug also has no selectivity in 
releasing thoughts and emotions and thus it can be unpredictable. 
Furthermore, following MDMA administration the body goes 
through neurochemical recovery whereby serotonin levels are low 
causing lethargy and depression (Baylen & Rosenberg, 2006).  
However, in the clinical trials to date there has been no report of 
any persisting MDMA-related harm in over 850 participants. 
 
Method 
Research philosophy and design 
	 154	
The introduction illuminated that to date there are no qualitative 
studies exploring the experience of MAP for PTSD. Quantitative 
research is limited in what it can explore of the individual’s 
experience. In contrast, qualitative methods enable a depth of 
exploration of individuals’ subjective experiences, facilitating a 
richer understanding of the phenomena. Thus, qualitative 
methodology seemed appropriate when attending to the research 
aims and questions of the present study (Willig, 2013).  
  
Since the research question seeks to explore the lived experience of 
MAP for treatment-resistant PTSD, interpretative 
phenomenological analysis (IPA) seemed the most appropriate 
choice of methodology, as it is understood to be a type of 
phenomenological inquiry that seeks to explore participants’ 
personal experiences and life-world at depth (Smith & Osborn, 
2003).  
 
To elaborate, when choosing which qualitative approach to use the 
researcher considered a number of options before determining that 
IPA was the most appropriate method. This is in line with Smith’s 
(2004) understanding of the process by which one chooses the 
correct method for analysis in qualitative work. Smith (2004) 
proposes that when deciding which method to choose the process 
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is not concerned with choosing a “tool for the job” as might be 
seen in quantitative research, instead the work is to identify “what 
the job is” (p.43).  Thus, in keeping with this, in terms of the 
present study, the fundamental rationale for choosing IPA over 
other approaches was because it was deemed consistent with the 
research question’s epistemological position. 
 
To demonstrate the rationale for choosing IPA for the present 
study further I will now compare it with grounded theory (GT), 
another common approach. GT is also considered to be an 
inductivist approach however, in contrast to IPA, it is argued that 
GT seeks to develop a theoretical-level account of the 
phenomenon. Thus since the interpretative phenomenological 
experience of the demographic in the present study has not been 
explored at all to date it was thought that the divide between 
analysis and generating a theoretical framework would be too 
wide. Rather the endeavour of the current study was to carry out an 
in depth analysis of the lived experienced of participants, placing 
emphasis on the similarities and differences between their 
idiosyncratic experiences of MAP, focussing on capturing the rich 
and nuanced individual experience of each participant. 
 
Sampling and Participants  
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IPA is characterised by purposive homogeneous sampling whereby 
small numbers of participants (between 4 - 11) are selected for 
their capacity to illuminate specific research questions (Smith & 
Osborn, 2003). Given the limited research in the field thus far, and 
the subsequent small population of individuals who have partaken 
in MAP to treat PTSD, the sample was kept small. In addition, it 
was felt that the scope of this research supported the need for a 
small sample to ensure that rich analysis could be conducted, with 
space to report the findings elaborately at depth. It was decided 
that a sample of 7 participants would be optimal. 
  
Inclusion criteria stipulated that individuals must have participated 
in a recent (the last 5 years) MAP for treatment resistant PTSD 
trial. Regarding participant recruitment, the researcher made 
contact with a charity directly involved in the funding of this 
research in America called the Multidisciplinary Association for 
Psychedelic Studies (MAPS). The administrators of this charity 
agreed to send out an email advertisement to the individuals whom 
had participated in MAP trials (Appendix 1). From this point of 
contact a process of chain referral or ‘snowballing’ occurred 
generating a list of individuals who met the criteria. 7 individuals 
contacted the researcher showing interest in the study, and all were 
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responded to with information regarding what participation in the 
study involved and an invitation for them to participate (Appendix 
2). 6 out of 7 of these individuals replied and agreed to take part. 
Since all of the studies that have been conducted thus far in this 
area have been located in North America all of the participants 
who responded resided in America. 
  
Data Collection 
Given that the material being collected was personal and intimate 
in nature, semi-structured interviews seemed the most appropriate 
form of data collection (Brocki & Wearden 2006). The interview 
schedule was devised in line with Smith and Osborne’s (2003) 
guidelines. 
  
The interviewer set out to enter the personal frame of reference of 
the participant. (Willig, 2013). Hence questions were non-directive 
with the aim of maximising the potential to explore the 
participant’s experience, without influencing direction. The 
interpretative element of IPA determines that the influence of the 
researcher is ‘inescapable’ in the knowledge that is produced. With 
this in mind, attention was placed upon reflection of my role as 
researcher in the interpretations that emerged at every stage of the 
research process (Larkin & Thompson, 2012; Yardley, 2000).  
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Interviews lasted between 45-60 minutes and were recorded and 
transcribed before analysis.  
 
The interviews were conducted using video/phone technologies. 
This decision was made due to financial and time restraints within 
the scope of this study, given that all participants were based in 
America. This approach was further supported when taking into 
account how it contributed to minimising ecological dilemmas in 
terms of the researcher travelling to America. The researcher used 
Skype which is an internet telephony software which allows 
videoconferencing via a web cam. It was considered that the use of 
videoconferencing enabled an experience that was closer to an in-
person encounter (Slade, Emery & Lieberman, 1997). Indeed an 
advantage of skype was that it enabled nonverbal communication 
to be captured which felt important in the context of an IPA study. 
In addition, Skype calls are  recorded and transcribed in the same 
way as face-to-face interviews (Oliffe, 2010). 
 
Data Analysis 
The first stage of analysis was to undertake a detailed reading and 
rereading of participant’s transcripts, alongside listening to their 
audiotapes. This generated an understanding of ideas and feelings 
	 159	
the participants were expressing. During this initial stage, salient 
topics, feelings, possible labels of themes and general ideas were 
generated and jotted down on each transcript (see appendix 5). The 
stage that followed involved the clustering of similar topics, 
feelings and ideas together under themes, which in turn facilitated 
a list of themes for each individual transcript to be produced.  
 
The next step of analysis involved comparing across the corpus of 
participant’s transcripts; enabling a generation of consolidated 
themes for the entire sample. A smaller number of ‘superordinate’ 
themes emerged following a process of making connections 
between themes; these were a reflection of overarching ideas 
which appeared common within all subsets of themes. This process 
was iterative in nature as emerging superordinate themes were 
continuously checked and cross-linked against participants’ 
transcripts to allow each individual’s experience to be clearly 
maintained and represented in the data. 
 
Ethical considerations 
Ethical approval was granted and steps were taken to ensure that 
the study met with the BPS (BPS, 2010) and HCPC (HCPC, 2012) 
codes of conduct. 
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Participants were informed of the risks and benefits of partaking 
and their right to withdraw at any point, as well as where to seek 
help should they need support during or after the study. 
Participants gave informed consent prior to partaking in the study 
(Appendix 2). 
 
Following participation, individuals were debriefed on the aims of 
the study (Appendix 3) and their confidentiality was, and will 
continue to be, maintained. All names used in the analysis of this 
study are pseudonyms.  
 
Analysis 
Analysis revealed three superordinate themes which are presented 
here. These are as follows: 1) Existential Freedom 2) Beyond the 
Cartesian-split 3) A journey back in time. Please see Table 1. 
below for an illustration of the superordinate themes with their 
respective subordinate themes. All of the themes have been 
presented here due to their value in attending to the research 
question. However due to the scope of the present study the third 
superordinate theme was restricted in terms of the extent to which 
it could be represented thus  
Table 1. 
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Superordinate Themes Subordinate Themes 
1. Existential Freedom 1. Living authentically: truth 
vs. denial. 
2. Released from fear’s 
captivity  
3. Making meaning in the 
tragedy. 
 
2. Beyond the Cartesian-split 1. An intellectual 
understanding vs. an 
embodied knowing  
2.  Basking in novel felt 
experiences. 
 
3. A journey back in time 1. Reclaiming lost parts of the 
self 
2. Being there and not being 
there  
3. “The maternal container”: 
A personification of 
MDMA. 
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Superordinate Theme One: Existential Freedom 
“I saw my soul out in the universe, it was beautiful. I saw what I 
had been enduring for all of those years and I knew I didn’t want 
to die like that” 
 
Participants used evocative, ethereal, language to describe the 
cosmos and to illustrate the shift they'd experienced during MAP. 
Such connection seemed to support them to have an altered 
perspective regarding the trauma they had endured.  They spoke 
about becoming connected with their own agency, autonomy and 
choice.  Overall, they described an experience of being opened up 
to new opportunities and possibilities, where previously there had 
been only fear and inhibition, Thus, the three sub themes are: 
Living authentically: truth vs. denial, Released from fear’s 
captivity and Making meaning in the tragedy.  
 
Subordinate Theme One: Living Authentically: Truth v.s 
Denial 
“On MDMA it’s just the truth that you see.  You can’t hide, so it’s 
being willing to be shown what is in front of you and accept, versus 
deny it”  
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This theme explores how participants become more ‘authentic’ 
with themselves and others. Participants talked about coming from 
a place of internal denial and shifting to a place of truth. This 
theme also captured participants’ reflections on the experience 
enabling them to move out of a ‘passive’ mode of living, into a 
mode wherein they were able to be take responsibility for their 
lives and recognise  that inherent in human existence there is 
always a degree of choice.    
 
Arguably, this is exemplified in Hannah’s explanation of how 
during the MAP experience, she could take ‘charge’ of her life and 
see her part in the traumatic incident: 
 
“it puts you back in the driver’s seat, showing you that 
you were a participant,, you were there and there were 
options and you chose certain options over others” 
 
By using the metaphor of “the driver’s seat” Hannah emphasises 
how the MDMA facilitated her to move back into a position of 
actively engaging with her life. To elaborate, the metaphor perhaps 
implies that she had been living in the ‘passenger seat’ prior to 
MAP, moving through life in a passive mode and allowing others 
	 164	
to navigate her journey. This metaphor aligns with Yalom’s (1991) 
idea of authentic living being about ‘actively choosing’ as opposed 
to living by ‘happenstance’.  
 
Furthermore, her description of how the experience illuminated a 
different way of looking at her part in the trauma, suggests she is 
now more honest in relation to herself. Indeed, she explains how 
she became more aware of her choice and responsibility.  This 
aligns with Sartre's acknowledgment of responsibility as a given of 
existence, since we always have some degree of choice in any 
given situation (1997). It seems as if Hannah  moves away from 
living in bad faith as she no longer needs to lie to herself and can 
thus live more authentically (Deurzen, 2010).  
 
Lucy explains how during MAP she noticed that she previously 
allowed others to make choices for her thus avoiding 
responsibility: 
 
“The responsibility part was the wakeup call for me to 
take charge of my life, until then I was existing and 
allowing things to continue to happen.”  
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By using the metaphor of a “wakeup call” Lucy demonstrates the 
extent to which MAP had a transforming impact on her awareness 
and existential experience. The excerpt evokes an image of her 
being asleep; again, like Hannah, she explains how her approach to 
life had been one of happenstance. Thus, one could argue that, for 
Lucy, this experience was comparable to an ‘awakening’.  Yalom 
talks about how awareness of death can act as a reminder of the 
significance of life and spark motivation for living (Yalom, 1991).  
 
Two other participants spoke about how they felt more able to 
express themselves authentically in the intersubjective space 
during and after MAP: 
 
“I always felt like I was wearing masks,” 
Historically masks served a number of functions, protection, 
disguise, performance and ritual practices. Thus, Daisy’s analogy 
of “wearing masks” could be taken in a number of ways, it evokes 
an image of her hiding her authentic self. Whilst this experience 
seems to have been one where she felt she was showing herself 
more authentically, I wondered whether it is also one of feeling 
exposed and in the exposure, somehow ‘seen’.  
	 166	
 
Similarly, Lucy talks about being more authentic with her children: 
 
“I’m so much closer to my kids now.  I feel like I’m real, 
they’re real.”  
 
Lucy expresses a shift in proximity to her children, developing a 
capacity to be authentic with them. Indeed, Lucy’s use of the word 
“real” three times perhaps implies that previously she had been 
somehow ‘superficial’ or fake (like a mask).  Yalom (1991) 
suggests that human connectedness enables us to live a meaningful 
life. Perhaps Charlotte and Lucy are describing a process of 
finding this connection.  
 
Subordinate Theme Two: Released from fear’s captivity 
 
“The treatment was a true birth of who I really was and what I 
really wanted, I was actually alive and excited for the future.” 
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This theme seeks to capture participant’s descriptions of being 
freed from the imprisonment of their fear. The accounts appear to 
indicate how they were unable to partake in life because of a deep-
seated fear of future uncertainty and a sense of overwhelming 
futility. Their journeys depict how they progressed to a place of 
excitement and enthusiasm for their future. For example, Daisy 
says:  
 
“My hopes in the beginning were “I hope I can survive 
for Sarah’s [pseudonym] sake.” But by the end of this my 
hopes and dreams skyrocketed”  
  
Daisy captures this sense of a drastic shift from hopelessness to 
infinite freedom in relation to her possibilities and opportunities 
for the future. Indeed, her use of the word “skyrocketed” reflects 
being catapulted into the infinity of space.The sense of going ‘up’ 
in the rocket further supports an impression of growth at an 
accelerated speed.  
 
In the following excerpt Charlotte  explains how she was freed of 
fear.   
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“I can call people.  I can hug my husband, I don’t hate 
being in the shower.  All things I could not do. You just 
keep getting brighter and more alive”  
 
Charlotte’s comparison of her inability to do normal things, to her 
sense of fearlessness captures the grandness of the shift.  Her 
reference to becoming “more alive” arguably invites an 
impression of a resurrection as does the reference to ‘brightness’ 
which has an essence of her rising up from nothing to a radiant and 
powerful individual.  
 
Charlotte goes on to describe feeling freed from her inhibitions and 
finding relationship with her children: 
 
“I used to  feel wrong about holding their (her children’s) 
hands, I think that was because there were so many 
boundaries crossed when I was younger. I remember 
being home and holding my daughters hand and noticing 
“wait this isn’t terrible, this is my little person.”  
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She describes an embodied shift in her expression of relationality 
and physical intimacy. Her intersubjective world is opened up, 
such that she can allow herself to physically connect with her 
daughter. The poetic referral to her child as “my little person” 
gives a sense of her capacity to see her daughter with maternal 
affection. 
 
Subordinate Theme Three: A Hero’s journey 
“ I went from a strike on a box of matches to a star” 
 
The narratives appear to illustrate a journey from a meaningless 
existence laden with a sense of being ‘stuck’ and a ‘victim’ in the 
world, to a discovery of a new found meaning in the trauma. 
Embedded in their experiences, was a sense of how participants 
were creative with regards to conceptualization of their trauma. 
Indeed, I found accounts to be reminiscent of Frankl’s notion of 
“tragic optimism” which depicts the human capacity to find 
meaning in the most horrific of circumstances (Frankl, 2004). 
 
“I was looking at the setbacks in my life a lot differently. It 
made me feel like I’d been on a hero’s journey because I’d 
got to face death.” 
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In the above excerpt, Matt is discussing how he was able to re-
conceptualise his trauma. The reference to “hero’s journey”, 
conveys his experience as a ‘mythological tale’, where he was 
heroic and triumphant in the face of tragedy.  Myths are defined as 
timeless tales that seek to understand, portray and sculpt the human 
experience. They capture the realm of human fear and desire in 
order to offer narratives that better understand what it means to be 
human (Armstrong, 2006).  Perhaps, Matt has drawn upon myth to 
make sense of his experience and construct a meaning that enables 
him to re-engage with life. Ernesto Spinelli proposes that we 
humans seek to find meaning in our experience such that we can 
see it with value and purpose (Spinelli, 2005). This echoes Matt's 
portrayal; he encountered a violent near-death experience and yet 
still sees the value of the experience.  
 
In the following excerpt Daisy recalls a profound moment in her 
experience where she visually hallucinated and communed with 
her husband, whom she had witnessed being murdered: 
 
“I noticed the stars and they began to connect with each 
other. They became an image of my husband. he had grown 
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these wings, he threw his winged hands, up over his head 
and they shot up into the darkness, he was bringing me up 
to the scale of where he was.  I got the feeling that what 
that meant was he’s not only still here, he’s everywhere and 
I might have him more than I had him before” 
 
Daisy describes an experience of connecting with the infinite size 
and grandeur of the universe. Her sense of the vast presence of her 
late husband in relation to herself, appears to put her existence into 
perspective, allowing her to feel held and connected to the 
universe. There is also arguably a religious, or spiritual essence. 
Her final comment is suggestive of her finding meaning in the 
tragedy. The essence of magic and the supernatural suggests that 
she has, like Matt, previously found solace in denial and avoidance 
of the tragedy.  
 
Beth also describes a powerful visual experience that supported a 
shift in the way she viewed her traumatic history: 
 
“I would see myself at age five, this strong little girl 
dancing. It was, wonderful because I saw the strength of 
my own self and my ability to get through some horrific 
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experiences [...] and then it projected out to the end of my 
life and I remember seeing all my coping mechanisms not 
working for me anymore, and that they lead me to a very 
lonely end of life. And I remember saying no” 
 
Beth’s reference to seeing herself “dancing” gives a sense of 
connecting with a part of herself that is able to be free spirited in 
adversity. During MAP she appears to have learnt of her own 
capacity to find joy and value even in a world where she is being 
hurt.  
 
In addition, Beth’s experience suggests a sense of temporality 
being brought into focus, which Heidegger proposes is inherent to 
existence (Landridge, 2007). Stolorow suggests that in trauma 
temporal unity is lost in terms of the flow between past and future 
(Stolorow, 2007). Here, Beth appears to find a way to have 
cohesion between her past, present and future.  
 
Superordinate Theme Two: Beyond the Cartesian split: 
“There was this connection that was made between what my brain 
was saying and what my body and my heart were feeling, where 
that understanding actually physically happened.”   
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All participants expressed a sense of ‘turning on’ to their embodied 
experience during the therapy. The narratives conveyed a sense of 
them having existed in a Cartesian- split where they talked about 
psychological and therapeutic language intellectually but were 
unable to connect with it on an embodied level. In addition, they 
described powerful experiences of being wholly immersed in 
feeling states and re-engaging with feelings that they had 
previously disconnected from as seen in Charlotte’s comment: 
 
“Well I felt sad, I felt scared, I felt everything I felt 
everything I’d pushed away”. 
 
In light of the above, two themes were identified: An intellectual 
understanding vs. an embodied knowing and Basking in novel felt 
experiences. 
 
Subordinate Theme One: From an intellectual understanding 
to an embodied knowing 
 “There’s not a whole lot of, you know, logic-ing and working 
yourself through something that can happen when you don’t feel 
it”  
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This theme captures how participants find it very difficult to 
engage with an embodied understanding of many ‘feeling based’ 
concepts. The theme reflects how they experienced a powerful 
shift to feeling what was talked about rather than remaining at a 
cognisant level. Hannah says: 
 
“My experience without MDMA and having just talk 
therapy, it was so cerebral and I don’t really think you 
can get at the deepest core issues with traumatic 
experience because so much, in my opinion, gets stored in 
the body through tissues and I couldn’t feel it before” 
 
Hannah differentiates her experience with MDMA and without, in 
terms of how it moved from an intellectual experience to a felt 
experience. Her use of the word “cerebral” gives the impression 
that she had been engaging in therapy from a cognitive place, with 
an absence of experiencing on an embodied level. Further, her 
connection to the trauma being situated in her body gives the 
impression that through the MAP experience the trauma was 
somehow unlocked from deep within her and enabled to be 
processed.  
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Daisy describes how her body became almost channelled by the 
MDMA and began moving intuitively into different positions:  
 
“I was stretching trying to get comfortable and then I felt 
the compulsion to bend over and sit cross legged in a ball 
and I could move but it felt really good not to move. It was 
a profound feeling… imagine if someone’s being 
electrocuted and their body moves independently of them 
because energy’s going through it, I felt really tight and 
rigid at one point like I was frozen, it felt like I had been 
that tight and rigid for years and I just had let go of it in 
that moment.” 
 
Daisy’s description of feeling ‘rigid’ and ‘tight’ may refer to how 
she carried the trauma in her body. It sounds as if her movements 
were a way of her body going through a process of ‘undoing’ past 
events. The sense of being ‘overtaken’ by something physically is 
reminiscent of a religious or spiritual experience where people 
describe a ‘divine intervention’. Finally, like Hannah, it appears 
that something unpleasant had been unleashed and expelled from 
deep within her body through physical movement. 
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In the following excerpts participants appear to be describing a 
shift in their experience of the intersubjective space.  
 
Lucy talks about how she had always felt as if she were “behind 
bars” perhaps due to being unable to feel and connect with the 
world: 
 
“I had always felt kind of behind, like as if you were 
behind all of these walls, and then all of a sudden you 
start to feel  almost like there’s this thread, that  links you 
and everyone and everything around you together. Like 
you’re not floating in nothing anymore” 
 
Lucy’s reference to “walls” and “floating in nothing” perhaps 
reflects how she existed largely in a dissociative state.   She 
describes how it had always been this way. Thus ideas of infant 
attachment theory are possibly evoked, in terms of how she learnt 
to cope in her early environment. Indeed, Kohut (1984) describes 
how in relational trauma infants will “wall themselves off” from 
relationship.  
 
In the following excerpt Charlotte comments on the shift in her 
relationship with the therapists: 
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 “They were both so compassionate and caring…during 
the session it was a very physical and emotional and 
psychological understanding that these people are there 
for me with full love and acceptance” 
 
Charlotte appears to physically experience the therapists deeply 
felt intersubjective understanding of her pain for the first time. 
 
Finally, Matt describes how he noticed a change in his voice, as if 
he was talking from his “chest”: 
 
“like my voice, I wasn’t talking from my throat anymore, I 
was talking from my chest […]  
 
I wondered whether when he said chest he was describing talking 
from a more ‘heartfelt’ and thus embodied place.  
 
Subordinate Theme Two: Basking in novel felt experiences 
“You just go from happy to sad and, you’re just completely in it, 
really into just feeling the experience you know and enjoying it.” 
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Participants’ narratives described moments where they felt fully 
immersed in a range of feelings during their MDMA-assisted 
psychotherapy. It was as if they were completely in an 
"experiencing" mode. Perhaps we are seeing them move into a 
place of, in Sartre’s terms, authentic living whereby they are 
emphasising experiencing over knowledge (Sartre, 2003).  
 
Charlotte describes how the MDMA-assisted psychotherapy, 
involved many emotional experiences, both positive and negative: 
 
“I felt the whole range of everything you could ever want 
and not want to feel.  … one of my goals was to feel happy 
at some point and I did, it did.   I felt loved, it’s like you 
are  starving for it and I felt it. We stopped and I snuggled 
into it. It was like the first time I’d felt peace, happiness 
and love ever.” 
 
The term “snuggled” gives the impression that she is leaning into 
the emotion and indulging in it. Similarly, her statement of holding 
onto the “moment” gives the impression that she allowed herself to 
be bathed in this positive effect and perhaps entered a mindful state 
of experiencing and awareness. There is a powerful 
communication of a rich, wholesome tone in Daisy’s language, 
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drawing on words such as “peace” and “love”. Indeed, the 
language and phrasing evokes an image of a resurrection of her 
humanity and sense of ‘aliveness’.  This could perhaps be likened 
to coming alive as in a baptism experience. 
 
Similarly, Charlotte describes an experience of crying from a place 
of compassion for the pain  she had endured.  
 
“It was more like a cry that you feel and not necessarily a 
cry where you just feel terror.  It was like I started 
mourning, and it was really freeing.  I would just bawl, I 
swear I felt like my chest hurt. I was crying because it was  
terribly sad that this happened, how terribly sad that you 
never really got to truly exist as a child” 
 
Charlotte’s emphasis of the intensity of her crying with the world 
“bawl” portrays a deeply cathartic experience of expressing and 
expelling the pain that she had been carrying. Indeed her 
acknowledgement of the experience as “freeing” gives the 
impression of a release.  
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Superordinate Theme Three: A journey through time 
 
Participants talked in vivid detail about their experience of going 
back through time and being with their trauma and pain. They 
spoke about reclaiming parts of themselves that they had betrayed, 
lost or  previously submerged because of the trauma. In addition, 
they spoke about their capacity to  tolerate  difficult memories. 
Finally, participants appeared to talk about the MDMA as an 
externalised ‘thing’ which acted as a pillar of love and support. 
Thus the three subordinate themes are: Reclaiming lost parts of the 
self, Being there and not being there and “The maternal container”: 
A personification of MDMA.  
 
Subordinate Theme One: Reclaiming the lost self 
 “I’m going to pat right here and take care of little me for however 
long is needed and just cry for real.” 
 
Participants described how during MAP the traumatised aspects of 
themselves were brought into awareness with love and 
compassion. I formed the impression that they were describing  
how they had betrayed and abandoned vulnerable aspects of their 
being and these were reclaimed during MAP. They also noted how 
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desirable parts of themselves had also been discovered. In the 
following excerpt, Katy explains how she was able to reclaim a 
traumatised part of herself: 
 
“They had this small doll and her hair was all over the 
place and it was kind of ugly.  It was all messed up this 
doll, it was kind of that part of myself that I really hated 
and I just threw the doll over to the other side of the room.  
I said “I don’t want anything to do with that” and by the 
end of the experience it was so beautiful and I was just 
holding her to my heart and it makes me cry just thinking 
of it, I was like “oh sweetie you’ve just had it so hard, I’m 
so sorry I hated you.”  
 
Katy describes how she was able to recognise, through the doll, a 
part of herself she had discarded and been disgusted by, referring 
to the doll as “ugly”. She appeared to have accessed a loving 
maternal adult inside of herself that can now take care of the 
wounded child. 
 
Similarly, in the following excerpt, Daisy explains the feelings that 
she had previously held towards herself in terms of how a mother 
relates to her baby: 
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“I think it lets you see yourself like a mother sees her 
baby.   It seemed so overly simple but to be able to look at 
myself with love and compassion instead of fear, shame 
and dread.” 
 
Daisy notes how she came to look at herself with newfound “love 
and compassion”. Her description of the feelings being akin to a 
mother and baby reinforces the impression of a true element of 
self-care.  Taken together with her comparison of looking at 
herself with “dread”, there is a sense that she is reclaiming her 
traumatised and abandoned self with love and maternal nurture. 
 
Charlotte talks in terms of how she had deserted the younger part 
of herself: 
 
“I had this wounded little child and she’s sitting, she’s a 
part of me and I left and I said, I’m going to become an 
adult, do well and there might have been a thousand foot 
concrete wall between me and reaching her and in one 
day we knocked that whole barrier down. And it wasn’t 
reachable before I could just tell you, I could not have 
reached there.”  
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Possibly Charlotte is describing a process whereby she betrayed 
her younger self, leaving her vulnerable and wounded parts behind 
in pursuit of security and a better life. She describes how this 
formed a “concrete wall” between herself and that part.  Her 
notion of knocking it down is perhaps reflecting how she 
experienced an unlocking of the hurt and trauma during MAP that 
had been deeply suppressed.  
 
In contrast, below participants describe discovering the good parts 
of themselves. Katy describes her experience using a story where a 
“golden buddha” was uncovered:  
 
“there was a golden Buddha discovered somewhere near 
Thailand. It was back in very old times and they had 
covered this golden Buddha with mounds and mounds of 
dirt so that during war times it wouldn’t get stolen. Many, 
many years later someone saw a glint of gold shining 
through and they dug through all of the dirt and found the 
golden Buddha. I thought that was a perfect metaphor for 
my experience. It had all this dirt. It was covering up this 
golden place inside me , I was for the first time able to, 
connect on all levels.” 
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Katy explains how the Buddha had been hidden under “mounds of 
dirt”. The colour of the Buddha was meaningful to me, “Golden” 
resembles treasure and richness, which indicates that she found 
something valuable underneath all of her trauma. I also find the 
reference to time in her analogy interesting. She explains how the 
golden buddha was revealed “many, many years later”. I wondered 
whether she was describing her sense of how many years she lived 
in a disconnected mode where her essence was submerged and 
unavailable to her. 
 
 Hannah also describes an experience of discovering herself: 
 
“It was almost like you had been there, asleep, like it 
always had been autumn inside and then all of a sudden 
there you were.”   
 
Here I form the impression that Hannah’s reference to the seasons 
is like her essence had been submerged. Indeed, in Autumn the 
leaves are falling rapidly and covering everything, furthermore we 
are waiting for the cold, bitterness of winter with no sight of 
summer. Hannah appears to uncover the warmth of summer inside 
of herself and allow it to emerge. 
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Subordinate Theme Two: “Being there and not being there” 
 
“I wasn’t dissociating like I used to so I was able to stay more 
present”. 
 
Participants explained how during MAP their capacity to tolerate 
the memory was far stronger. For example, Matt compares it to 
watching the memory on a “TV screen”. The impression is that 
they were able to be in the memory whilst simultaneously 
observing the memory. This experience is eloquently captured in 
the following excerpt from Daisy: 
 
“whenever I would have flashbacks my body thought I 
was going to die. With the drug, it was more like watching 
a movie, It magically makes it to where you’re there but 
not there.” 
 
Daisy’s reference to the ‘magical’ quality of the experience 
perhaps reflects how unimaginable it would have been to her 
previously to be with the memory. Moreover, perhaps she is 
describing a mindful way of being with the memory. Indeed, there 
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is a sense of maybe  an ‘observer self’ that allows here to take a 
metacognitive approach to being with the trauma, thus part of her 
can have ‘one foot out’ such that she is not literally relieving the 
memory with the same terror.   
 
Similarly, in the following excerpt Charlotte appears to be 
articulating an experience of revisiting the trauma memories, 
whilst at the same time having a degree of distance from them, 
which made doing so tolerable: 
 
“It was painful but it wasn’t as impossible. I mean pain is… 
pain isn’t a big deal if you’re not terrified during it.  I guess 
it was less scary… see it was scary too, I just felt removed 
from it.” 
 
Charlotte’s reference to it not being “impossible” perhaps reflects 
the power of the drug to enable her to tolerate the experience of 
revisiting memories. She appears to be struggling to articulate how 
the MAP enabled this, as she at first says it was “less scary” and 
then retracts this statement. This gives an indication of how the 
experience somehow creates a situation where you are present with 
the memory whilst also not being simultaneously which appears, in 
Charlotte’s case, hard to describe.  
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Subordinate theme three: The “maternal container”: A 
personification of MDMA (Bion, 1959)  
“I wanted to heal and it felt ok to go there [the memories] because 
I knew I was so well taken care of and like I said, within this 
container of such love that I could do anything” 
 
Participants appear to be aware of their capacity to revisit 
memories and tolerate the intense effect that emerged with MAP. 
There is a sense that at times MDMA becomes personified as a 
‘maternal figure’ for them. I formed the impression that perhaps 
MDMA was experienced as, in psychodynamic terms, a ‘holding’ 
and ‘containing’ figure that  allowed them to revisit memories in 
the knowledge that they would be safe.   
 
In the following excerpt Charlotte describes how she felt supported 
by the MAP. She uses the placebo experience to illustrate what the 
MAP experience provided: 
 
“In the placebo I described it to them like I was having to 
drag the help along with me and I felt so hurt and 
wounded, I really needed to be picked up and carried a 
little by the medicine because that’s how it feels.” 
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Charlotte appears to personify the drug by acknowledging how it 
gave her the feeling of being “picked up and carried” as if she is a 
baby being cradled by the caregiver. Possibly, in this instance, the 
drug is experienced as a ‘maternal figure’ that provides her with a 
sense of ‘holding’, to use Winnicott’s words (Winnicott, 1954), as 
she journeys back to her trauma. 
 
In the following excerpt, unlike Charlotte, Hannah does not 
describe the MDMA as a ‘mother’ however she refers to the 
experiences as enabling her to access a maternal aspect of herself, 
which then allows her to attend to an internal child part: 
 
“It let’s you see yourself like a mother sees a child, you 
know?  I don’t know why it does that, I mean it just takes 
away whatever chemically give you fear and allows you all 
the loving, you know mommy/baby hormones” 
 
Hannah’s reference to parenting implies that she is experiencing 
the MAP as facilitating an experience of accessing an internal 
maternal figure. Furthermore her suggestion that it takes away 
“fear” and instead offers a loving parental relationship perhaps 
reflects how the MAP is experienced as a comforting, maternal 
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figure. Further, her reference to “baby” may reflect s a 
vulnerability that she could access because she felt she could 
respond with love as opposed to fear in this mode. 
 
Discussion  
 
The results of this study have explored the lived experience of 
MAP. The researcher identified three superordinate themes from 
the analysis; ‘Existential Freedom’, ‘Beyond the Cartesian-split’ 
and ‘Journey through time’. The results from the presented themes  
appear to highlight how valuable and important participants found 
the experience in supporting them to engage with psychotherapy 
and process the pain of their individual traumas. In this way the 
study can be said to support the rapidly emerging literature of 
randomised control trials which have conveyed a relationship 
between MDMA and recovery on the CAPS scale for PTSD (see 
review, Mitohoefer 2016).  Overall, the narratives appeared to 
present an image of participants having been on a powerful journey 
which was heavily related to their experience of time. Indeed 
participants’ experiences could be said to involve them being 
transported back in time to their past, being fully immersed in the 
present and finding a way to be engage with the uncertainty of a 
future.  
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In the following discussion, I will investigate the most significant 
findings in relation to the research/literature highlighted in chapter 
1. However, due to the nature of IPA, and its non-assumptive 
stance, many unexpected findings emerged from the data. These 
will be explored from different perspectives to reflect the apparent 
nature of these findings. These include, existentialism, 
neuroscience, mindfulness and attachment theory. Despite the 
potential epistemological/ontological conflict between IPA and the 
latter in particular, it was deemed an appropriate lens for the 
discussion, as it was led and evidenced by the data. 
  
‘Existential Freedom’: A new relationship to uncertainty 
Arguably the above theme lends itself to exploration from an 
existential perspective. Indeed, this theme is characterised by 
discussions of choice, authenticity, opportunity, possibility, 
freedom and meaning.  
 
With regards to subthemes ‘Living authentically’ and ‘Released 
from fear’s captivity’   one could be drawn to think of  how 
participants are describing a shift in their relationship to 
uncertainty.  In existential terms uncertainty is considered an 
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ontological given of our existence, coming increasingly into focus 
in the face of ‘ultimate concerns’ (van Deurzen, 2010) that 
characterise human existence such as isolation, meaninglessness, 
death and freedom. Participants’ experiences of trauma appear to 
bring all of these facets of existence into their awareness in a 
powerful way.  
 
Van Duerzen (2010 p.153) explains how uncertainty manifests 
significantly in terms of choice, as we are never able to know what 
the outcome of our decisions will be. Thus, everyday living 
involves being presented with a vast amount of choice and 
possibilities. This is seen in the theme of ‘Living authentically’ 
where participants appear to describe having lived for many years 
in a mode of happenstance, whereby they negate responsibility for 
their actions and choices because of fear of the outcome. Such a 
response to choice is recognised by Yalom (1980), he purports that 
avoiding choice can be a strategy to defend against the anxiety that 
arises with regards to the outcome of making decisions elaborated 
on below. This offers a description of strategies that people appear 
to employ as a way of defending against the inescapable 
uncertainty that is inherent in our freedom. He suggests how one 
may choose to avoid making choices and wherever possible 
delegate choice and responsibility for their life unto others. In this 
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theme participants describe exploring the experience of a 
transformation in regards to their capacity to actively engage with 
their agency and choice. 
 
In the theme  ‘Freed from fear’s captivity’ we see a shift in 
participants’ from a place of fear regarding uncertainty about the 
future, to an excitement and enthusiasm about what it may hold. 
Such a shift is consistent with literature that suggests uncertainty 
can also be experienced as motivating (Gilbert, 2009). Qualitative 
research suggests that differences in one’s relationship to 
uncertainty may be a product of their dispositional stance towards 
it, in terms of whether they deem uncertainty to be constructive or 
destructive (Gilbert, 2009). The author elaborates, explaining how 
our responses to uncertainty can either serve to immobilise or 
intrigue regarding the possibilities that may emerge.  Arguably, we 
see in both “Living authentically” and “Released from fear’s 
captivity” participants shifting from a place of ontically appraising 
uncertainty and freedom as destructive to finding that it is 
constructive and filled with possibility and opportunity.    
 
‘Making meaning in the tragedy’: Is denial a necessary 
component of human existence? 
	 193	
In the theme of ‘Making meaning in the tragedy’ participants 
describe being able to conceptualise their trauma in a way that 
supported them to be able to attribute meaning and purpose. 
Spinelli (2005) proposes that humans have evolved systems that 
seek to creatively make meaning and find purpose in our 
experience. He suggests that reaching acceptable or reasonable 
explanations for events supports individuals to reduce their 
anxiety, implying that anxiety can be seen as a response to things 
that appear inexplicable. Arguably we see this in the example of 
Daisy, and her visualisation of her late husband. Indeed, Daisy 
now understands his death to have left her with closeness to him 
that is greater than it was when he was alive. Similarly, in the case 
of Matt, he is now able to understand his near-death experience to 
have provided him with a ‘hero’s journey’, supporting the idea that 
he is able to find a suitable and satisfying meaning in the 
experience.  
 
The suggestion of participants having found ‘Existential Freedom’, 
through new meanings around their trauma narratives, can be 
further supported in Frankl’s work. Frankl (2004) emphasises 
meaning making as a primary motivator for living. He considers 
that we are driven through life by an urge to discover meaning in 
the face of what he terms the “tragic triad” (Frankl, 2004 p.139); 
	 194	
human suffering, guilt and death. He postulates that humans have 
the capacity to reconceptualise suffering as achievement, coining 
this “tragic optimism” (Frankl, 2004 p.139). Again, perhaps this 
occurs in the MAP experience for the participants. For example, 
Lucy visualises herself as a child and sees the strength of her 
being, noting how she was moved by her capacity to endure the 
trauma that she experienced. She then therefore understands her 
trauma to be a reflection of her strength and her capacity to endure 
challenging experiences.  
 
On the other hand, I wonder to what extent ‘Making meaning in 
the tragedy’ reflects participants reinstating some denial about their 
trauma into their narratives. In contrast to the previous state of 
denial they lived with, this appears to help them to emerge as more 
able to lead a fulfilling life. Indeed, Heidegger’s being-towards-
death, suggests that humans seek to hide from the inevitable finite 
nature of our existence. He proposed that when we are faced with 
the concept of death, either personally or through bereavement, we 
are forced to acknowledge the lack of meaning and purpose in life 
that subsequently induces experiences of anxiety (Heidegger, 
2010). Thus, maybe MAP enabled participants to reinstate a 
healthy, or necessary, level of denial in order to function. To 
elaborate, one could argue that this invites us to think about 
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whether meaning making serves to function as a facilitator of 
denial.  
 
For example, in the case of Daisy her visualisation of her husband 
may in fact represent a denial of death and offer a belief in 
immortality. Referring to her husband as being “more there” for 
her than he was before arguably gives an impression of her now 
seeing him as a God like, omnipotent and benevolent figure that 
she can depend on. This is consistent with Yalom’s suggestion that 
a common strategy people draw upon to deny death is an irrational 
belief in an ‘ultimate rescuer’ or god-like entity that can somehow 
protect them from the inevitability of death (Yalom, 1991).  
 
‘Beyond the Cartesian Split’: A matter of the right hemisphere 
and left hemisphere of the brain working in harmony? 
Beyond the Cartesian-split, illustrates participants’ to have lived in 
a mode of dissociation whereby they experience a disconnection 
both intra and inter subjectively. The theme presents participants’ 
experiences of shifting to a state of embodied experiencing 
wherein they describe moving from a place of connecting on a 
purely cognisant level with themselves and others, to  powerful 
connections with their bodies and feelings on an embodied level. 
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Contemporary trauma literature has investigated the phenomena of 
dissociation, with regards to sufferers of PTSD, extensively from a 
neuroscientific perspective (Van der Kolk, 2014). Thus it seems 
important to understand how the present study contributes to this 
literature base. Below is a brief description of this evidence base 
followed by an explanation of how this connects with the theme. 
 
Extensive neuroscientific research supports that the right 
hemisphere of the brain is understood to be active in regulating 
both negative and positive affective states, coping with novelty, 
stress and interpersonal relationships. Whereas, the left hemisphere 
is understood to be responsible for rational thought, speech, 
thinking, analysing and organising our experiences in a way that 
makes sense to us. The complex right brain system allows 
individuals to switch internal bodily based affective states in 
response to perceived changes in the external environment thus 
maintaining a cohesive sense of self both in the autonomous and 
interconnected context (Fonagy, 2018; Schore, 2015; Van der 
Kolk, 2014). 
 
In PTSD sufferers research has indicated that often the function of 
the right hemisphere of the brain is maladaptive whereby they 
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experience prolonged frequent and intense episodes of affect 
dysregulation and poor emotional communication both intra and 
inter subjectively (Schore, 2003). During the MAP experience as 
emphasised in ‘Beyond the Cartesian-split’, participants arguably 
find a way to utilise their right brain, moving from a place of 
dissociation to enhanced emotional connection with themselves 
and the therapist. They note how they were now able to feel 
previously unavailable emotional experiences. Thus, perhaps 
MDMA facilitated the regulation of the autonomic nervous system, 
responsible for fight, flight, freeze (the dissociated state) and in 
turn enabled them to access embodied feelings.  
 
Moreover, participants potentially demonstrate how they were also 
engaging their left brain simultaneously, in terms of thinking and 
making sense of their emotional experience.  Van der Kolk (2014) 
has written extensively on trauma and claims that, in the full 
recovery of trauma it is necessary for both sides of the brain to be 
alert and actively engaged, harmoniously working alongside each 
other to process the trauma. Indeed, such a theory perhaps 
resonates with participant Matt’s experience of attempting to work 
through his trauma prior to MAP, he comments “there is not a 
whole lot of logic-ing and working yourself through something that 
can happen when you don’t feel it”. Perhaps Matt is describing the 
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limitations of trying to process trauma when only the left brain is 
available to you. In contrast, an example of where the left brain 
and right brain are functioning in harmony is illustrated in Daisy’s 
comment of her experience during MAP “it was more like a cry 
that you feel and not necessarily a cry where you just feel terror 
[…] I was crying because it was terribly sad that this happened”. 
Here perhaps Daisy is describing how she was functioning from a 
place of high arousal when crying prior to MAP, however it 
appears that during MAP she moved to a place of being able to feel 
the underlying pain and make sense of why she was crying. Thus 
she was thinking and feeling in unison ergo we can hypothesise 
that perhaps her left and right brain were working collaboratively.. 
In summary, perhaps what we can deduce about the participants 
experiences with regards to ‘Beyond the Cartesian-split’ is that 
MAP is facilitating participants to engage with their whole self as a 
result of supporting access and collaboration between the right and 
left hemispheres of the brain. 
 
‘Uncovering the golden buddha’: An act of mindfulness? 
Research and practice has recently yielded a vast body of evidence 
to suggest that mindfulness can be a powerful approach for 
working with trauma. Mindfulness has been defined as 
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“...an act of hospitality. A way of learning to treat ourselves with 
kindness and care that slowly begins to percolate into the deepest 
recesses of our being. The process has everything to do with self-
compassion when facing the rough, shadowy, difficult, aspects of 
our lives....” (Santorelli, 2014, p. 1)  
 
Santorelli (2014) captures the essence of what underlies the 
experience that participants report in ‘Uncovering the Golden 
Buddha’. Indeed, here we see participants opening up their hearts 
to the parts of themselves that they find less desirable and greeting 
them with love and compassion. Thus, perhaps the MAP 
experience reflects the MDMA fostering a mindful and 
compassionate mode when relating to their entire self.  
 
 
‘Being there and not being there’: Could this be a process of 
dual awareness? 
Mindfulness theory is particularly relevant with regards to the 
theme of “Being there and not being there”, Mindfulness is 
thought to facilitate “dual awareness” and "parallel processing” 
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allowing the individual to analyse their past whilst also being in 
the present. Mindfulness is therefore essential to trauma work as it 
minimises the risk of traumatisation (Ogden, 2006). Such dual 
awareness allows individuals to connect to their child self's painful 
emotions whilst in parallel being aware and managing to hold a 
loving and supporting side of themselves enabling them to tolerate 
such intense emotions. 
 
It may suggest that this is what participants were experiencing 
differently when they describe revisiting the memory and “being 
there” whilst simultaneously “not being there”. Indeed, Fisher 
(2017) explains that when a client identifies the lens through which 
they look, they begin to notice their feelings, reactions and actions 
from a “meta-awareness perspective”. In doing so, they learn to 
separate themselves from painful, intense reactions and see them as 
their child self's difficult experiences, referring to these as “his” or 
“her distress”. Perhaps for the first time, in this theme participants 
are able to have a relationship to a distressing feeling rather than 
being consumed by it.  
 
‘Reclaiming the lost self’: Is it all about the internal attachment 
bonds? 
	 201	
Here we see a shift in participants from a place of self-alienation to 
a place of welcoming the whole self. Fisher (2017, pp 79), who 
worked closely both academically and clinically with professor 
Van Der Kolk in the field of trauma, explains that individuals 
suffering with severe trauma often experience a yearning to “like” 
themselves and seek to disown the traumatic experiences. Such 
processes are said to result in a profound alienation from self:  
For individuals to feel safe in relationship, they are required to 
show compassion to both themselves and the other. Indeed Siegel, 
(1999 p.21) states that “earned secure attachment” leads to 
emotional resilience. By internalising secure attachment, people 
can tolerate emotions such as anxiety, frustration and hurt. 
However, to earn the resilience ourselves we have to fully accept 
every part of us, to the parts we hate, to the vulnerable parts, to the 
hostile parts, to the parts we love Fisher (2017). In the method of 
most psychotherapeutic models is the belief that healing is 
achieved as an outcome from relational processes. If an individual 
is hurt in an unsafe relationship then their wound must be healed in 
a relational safety. 
 
However, Fisher (2017) proposes that it is the quality of internal 
attachment bonds, rather than interpersonal attachments, that are 
determinant of our ability to feel safe in relationship to the world 
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and ourselves. She postulates that it is the attachment to ourselves 
that contributes most strongly to our sense of well being as 
opposed to the attachment we feel to and from others. Fisher (2017 
p.213) posed the questions “What if being witnessed as we recall 
painful events does not heal the injuries caused by those 
experiences? And what if compassion for the child who lived 
through these events is more important than knowing the details of 
what happened?”  She proposes that when each part of our person 
can feel lovingly held we gain a feeling of internal safety and 
worthiness, often for the first time. She suggests that the first part 
of the work involves having a curiosity towards this “other” whom 
we carry internally but with whom we are not very well 
acquainted.   
 
Arguably the presented analysis supports this theory. ‘Uncovering 
the golden buddha’, appears to demonstrate a shift in the quality of 
the participants ‘internal attachment bonds’. Perhaps this 
seemingly internal shift is what enables them to revisit their trauma 
and tolerate the affect associated with it. In “reclaiming the lost 
self” we see participants go through a process of meeting their 
traumatised parts, with compassion. Furthermore, we see them 
finding the loving and wholesome parts of themselves, which 
equally appear to have been estranged from them prior to their 
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MAP experience. Finally, we see how they seemingly  draw on 
this new-found compassion and self-love internally to meet their 
trauma memories in a way that feels holding and containing.  
 
‘The “maternal container” (Bion, 1962 p.17): A personification 
of MDMA’: Is MDMA the good enough mother?   
Finally, with regards to the theme ‘The “maternal container” 
(Bion, 1962 p.17): A personification of MDMA’, in contrast, to the 
aforementioned experience of a shift in one’s internal attachment 
system, the theme explores how participants appeared to 
externalise the support that they felt during MAP in the form of 
personifying the MDMA. They appear to see the MDMA as a 
literal mother figure, which serves to support their capacity to 
engage with therapy. Whilst a psychodynamic lense is arguably 
incongruent with the phenomenological lense of IPA, CoP is 
pluralistic in nature and thus I have drawn upon psychodynamic 
theory here as the discourses in the final theme felt closely akin to 
that of this therapeutic model  (Strawbridge & Woolfe, 2010). 
 
To a large extent, the psychodynamic model understands one of 
the fundamental needs of therapy to be the following experience: 
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“What is needed is a form of holding, such as a mother gives to 
her distressed child. [...] It can be crucial for a patient to be thus 
held in order to recover, or to discover maybe for the first time, a 
capacity for managing life and life’s difficulties without continued 
avoidance or suppression” (Casement, 1985 p.133). 
 
This view is largely founded on the work of Bion (1962) and 
Winnicott (1954), which I will expand on briefly here. Bion 
postulates that an infant becomes overwhelmed by their experience 
as they have not developed sufficient internal controls. The role of 
the mother therefore is to provide a containing function helping the 
baby develop self-regulation. The infant internalises such 
containment, experiencing the mother’s emotional availability, 
allowing for the development of their own capacity to contain.  
 
‘Holding environment’ is the term Winnicott (1953 p.10) used to 
describe the best conditions for ‘good enough’ parenting. 
Winnicott postulated that emotional problems could be the 
outcome of an individual who had been deprived of such holding 
environments as an infant. He therefore concluded that it is 
essential to have a level of holding for the therapeutic 
environment. Thus, perhaps the participants experience of MDMA 
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is as a holding figure. Such a view is consistent with qualitative 
literature on individuals who have explored their experiences of 
other entheogenic substances such as the popular psychedelic 
‘ayahuasca’. Indeed Loiziage Velders (2014) study reflected how 
people referred to ayahuasca as “mother ayahuasca”. 
 
Future research 
This study has contributed towards greater understanding and 
clarification of the lived experience of MAP. It supports the 
current emerging literature base that MDMA is a potentially 
fruitful adjunct to psychotherapy in the treatment of PTSD.   
 
Here it has been suggested that MAP appears to support an 
integration of ideas, such as existentialism, psychodynamic theory 
and third wave mindfulness based therapies. However, at this stage 
there is no distinct understanding of which psychotherapeutic 
model is being engaged during MAP. Thus, it is of importance to 
better understand how best to work psychotherapeutically with this 
drug.  It is possible that a grounded theory exploration could offer 
a useful platform from which to explore this.   
 
Furthermore, perhaps neuroscientific advances can be made in the 
exploration of what is occurring in the right hemisphere of the 
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brain during MAP. It would be interesting to understand the 
interaction that occurs between the left and right hemispheres. 
 
Limitations 
 
Despite efforts to homogenise the study sample, there was only 
one male participant. Research shows that males may be more 
reluctant to get in touch with, and talk about, their feelings and so 
tend to be less likely to access therapy (Holmes, 2015). Thus 
perhaps this study's findings may have been different if more men 
had been recruited. 
 
In addition, types of trauma differed and again the sample was 
arguably not as homogenous as it could have been. However, given 
the relatively small number of people who have undergone MAP 
thus far, it would not be possible to narrow this any further at this 
stage. 
 
This research invited participants to recall an experience that 
occurred 4 years ago. Thus, memory recall may have been 
variable, subject to significant interpretation and potentially have 
missed some of the experience entirely. Thus one could argue that 
IPA explores the memory of experience as opposed to the 
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experience itself. However, Smith (2003) argues that the narratives 
are valid if they represent participants’ experiences in the absence 
of an inference with their truth and reality.   
 
As aforementioned, interviews were conducted using Skype video 
technology due to the distance of the participants from the 
researcher. Thus it could be that some of the detailed, intricate, 
sensitive aspects of their lived experience were missed when using 
this interview forum. Perhaps participants felt less able to open up 
entirely due to the sense of physical distance between them and the 
researcher. However, during my reflective process regarding this 
aspect of the research, I did not experience the process as distance 
or lacking intimacy. Rather I found myself being surprised by the 
level of intimacy that appeared present between the participants 
and myself over skype. When considering this in the context of the 
current literature on the topic the interview experience appears 
aligned with Hanna’s (2012) proposal that one of the benefits of 
video call based interviews is that the researcher and the 
participant can remain in an environment which feels ‘safe’ and 
familiar to them whilst not imposing on one another’s personal 
space. He explains how offering the participant the option of 
staying in their own home when being interviewed, without the 
physical presence of the researcher encroaching on their space, 
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may facilitate them to open up and feel more comfortable. He 
comments how this might also be the case for the researcher who 
may be able to be more present and attuned in the comfort of their 
own personal space. 
 
Conclusion 
 
Participants offered bright and enlightening accounts of their 
experience of MAP. They seemed to be powerfully moved by the 
experience and communicated a strong sense of living without 
crippling fear following MAP. Whilst this research has explored 
the lived experience of this small sample and does not seek to 
make generalisable claims, the participants passionate and detailed 
accounts arguably propose a strong argument for future research 
into the field of MAP both for PTSD and potentially for other 
manifestations of human distress. Furthermore, given the current 
socio-economic climate of the NHS and its subsequent emphasis 
on time-limited/solution-focussed evidence based practices 
(Rafalin, 2010), perhaps this treatment could be an adjunct to the 
strains of services offered at present. 
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Appendix 1. 
 
 
Information Sheet 
 
Full study title: An Interpretative Phenomenological Analysis of MDMA Assisted 
Psychotherapy for PTSD. 
 
Dear participant, 
 
I am a trainee counselling psychologist at the University of Surrey and I would like to 
invite you to take part in a study that I am conducting. 
 
What is the purpose of the study? 
The study I am conduction aims to explore what individuals experiences are of having 
psychotherapy which is assisted by MDMA. I would be grateful if you would read the 
information sheet provided in order for you to be informed about what participation 
would involve.  
 
Taking part 
Taking part in the study will involve being asked to attend a 60-90 minute interview that 
will be recorded. In this interview you will be asked a number of open questions about 
your experiences of MDMA assisted psychotherapy treatment. In order to be eligible to 
take part you will of needed to have been a participant in a trial within the last 10 years 
which involved you having psychotherapy when you had been administered a MDMA 
substance. 
 
Are there possible disadvantages to taking part? 
During or after participating in this study it is possible that you may feel upset as a result 
of the material that is discussed. If the interview does upset you in some way you are 
encouraged to seek help from counselling services such as the Samaritans who are 
contactable via the following number ‘1800283-TALK’ or website 
http://www.samaritans.org/how-we-can-help-you/contact-us. Further information and 
support regarding psychedelic use can also be sought from http://www.maps.org/, a 
multidisciplinary association that are conducting research in the area of psychedelics and 
supporting individuals who have experienced them.You will also be given breaks during 
the interview if you should wish to.  
 
What if there is a problem? 
If you would like to complain about any area of the study you may contact the researcher. 
You can also contact Dr Stelios Gkouskos, the supervisor of the 
project  (s.gkouskos@surrey.ac.uk). 
 
Who has reviewed the study? 
The University of Surrey Faculty of health and medical sciences ethics committee has 
ethically approved this study.   
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Will all information shared be confidential and secure? 
Interview are to be recorded using a Dictaphone and then transcribed onto a password 
secure document. The information you share will be kept strictly confidential. Only the 
researcher and the researcher’s supervisor Dr. Stelios Gkouskos will have access to the 
information. When the project is complete all data and personal information collected 
will be destroyed. In the write up of the research all identifiable information will be 
changed in order to protect participant confidentiality.  
 
Decision regarding whether to take part in the study 
If you were to take part in this study you would be invited to set up a date and time that 
was convenient for you and the researcher to complete the interview. The interview 
would take place in a safe, quiet and neutral location that invites you to talk freely about 
your experience. Please note that participation in this study is voluntary and you are free 
to decline to participate. In addition should you partake in the study you are free to leave 
the study at any time. 
 
Yours sincerely, 
 
Michelle Ruger 
Counselling Psychologist in training 
 
Researcher contact details: 
Michelle Ruger, email: m.ruger@surrey.ac.uk 
 
Supervisor 
Dr. Stelios Gkouskos, s.gkouskos@surrey.ac.uk 
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Appendix 2. 
 
Consent Form 
 
Study Title: An Interpretative Phenomenological Analysis of MDMA Assisted 
Psychotherapy for PTSD 
 
● I confirm that I have read and understood the information sheet/letter of invitation 
for this study.  
 
● I have been informed of the purpose, risks, and benefits of taking part.  
 
● I understand what my involvement will entail and any questions have been 
answered to my satisfaction.  
 
● I understand that my participation is entirely voluntary, and that I can withdraw at 
any time without prejudice.  
 
● I understand that all information obtained will be confidential.  
 
● I agree that research data gathered for the study may be published provided that I 
cannot be identified as a subject. 
 
● Contact information has been provided should I (a) wish to seek further 
information from the investigator at any time for purposes of clarification (b) wish 
to make a complaint.  
    
 
       Participant’s Signature---------------------------------------------------------------------------
-- 
 
       Date ------------------------------------------------------------------------------------------------
-- 
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Appendix 3. 
 
Debrief Form 
 
Study Title: An Interpretative Phenomenological Analysis of MDMA Assisted 
Psychotherapy for PTSD 
Dear participant, 
 
Thank you for participating in this research.  
 
This study looked to better understand how individuals experienced MDMA assisted 
psychotherapy for PTSD treatment. The rationale for this study was that recent research 
has shown that psychedelics can act as a beneficial adjunct to psychotherapy and so it is 
possible that such treatment may become available in the future. To date no research has 
explored how people who have received this treatment experienced it leaving a gap in 
knowledge of the utility of the treatment. Therefore this study is seeking to understand 
this better. If you have any further questions regarding this study please do not hesitate to 
contact the researcher. 
 
As previously mentioned it is possible that partaking in this research may have evoked 
some difficult feelings or left you feeling in some way negatively effected. If you feel 
that you would like psychological support please contact the Samaritans on 1800273-
TALK or alternatively you can visit their website http://www.samaritans.org/how-we-
can-help-you/contact-us. Further information and support regarding MDMA use can also 
be sought from http://www.maps.org/, a multidisciplinary association that are conducting 
research in the area of psychedelics and supporting individuals who have experienced 
them. 
 
Yours sincerely, 
 
Michelle Ruger 
 
Researcher contact details: 
Michelle Ruger, email: m.ruger@surrey.ac.uk 
 
Supervisor 
Dr. Stelios Gkouskos, email: s.gkouskos@surrey.ac.uk 	  
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Appendix 4. 
 
Interview Schedule 
 
Project Title: An Interpretative Phenomenological Analysis of MDMA Assisted 
Psychotherapy for PTSD 
 
 
Preliminary Questions: 
1. What trial were you involved with? 
2. What was your presenting issue at the time when you received the treatment? 
3. Had you received any psychopharmacology or psychotherapeutic interventions 
prior to engaging with this treatment? 
 
Exploratory Questions: 
1. How did you feel prior to being administered the MDMA?  
● Thoughts and feelings in psychotherapy sessions before the psychedelic session  
● Apprehension/Hope/Excitement/Fear 
● Therapeutic relationship experience 
● Feelings/thoughts immediately before being administered the substance 
 
2. Can you describe how you felt during the session where you were administered the 
MDMA? 
● Bodily sensations/Feelings/Thoughts/Memories/Imagery/Spirituality 
● The how of the therapeutic relationship 
● Relationship to self  
● Relationship to Other 
 
3. Can you talk about how you experienced the psychotherapy sessions that you attended 
after the MDMA session? 
● Any differences relationally?  
● Explore integration and consolidation of the process/adjustment 
  
4. How has the experience impacted your life beyond the treatment?    
● What comes up now as you look back on your experience? 
● Relationships 
● Overall well being 
● Adjustment 
 
5. Is there anything else that you feel you would like to talk about in relation to this 
topic? 	  
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Appendix 5. 
 
Excerpt of clean transcript (Charlotte) 
It’s quite hard even to remember it now, I can see.  Thank you for sharing that. 
 
Yeah, I spent the next 10 years and years before, you know, in every therapy you can 
imagine on every medication you can imagine until at 29 years they said “here there’s a 
study it might help you a little”.  I said “sure, it’s something let’s try it”.  
 
So can you tell me about what therapies and things you had tried before and your 
experience of those? How they’d been? 
 
So I did traditional talk therapy and I mean honestly it doesn’t really help anybody I don’t 
think.  I didn’t me.  Like I said every medication out there.  I did EMDR therapy and I 
felt like that went, really just brought stuff up to the surface that was painful and didn’t 
give you a way to work through it or to cope with it being there at all, like it just made 
things worse.  I did a somatic therapy and that was right around the time that I found out 
about the study and that actually, I felt was helpful and actually use that during the study.  
When I started that therapy I was 79 lbs and during that we were able to get me up to a 
healthy weight to be able to even be in the study.  That was probably the only one I felt 
like; I can’t even remember what they’re all called.  I mean there’s cognitive behavioural 
therapy; I mean the whole… nothing. There’s not a whole lot of, you know, logic-ing and 
working yourself through something that can happen if you feel it. 
 
Thank you that’s really helpful to kind of hear about those experiences.  So, you’ve 
touched on it a little bit, but can you describe to me how you felt prior to being 
administered the MDMA? 
 
How much prior like? 
 
Let’s talk about kind of when you found out about the study and yeah that kind of 
period initially.  
 
Ok, so like around the time I found out about the study that’s when I had been doing the 
semantic therapy and it had helped me to kind of put some physical mask back on and be 
ok with putting food in my mouth.  But that’s kind of where I’d gotten too.  That’s about 
it.  I had also gained the ability to, at times, be able to tell my therapist “no”.  Which was 
good, especially going into the study and later, but I think that my therapist was kind of at 
a point where he was thinking “this is going to take forever.  If we can get you into this 
study it might take a year or two off of what we have to do” and he had told me we’ve 
got at least 10 more years before we can really get anywhere and I mean, you know, I 
was still a complete mess, like if you can imagine you crumble a paper, that’s what I felt 
like.  I could not nothing.  I spent my day just crying and waiting for my husband to come 
home.  It was terrible, honestly it was terrible.  Everything… it never stopped.  
Everything I thought about was just everything from then, everything from back then, it 
just kept replaying.  
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Ok my next question is how did you feel right before you were administered the 
MDMA? 
 
I was terrified.  I was terrified, I kept thinking I’m not going to be able to do this, I can’t 
take this pill.  My husband came in with me and he went to work that day, but he stayed 
with me and went in late and he’s a teacher and I was like “if you don’t stay, I can’t do 
this, I can’t take this pill” and I thought “ok I’m either going to just sit here, I’m just 
gonna throw it back” and that’s how I kind of got through that moment because I was just 
like “ok here we go”. 
 
If we could just describe, talk about how you felt during the sessions before you 
were administered the MDMA, because as I understand it you kind of have… is it 
three sessions before with Bruce and Marcella? 
 
Yeah. 
 
What were those… how did you find those?  What came up? 
 
You know very difficult. Looking back I’m really grateful for them.  it’s a lot of kind of 
talking about how you are in the moment, it’s not just like a whole lot of dragging up 
what happened, you know, and not necessarily you can but that’s not what it’s intended 
for.  It’s a lot of kind of intention and goal setting like “what do we want get out this? 
What’s actually going to be helpful, what do we want from this? How do we think that 
we can go about getting there?” and I think in a way also it kind of gives the therapists 
kind of an insight into how you work and they kind of catch on to things that might be 
helpful when they work with you.  so I think they were really good, they were really 
good.  I pretty much always left crying and I mean everybody was super nice and [deals 
with dog] 
 
How was it with the therapists? 
 
But I think for me, getting to the point where it was like “ok can I work with Marcella? 
How is this going to be?”  I didn’t completely have like the fully like “I trust you with 
everything” at that point.  That did not happen until the MDMA sessions for me.  
 
Right, I see what you mean.  So now I’d like to move onto the MDMA sessions.  So if 
we start with the first one, I just wanted you to kind of describe that and talk me 
through how it was for you.  
 
I was actually one of those, I don’t know if you’d say lucky or unlucky people who got 
placebo first.  So I had two sessions of full on like minimal minimal dose MDMA and 
then I had three of the full MDMA.   Placebo is terrible I will tell you.  It is hellacious, it 
was eight hours of just mostly on your own, being pushed through it, I mean by the little 
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tiny bit of MDMA.  It’s kind of like the EMDR, it was enough to just bring up a bunch of 
stuff to the surface but you don’t feel the support that you do in the full MDMA sessions.  
 
 
Right I see what you mean.   
 
So during the full MDMA sessions… so I guess where did you want me to start again? 
 
Well actually it's very interesting to hear about those initial sessions with the 
placebo because you were given enough, if I understand you correctly, of the drug to 
feel a very subtle effect but not enough to feel what you describe as kind of being 
supported, I think that was the word you used.  Can you talk to me about those 
experiences and then we’ll go onto… 
 
Like I said… go ahead.  
 
Then we will go on to the MDMA full dose as well.  
 
In the placebo I described it to them like I was having to drag the help along with me and 
I felt so hurt and wounded, I really needed to be picked up and carried a little by the 
medicine because that’s how it feels in the full dose. So in the placebo yeah It kind of, it’s 
like it opens this doorway and you know I had gone in here and you don’t know if its 
placebo.  So I’m in this mindset where it’s like, “ok I’m just going to squeeze everything 
I can out of the opportunity” and thinking “if this is the MDMA oh god, this is terrible 
and if there’s something here for me to help I’m going to try and get it”.  So you just keep 
going and you keep trying to work through things which really just end up incredibly 
painful because you don’t have like the feeling that it’s holding you and supporting you 
as much.  It’s like poking holes through everything.  
 
It’s just bringing it up without the kind of support that you thought you needed. 
 
Right, it was more of a practice in feeling it for me at the two placebo sessions than really 
working through it completely.  But again I honestly, I’m glad that I had it.  It…I think 
that those two extra sessions gave me kind of the opportunity to be like, “ok here’s all 
this terrible stuff that I really do want to work through later” because I just felt all of this 
and I don’t want to do that again every day, forever. 
 
When you said it brought things up, what sort of things? 
 
I guess lots memories that I didn’t want to think about, lots of them and in vivid 
detail.  As though you can really just see it, you can feel it, it's right there and you’re in it, 
a part of it.  Yeah, it’s really and there’s not a whole lot of getting away.  I mean you 
could, you could say “no I don’t want to do this” and just pull back from it but not 
knowing whether or not you’ve got MDMA or placebo, doing that I had to have had 
MDMA kind of shuts down your chance of getting anything good out of this, you know, 
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opportunities so I just kept going. It was horrendous, honestly it was some of the hardest 
stuff I’ve ever had to do.  
 
How did you find you were after those sessions? 
 
I didn’t stop crying, I didn’t not stop crying between there and the next one.  It just kept 
coming.  
 
Just really really painful.   
 
Yeah. 
 
So then you went from those two placebos straight to the full MDMA dose? 
 
Yes, yes.  
 
How was that one? Can you describe kind of how that went for you? 
 
So different, so different.  Let’s see I think after it was like 15 or 20 minutes you start, I 
started to kind of feel like “oh my gosh I’m alive” and you start to feel parts of yourself 
that you didn’t know you could ever recognise, like internally, it was, it was incredible.  I 
can remember sitting up and saying “oh wait, hey guys” and I remember waving at the 
therapists and saying “I’m here, hi”.  All of a sudden you just start noticing all these parts 
of yourself.  There are also plenty of hours where you are just working through 
things.  There was plenty of time where it all just felt so real again, you know, the 
memories were there, the trauma was there.  it was all there, but I also felt a million times 
stronger, a million times more prepared, so supported, you know, just internally.  It gave 
me this feeling like “ok, ok there’s going to be another side, I don’t what it is, I’ve never 
seen it but it’s over there and I’m going there”.  I think that it was incredible too because 
I felt like this sudden connection to the therapist as well, so that was super helpful you 
know, when you don’t feel like you’re in the room alone.   I remember at one point 
looking at them and saying… I think this was actually my last session “oh my gosh I 
know why you guys are doing this, you’ve been here, you’ve hurt, I’m sorry” and I was 
just like “come here let me hold onto you”.  It’s like you just have this outpouring of 
empathy for yourself and for everybody else you can imagine.  Everything just, it lit up 
and it was… let me see, my first MDMA session was the one where I felt like, and it was 
incredible, I felt like a  moment of actual peace and it was for four minutes.  I had these 
headphones on and you know they have the blindfold on you and I was listening to the 
music they played and there was this one song that came on and for four minutes I was 
just quiet and I just fell into, I was like “oh my gosh” and afterwards “What was that? 
Will it come back? Is this over?” So we kind of got to work with that but that was, that 
was amazing.  
 
You’ve talked about so much I just wanted to come back to kind of what you 
described in the initial, if we just for a moment go to the first thing that you talked 
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about was this coming up and being like “hello”  can you tell me more about that? 
What was that for you? How was that? 
 
It was like meeting yourself at the same time as introducing yourself to someone.  It was 
almost like you had been there, asleep, like it always had been autumn inside and then 
there you were and I just felt so much joy and wanted to let all of me out. I was the most 
excited thing on the planet at that moment, I really was.  It was… I wanted to find it all, I 
wanted to share it all and I did for a good 15 minutes or so.  
 
 
How did that look sort of, do you remember how it kind of looked? 
 
Well I honestly remember kind of like popping up and sitting up and you know, seeing 
that and then for 15, 20 however long I sat and I talked so much, so fast and so big I think 
that we danced slightly.  I think I hugged everyone, yeah, yeah. 
 
Can you describe how that was different from how you’d been before? 
 
Oh wow, it was like a different me.  Before it’s amazing because I’ve seen some of the 
tapes, but before I was just small and snuggled up and quiet and kind of “don’t look at 
me”, you could kind of barely hear me, always ready to cry.  Then afterward I was so big.  
It was like I suddenly had permission to take up so much space.  If you could feel like 
you were growing, that’s what it felt like. it was amazing.  
 
How do you feel though that session allowed that to happen? How do you 
understand that? 
 
I think that the same way that it felt like in the placebo sessions, it was poking 
holes.  Instead of just poking holes and letting all that terribleness through suddenly I had 
this bunch of cheesecloth where all of like everything good came through, you know, it’s 
like “wait, wait there’s more here” and it kind of floods you with more and you’re like 
“ok wait, there that is inside of me” and it just comes out, you can’t hold it in.   
 
You say, talk more about, what’s that for you? What was the good feeling? 
 
A lot, real, I used say that I was nothing, not nothing but the nothing.  I had felt like I 
honesty was the worst thing to have ever existed.  If there was evil it was me and in that 
moment it was gone like I felt like I was not the bad thing.  
 
You talked about the, sort of the times in the sessions where you would go back into 
kind of the more difficult stuff, can you talk me through that a bit more please? 
 
Well there would be times, you know, you have your blindfold, mind shades on, 
whatever they all them and your headphones, or you wouldn’t and you’d be sitting there 
talking and something.  Almost like it kind of rose up from inside you it’s like “hey I’m 
here, do you want to talk? Do you want to deal with me right now?”  and I was really 
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glad because beforehand they had given me the analogy that it’s kind of like a dance 
partner “do you want to dance?” and you can say “yes or  no, go away” you know and 
there were times where I was like “no go away I can’t do this one yet”  but then there 
were times when it just came up and you just fell into it and everything felt really pretty 
terrible but I also felt like I could look at it, like I could see it better, I could see things 
clearer, I didn’t have to hide from it so much.  There was a lot of like actually… like it 
was a physical replay of things that had happened, it was like if you watched it and 
watched what I did it was like you could just see everything that had gone on.  It was 
right there, but it was almost like you got to complete it better.  Like having gone through 
it that way at that moment with that kind of internal/external support gave you almost like 
a better resolution, if that makes sense.  Then afterwards you’re able to kind of see clearly 
a little better.  Kind of like, “oh wait, no I didn’t invite that upon myself” you know, the 
whole like “that’s not just what happens to girls”.  I remember saying “that’s just what 
happens to girls” and my therapist caught it and she said “What did you just say?” and I 
repeated it and I thought “oh my gosh, no, no, no, no, no, no, no” and so you like you just 
start this whole experience of feeling and then just healing it yourself as well.  It hurts so 
bad and then you just kind of like hold your little self and apologise to your little self like 
that that had even happened. 
 
You talked about kind of being there and it being there, do you mean like literally, 
you could see it in front of you and that was when the  mask was on or without the 
mask? 
 
So it was kind of… yeah, describe that in more detail if you can? 
 
It really was like what was in front of you or what had been in front of you before was 
not, like it was gone.  Like if you can remember back and you kind of think of how you 
imagined things or how you dreams things.  It was like you’re sitting there and you’re 
seeing those things though, it’s all honest to god right there in front of you.  Your hands 
are smaller, you are smaller, you don’t look the same.  I remember looking in the mirror 
to make sure I was the same and I was not. I saw like you know little six year old me and 
it all just kind of right now vanished and everything was there.  you just saw it all and I 
mean it sucked. That sucks, you don’t want to see, but I guess being able to see it, like I 
said with more of the support and kind of more of an idea that they maybe that wasn’t 
right kind of helps you to see it better then through six year old eyes.  
 
How did you find that kind of being that six year old? 
 
I mean it’s rough, it’s painful, it’s tragic but then when you remember for the first time of 
having one of these experiences that “wait I’m really not, you know, it all looks this way, 
I’m not looking the same, I look like this six year old but wait I know more, I do, I really 
do” and you start telling yourself this.  So then you’re able to guide yourself better and 
like as you wish someone would have done, you know.   I remember at one point going 
through that whole thing and like having it and seeing it all and then having Marcella 
come and just hold me like should have happened and I just snuggled in and felt it.  It did 
it kind of reset what should have been there.  
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Exploratory 
comments 
Original Transcript Emergent Themes 
 
She seems to be 
describing a shift to 
being more authentic 
with herself. 
 
Her reference to 
Woody Allen refers 
to a sense of living in 
a mode of denial that 
is not a choice. 
Despite her best 
efforts to be honest 
with herself she is too 
frightened to look at 
it. 
 
There is a fear of 
annihilation if she is 
to see reality but in 
fact it is the truth that 
rescues her from 
death. 
 
talking about how 
you cannot force 
feelings despite really 
wanting to. Unable to 
have compassion/love 
for herself just 
through thinking she 
should. 
 
Reference to herself 
as a mother figure. 
Conjures up feelings 
of internal attachment 
bonds. Her way of 
relating to herself has 
significantly changed 
on an embodied level 
 
 
Can you elaborate more on the new perspective that 
you mentioned? 
 
Yeah, I mean I was totally hiding so many things from 
myself and I didn’t know anybody, as far as I knew, 
that was trying so hard to see myself.  I was really 
actively working on it and it was impossible and you 
know you hear like Woody Allen saying “I’ve been in 
therapy 50 years”, whatever like it’s a joke.  People 
really want to see themselves, it’s not like they’re not 
trying, it’s not like the help isn’t trying to help them, it 
is impossible.  I’ll tell you why I think it’s impossible 
because I really thought I would die if I knew the things 
about myself that saved me. Because I was able to have 
compassion for myself and that is so different than fear.  
It’s the opposite of fear and I don’t know any other 
experience that would give that to someone because 
you can’t force yourself to have compassion for 
yourself, you can’t do it.  
 
What do you think it is about the MDMA that 
enabled that experience to happen?  How do you 
understand that to have happened? 
 
I think it just lets you see yourself like a mother to a 
child sees, you know.  I don’t know why it does that, I 
mean except for brain chemistry maybe there’s 
something that just takes away whatever chemically 
gives you fear and allows you all the loving, you know 
mommy/baby hormones or whatever all of a sudden.  I 
have no idea but that’s all it took.  It seemed so overly 
simple but to be able to look at myself with love  
 
 
 
 
 
 
Authentic living 
 
Seeing the truth 
 
Fear of truth, a 
preference for denial 
 
The truth as a rescuer 
 
The power of self 
compassion 
 
 
 
 
Being Mum to yourself 
 
The power of self love 
 
A maternal love 
 
 
 
